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ABSTRACT 
Tendons are crucial for locomotion, transferring forces from muscle to bone. They are subjected 
to high forces, and possess highly specialised hierarchical structures to function efficiently. 
Tendinopathies are debilitating tendon disorders common in both athletes and non-athletes. 
The unclear aetiology of tendinopathies has led to limited, generalised treatment, with poor 
regenerative outcomes for patients. Tendinopathies are thought to be instigated by changes in 
the local cellular environment, with tendon overuse generating matrix microdamage, which 
increases cellular shear. Shear is potentially an important mechanotransduction cue, but no 
mechanism is available to investigate this directly.  
To address this need, a fibre composite system based on polyethylene glycol (PEG) was 
developed, consisting of cell seeded PEG-peptide fibres encapsulated in a PEG matrix. 
Composites were developed to mimic the cell mechanical environment in tendons, creating 
shear-tension ratios equivalent to those seen physiologically (40% of applied strain transferred 
to the fibres; the remaining 60% as fibre shearing within the matrix). High shear-low tension 
(~25% tension, ~75% shear) and low shear-high tension (~60% tension, ~40% shear) 
environments were also developed to investigate non-physiological conditions.  
Broad spectrum gene expression analysis was performed to determine how different shear-
tension ratios affect the behaviour of tenocytes derived from healthy and tendinopathic human 
tendons. Tendinopathic tenocytes appeared more mechano-sensitive than healthy tenocytes 
(shear-tension mediated changes in versican, IL-8, TIMP-3, MMP-3 and MMP-13 expression) 
and showed a distinct basal profile similar to that observed in tendinopathic tissue (lower MMP-
3 and higher MMP-13 expression). Further investigation with bovine tenocytes found changing 
the cell attachment peptide in fibres from RGD to DGEA increased the sensitivity of tenocytes 
to the local shear-tension environment (shear-mediated changes in scleraxis, MMP-2 and COL-
3 expression). This suggests tenocytes are more responsive when attached to collagen-like 
materials, and consequently that specific integrins are involved in sensing the local shear-
tension environment.
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1.1 Tendon Composition and Structure 
Tendons play a key role in the locomotion; they function to transmit forces from muscle to bone 
allowing the production of movement about joints. Consequently tendons are used in everyday 
activities, being exerted more so in athletic sports where high forces are generated frequently. 
Tendons are able to function under these high tensile loads due to a specialised hierarchical 
structure which also contributes to a unique cellular environment.  
Tendons are essentially comprised of collagen, proteoglycans, cells and water, with water 
contributing ~70% of weight in a human tendon (Elliott, 1965). Collagen provides 75-90% of the 
total tendon dry weight (Bernard-Beaubois et al., 1997; Kjaer, 2004; Schulze-Tanzil et al., 2004) 
and more than 95% of the collagen present in tendons is type I (other types include III, V, VI, IX 
and XI). Other proteins present include fibronectin and elastin, with the latter being 1-2% of the 
total dry weight (Elliott, 1965; O'Brien, 1997).  
The hierarchical structure of tendons is summarised in Figure 1. At the nano-scale, collagen is 
comprised of three polypeptide α-chains of repeating Glycine-X-Y units (where X and Y are 
usually amino acids proline and hydroxyproline) intertwined into a triple helix, creating collagen 
molecules approximately 300nm in length. Closely packed collagen molecules overlap and form 
inter-molecular crosslinks at the C terminus of one molecule and N terminus of the other, with 
the assembled structure known as collagen fibrils. This method of crosslinking also creates a 
staggered arrangement of the molecules which results in collagen fibrils having visible 
microscopic bands every 67nm (D-periodicity of 67nm) (Baselt et al., 1993; Jozsa and Kannus, 
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1997; Kadler et al., 1996; Kannus, 2000; Silver et al., 2003). This forms the basic structural unit 
of collagen found in tissues.  
The terminology for the higher structural levels of the tendon hierarchy varies through 
literature. For this review, multiple collagen fibrils aligned parallel and grouped together are 
termed collagen fibres, primary bundles of fibres are referred to as subfascicles, secondary fibre 
bundles are termed fascicles and finally tertiary fibre bundles are called fascicle bundles (Figure 
1). In human tendons, the diameter of subfascicles range from 15µm to 400 µm while fascicles 
vary from 150µm to 1000µm, both depending on the type of tendon (Jozsa and Kannus, 1997; 
Silver et al., 2003).  
 
 
 
 
 
 
 
 
 
 
Figure 1: Hierarchical structure of a typical tendon starting from the repeating amino acid chain up to the 
macroscopic tendon unit. (Image adapted from Liu et al. (2008) and information collated from Franchi et al. 
(2007b); Jozsa and Kannus (1997); Silver et al. (2003)). 
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The orientation of collagen fibres allows efficient transmission of force, and as such fibres have 
been seen to exhibit a number of arrangements in different tendons to optimise mechanics. In 
most tendons collagen is predominantly aligned parallel to the axis of loading (Jozsa and 
Kannus, 1997; Kannus, 2000). Collagen fibres also display structures known as crimps which are 
visible as jagged sinusoidal like patterns extending along the length of fascicles (Figure 2). 
Crimps are thought to be a result of the tertiary structure of collagen fibres, possibly being 
maintained by the presence of elastin fibres, and exhibit a periodicity of 10-100µm (Freed and 
Doehring, 2005). The degree of crimping also differs from tendon to tendon with studies 
suggesting crimp angle could be dependent on the amount of tensile load the tendon has to 
bear (Jarvinen et al., 2004). A structural study by Magnusson et al. (2002) found that the angle 
of crimps in human Achilles tendons, both intact and ruptured, were between 35° to 37°. 
Ultrastructure analysis of collagen fibril crimping have shown that fibrils possess a left handed 
helical twist termed fibrillar crimps (Figure 2A) (Franchi et al., 2007a; Franchi et al., 2010). 
        
Figure 2: Scanning electron microscopy (SEM) of collagen fibril crimp structures in rat Achilles tendons. A)  Relaxed 
tendon sectioned longitudinally showing both crimp pattern and fibrillar crimps. B) Stretched tendon showing 
straightened fibrils. Scale bar = 1 µm (Franchi et al., 2007a).  
The high viscosity of tendon extracellular matrix (ECM) is thought to be primarily due to the 
proteoglycan (PG) content. PGs surround collagen fibrils and fibres, providing structural 
support, lubrication and spacing of collagen fibres which is essential for gliding and cross-tissue 
interactions (Sharma and Maffulli, 2005). Gliding at fascicle and intra-fascicle levels allows 
A B 
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contour flexibility and transmission of tension when tendons move over joints with varying 
angles of inclination (Benjamin et al., 2008). PGs present in tendons include small-leucine rich 
proteoglycans (SLRPs) decorin, biglycan, lumican and fibromodulin, along with larger PGs 
lubricin, aggrecan and versican. Common proteoglycans found in tendons and their roles are 
summarised in Table 1. Decorin, biglycan, fibromodulin and lumican have all been associated 
with the regulation of collagen type I fibrillogenesis (Birk et al., 1995; Dunkman et al., 2013; 
Jepsen et al., 2002; Schonherr, 1995; Yoon and Halper, 2005). The binding of SLRPs, such as 
decorin, to collagen fibrils has also been suggested as a mechanism for transferring stress 
between fibres, as the glycosaminoglycan (GAG) side chains of decorin are known to connect 
from one decorin molecule to another on an adjacent collagen fibril (Reese et al., 2013). Models 
have consequently proposed that tendon overload results in the breakage of connecting GAG 
chains and thus altered tendon mechanics (Redaelli et al., 2003; Vesentini et al., 2005). 
 
Figure 3: Schematic of collagen type I fibril, proteoglycan and other matrix protein interaction in tendons 
(Parkinson et al., 2011). 
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The content and distribution of ECM components has recently been shown to differ through 
the levels of the tendon hierarchy. For example, the inter-fascicular matrix (IFM), which is the 
ECM between fascicles, has been noted to contain specific localised components such as elastin, 
lubricin and versican (Thorpe et al., 2013a), with lubricin being particularly localised to the 
interface between collagen fibre bundles and the ECM (Sun et al., 2006).   
Table 1: Summary of PG structures and functions relevant in tendons. CS = chondroitin sulfate, DS = dermatan 
sulfate, KS = Keratan sulfate. (Information adapted from (Yoon and Halper, 2005) with added content as indicated). 
Name Core Protein 
Size (kDa) 
GAG Chain 
type 
Location in Tendons Suggested Roles 
Decorin 361 CS/DS1 Bound to fibrillar 
collagen. Also binds to 
TGFβ and EGFR1. 
Inhibits collagen 
fibrillogenesis1, 
stress transfer 
between fibres2. 
Biglycan 381 CS/DS1 Bound to fibrillar 
collagen. Not found in 
avian species1. 
Involved in 
fibrillogenesis1. 
Fibromodulin 421 KS1 Bound to fibrillar 
collagen1. 
Facilitates collagen 
fibril maturation1. 
Lumican 381 KS1 Bound to fibrillar 
collagen1. 
Inhibits size of 
collagen fibrils1. 
Lubricin 117-1503,4 CS/KS5,6 Found on the tendon 
surface, surrounding 
collagen bundles and 
localised to the 
IFM5,6,7,8. 
Lubrication - 
reduces friction 
coefficient5,6,7. 
Aggrecan 2201 CS/KS1 Linked to hyaluronan. 
Low levels found in 
tensional parts of 
tendon and high levels 
in compressed regions1. 
Provides structural 
support1. 
Versican 265-3701 CS/DS1 Linked to hyaluronan. 
Low levels found in 
tensional parts of 
tendons and slightly 
higher levels in 
compressed regions. 
Localised to the IFM8,9. 
Provides structural 
support1. 
 
1) Iozzo and Murdoch (1996), 2) Reese et al. (2013), 3) Abubacker et al. (2013), 4) Steele et al. (2013), 5) Juneja and 
Veillette (2013), 6) Schumacher et al. (1994), 7) Sun et al. (2006), 8) Thorpe et al. (2013a), 9) Reese et al. (2013). 
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Specialised cells found in tendons are known as tenocytes and contribute approximately 90-
95% of the cellular elements, with the remainder including chondrocytes, synovial cells and 
vascular cells (Jozsa and Kannus, 1997). Tenocytes are situated on the surface of collagen fibres, 
leading to their arrangement in rows parallel to the fibres. Tenocytes are also situated between 
fascicles in the IFM. These interfascicular tenocytes are more prolific and have a rounder 
morphology compared to intrafascicular tenocytes. There is currently significant interest in 
their phenotype and potential role in tendon homeostasis (Clegg et al., 2007; Richardson et al., 
2007; Spiesz et al., 2015; Thorpe et al., 2015a). Tendon progenitor stem cells (TSCs) have also 
been suggested to reside in tendons, with studies identifying populations in rabbit, mouse and 
human tendon tissue (Bi et al., 2007; de Mos et al., 2007; Zhang and Wang, 2010a; Zhang and 
Wang, 2013; Zhang and Wang, 2010b). Characterisation of tenocytes has found intracellular 
type I, III and V collagen within the cytoplasm, with type I collagen preferentially distributed 
around the nuclei. Type III collagen was also found distributed closer to the cell membrane and 
type V found in a fibrillary and vesicular form (Figure 4) (Gungormus and Kolankaya, 2008).  
Tendons typically appear white due to the low degree of vascularisation but they contain small 
thin-walled blood vessels. Some tendons, particularly those around bony prominences, are also 
known to have entirely avascular regions (Benjamin et al., 2008). Fibrous and synovial sheaths 
surround tendons, particularly those of the hand and feet, providing a friction reducing tunnel, 
to improve function over curved or longer distances. This is alternatively achieved (to a lesser 
degree) via a loose layer of connective tissue, often referred to as the paratenon, on tendons 
such as the Achilles tendon, where distinct synovial sheaths are not present (Jozsa and Kannus, 
1997). 
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Figure 4: Tri-colour immunofluorescence images of rat Achilles tenocytes in a high density culture system; A) 
collagen type I, B) collagen type III, C) collagen type V (fibrillar) and D) collagen type V (vesicular) antibody stained 
tenocytes after 3 weeks in a high density culture system (x80 magnification). E) Composite immunofluorescence 
image of tenocytes incubated for 7 weeks (4 weeks in monolayer and 3 weeks in a high density culture system) 
which showed positive staining for type I (blue, AMCA), type III (green, FITC) and type V collagen molecules (red, 
Texas Red fluorochrome) (x120 magnification). White arrows in B) indicate brighter collagen type III staining in 
tenocytes which are proliferating. (Adapted from Gungormus and Kolankaya (2008)). 
 
 
 
 
E 
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1.2 Function and Properties 
The tendon matrix, arranged in multiple hierarchical levels, provides a versatile structure 
allowing tendons to optimise their mechanics to function effectively. The strains tendons are 
exposed to varies, depending on functional demand and location. Two general categories exist 
to describe tendons based on their function; positional tendons which function to transmit 
forces from muscle to bone, and energy storing tendons which in addition to transferring forces, 
also store and release energy during locomotion to improve efficiency (Birch, 2007; Lichtwark 
and Wilson, 2005). 
The presence of PGs within tendon IFM and fascicular matrix contributes towards the 
viscoelastic properties of tendons; PGs are hydrophilic and also form bonds between collagen 
fibrils both longitudinally and transversely (Cribb and Scott, 1995). The exact mechanism 
providing tendons with the ability to stretch and recover large strains is unclear. Energy storing 
tendons can stretch further than others, and also appear to recoil more elastically, returning 
over 90% of the energy they store (Benjamin et al., 2008). The content of elastin is low at 1-2% 
of the dry mass of tendons, thus the aforementioned properties are a result of multiple 
interactions. Figure 5 shows the typical stress-strain curve of a tendon when stretched, with 
characteristic regions demonstrating the complexity of tendon extensibility. The first distinct 
feature is a toe region associated with crimps. Crimp structures are seen to straighten when 
load is initially applied and can revert back to the original crimped state upon the removal of 
load. Due to the number of crimps present in a tendon and their angles, the accumulation of 
their small reversible extensions generates a significant effect, requiring strains of up to 1.8% 
to fully straighten (Franchi et al., 2007a; Sasaki and Odajima, 1996a; Screen et al., 2003). The 
straightening and alignment of fibres along with fascicle rotation also contribute to this toe 
region (Screen et al., 2003; Thorpe et al., 2013b). The resulting non-linear extension results in 
high strains with low loads, hence the toe region allows deformation with limited direct collagen 
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loading, ensuring minimal fibrous tissue damage and also functioning to facilitate shock 
absorbance (Franchi et al., 2007a). 
 
Figure 5: Typical tendon stress-strain curve showing an initial toe region where crimp straightening and fibre 
alignment occur, then a broadly linear region consisting of fibre extension, fibre sliding and fascicle sliding, 
followed by microdamage and eventually tendon rupture. (Adapted from Wang (2006)).  
Once crimps have straightened and fibres have aligned, further load application results in a 
quasi-linear region of stress and strain. The collagen fibres within tendons have been observed 
to stretch, however the extent of fibre extension is seen to be less than that of the whole tendon 
(Fratzl et al., 1997; Rigozzi et al., 2013; Sasaki and Odajima, 1996a; Shepherd et al., 2014; Thorpe 
et al., 2013c). Physiologically, the fibres in tendon are seen to stretch by approximately 40% of 
the applied strain (Shepherd et al., 2014). Consequently, the extensibility of tendons past the 
toe region is due to a combination of fibre extension, fibre sliding (Figure 6) and fascicle sliding 
facilitated by the IFM (Cheng and Screen, 2007; Screen et al., 2003; Thorpe et al., 2015b). Even 
further application of load past the linear region surpasses the tendons extensibility 
mechanisms and results in microdamage of fibres and eventually complete tendon rupture.  
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Figure 6: Wistar rat tail tendons stained with a strain grid and then stretched under a confocal microscope using a 
specialised strain rig. Images show grid distortion under increasing strains, indicating fibre sliding (adapted from 
Cheng and Screen, 2007). 
Due to their function, energy storing tendons often experience high strains. For example, the 
human Achilles tendon is an energy storing tendon which sees average peak strains up to 4.6% 
whilst walking, 5.8% when running and 8.3% during one-legged hopping (Lichtwark and Wilson, 
2005; Lichtwark and Wilson, 2006). Similarly, the equine superficial digital flexor tendon (SDFT) 
experiences strains of up to 16% during galloping (Dowling et al., 2000). Comparison of the 
equine SDFT and positional common digital extensor tendon (CDET) found the capacity for 
fascicle sliding was greater in energy storing tendons. This has been attributed to differences in 
the IFM, with energy storing tendons possessing specialised IFM to provide greater extensibility 
(Thorpe et al., 2012). The fascicles within the SDFT tendon have also been observed to exhibit 
a helical substructure (Figure 7), which is absent in the CDET, suggesting more efficient energy 
storage in the SDFT through a spring-like mechanism (Thorpe et al., 2013b; Thorpe et al., 2014).  
Consequently, energy storing tendons are more elastic than positional tendons and have a 
higher fatigue resistance to function efficiently at larger strains (Thorpe et al., 2015b). The 
combination of the described mechanisms to allow tendon extensibility, in both energy storing 
and positional tendons, result in a complex intra-tendon environment during loading, consisting 
of both tension and shear. 
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Figure 7: Scanning electron microscope image of a) an equine energy storing tendon, SDFT, and b) an equine 
positional tendon, CDET. Scale bar = 200 µm. A helical substructure is observed in the SDFT fascicle which is absent 
in the CDET fascicle. This structure is consequently implicated as a specialisation of energy storing tendons, acting 
as a spring-like mechanism to store energy. (Adapted from Thorpe et al. (2015c)). 
The stiffness of tendons varies depending on location, age and physical activity, for example the 
equine energy storing tendon SDFT has been seen to be less stiff than the positional CDET 
(Thorpe et al., 2012). The Young’s modulus of the tendon associated with the medial 
gastrocnemius muscle in humans has been found to be between 0.28-1.16 GPa in vivo (Kubo et 
al., 2002; Maganaris and Paul, 2002), while the human Achilles has a modulus between 0.67-
1.07 GPa in vivo (Lichtwark and Wilson, 2005), and the human patellar tendon a modulus of 
2GPa in vitro (Svensson et al., 2012). Svensson et al. (2012) also characterised the modulus of 
isolated collagen fibrils, finding a value of 2.8GPa. The modulus of tendon derived individual 
collagen molecules has been seen to range from 3-9 GPa (Sasaki and Odajima, 1996b). 
  a) SDFT 
 b) CDET 
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Therefore the tendon hierarchy can be seen to be a compromise between the mechanical 
properties of collagen and the flexibility and extensibility needed to function efficiently at a 
given anatomical location. Ageing has been associated with changes in tendon properties; the 
bulk properties of equine tendons and their fascicles remained unchanged with increasing age, 
however the stiffness of the IFM increased with ageing, accompanied by reduced fascicle sliding 
(Thorpe et al., 2013c). Consequently, it has been proposed that ageing alters the extensibility 
mechanisms in tendons, with increased IFM stiffness resulting in less fascicle sliding and more 
fascicle extension. This higher strain transfer to fascicles could subsequently increase the risk 
of microdamage, potentially predisposing older tendons to injury (Thorpe et al., 2015c; Thorpe 
et al., 2013c). 
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1.3 Tendinopathy 
The term tendinopathy is used to cover a range of tendon injuries, including those referred to 
as tendinitis (pain accompanied with inflammation) and tendinosis (pain without 
inflammation).  Sporting activities generate high forces repeatedly and therefore it is not 
surprising that the yearly incidence of tendinopathies in sports are high; of all Achilles 
tendinopathies 24-64% are seen in runners, 23% of adolescent basketball players see patellar 
tendinopathy and 69% of young elite swimmers have supraspinatus tendinopathy (Cook et al., 
2000; Sein et al., 2010; Sorensen et al., 2007; Woo et al., 2007). However, tendinopathies are 
not isolated to sporting activities, as a sample of the general Dutch population has shown a 
2.35% incidence of Achilles tendinopathy in an entirely sedentary population, and rotator cuff 
tendinopathies, especially the supraspinatus, are common in the elderly (de Jonge et al., 2011; 
Woo et al., 2007).  
There are many factors associated with tendinopathy, both intrinsic and extrinsic. Intrinsic 
factors include age, gender, anatomical variations, biomechanics and systemic diseases, while 
extrinsic factors include profession, sports, training errors, repetitive physical load and 
abnormal movement (Rees et al., 2006; Riley, 2004; Seitz et al., 2011). 
The causes and mechanisms behind tendinopathies are not fully understood, with the role of 
inflammation often debated and tendon overuse usually attributed as a primary factor 
(Arnoczky et al., 2007; Arnoczky et al., 2002b; Dakin et al., 2014; Fredberg and Stengaard-
Pedersen, 2008; Fung et al., 2010; Khan et al., 1999; Rees et al., 2013). Tendon overuse can lead 
to microdamage throughout the matrix, disrupting the matrix organisation and changing cell-
matrix interactions. The disrupted tendon matrix is theorised by some to cause under 
stimulation of tenocytes, with studies showing increased collagenase expression when cells are 
stress deprived (Arnoczky et al., 2007). On the other hand some researchers think over-
stimulation is a factor instead; an in vitro study by Zhang and Wang (2010b) found cells within 
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tendons changed their phenotype when stretched, differentiating towards adipocytes, 
chondrocytes and osteoblasts, whereas lower strain percentages maintained the tenocyte 
phenotype (Zhang and Wang, 2010b). In both cases the altered interactions are said to 
eventually contribute to further tendon degradation. 
Although the aetiology is unclear and debated, most researchers agree tendinopathies are a 
degenerative pathological process, usually thought to be a failed response in tendon healing 
(Arnoczky et al., 2007; Cook et al., 2004; Magnan et al., 2014; Reinking, 2012; Scott and Bahr, 
2009; Shearn et al., 2011).  
1.3.1 Tendinopathy Features and Changes 
Painful human tendons show a number of abnormal signs, such as increased cellularity, 
rounded cells, disrupted fibrillar structure and reduced preferential cell orientation (Figure 8), 
while ruptured tendons generally show reduced cellularity and loss of fibrillar structure (Busch 
et al., 2013; Jones et al., 2006). Characterisation of ruptured Achilles tendons have found the 
tissue to be more severely degenerated than tendinopathic Achilles tendons, implying that 
tendinopathies may increase the susceptibility to further tendon injury (Tallon et al., 2001b).  
   
Figure 8: Comparison of healthy (A), slightly (B) and severely degenerated (C) human finger tendon after 
haematoxylin and eosin staining. Collagen fibres are stained pink and cells are stained violet. Slightly degenerated 
tendon (B) looks similar to healthy tendon (A), with minor differences such as looser tissue surrounding fascicles 
in the slightly degenerated tendon. Severely degenerated tendon (C) exhibits more significant changes such as 
irregular collagen arrangement, high cellularity and neovascularisation. (Adapted from Busch et al. (2013)).  
             A) Healthy                    B) Slightly Degenerated        C) Severely Degenerated 
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Hyper cellularity and increased vascularisation have been used to identify tendinopathic tissue 
(Fu et al., 2002; Khan et al., 1999), with the equivalent of 3 weeks overuse exercise exhibiting 
these changes in in vivo models (Andersson et al., 2011). Interestingly, the same in vivo model 
also found endogenous neuropeptide production increased after 1 week of overuse activity, 
indicating that neuropeptide production precedes tendon damage and proposing a link with 
tendinopathy (Backman et al., 2011). Neurovascularisation was also seen to occur in damaged 
or ruptured tendons, which then disappeared with healing, suggesting the neuropeptides 
produced were directed towards the neurovascularised sites. Acetylcholine, another neuron 
associated substance, has been shown to increase tenocyte proliferation upon addition to 
culture, while the tenocytes themselves were found to produce and release enzymes associated 
with acetylcholine synthesis (Fong et al., 2013). 
Comparison of healthy and tendinopathic tendons has found that diseased tendons exhibit 
increased PG content (Riley, 2008), with the pathological posterior tibialis tendon (PTT) showing 
higher collagen type I, collagen type III, aggrecan, biglycan, MMP-2 and MMP-13 and reduced 
MMP-3 and ADAMTS-5 gene expression compared with healthy PTT (Corps et al., 2012). The 
ratio of collagen type III to collagen type I has also been shown to increase when characterised 
in injured rotator cuff tendons (Riley et al., 1994b). ADAMTS-4 gene expression is higher in 
ruptured Achilles tendon (Corps et al., 2008) as is decorin expression, while painful Achilles 
tendons have shown a significant increase in aggrecan and biglycan gene expression when 
compared to healthy Achilles tendons (Corps et al., 2006). Lower versican (Corps et al., 2004) 
and MMP-3 gene expression has been observed in tendinopathic Achilles tendons whereas 
collagen type I, type III and Tenascin-C gene expression were larger (Ireland et al., 2001). 
Tendinopathy has also shown increased MMP-1, procollagen type I and reduced TIMP-1 
through immunolabelling of tendinopathic and healthy patellar tendons (Fu et al., 2002). Lower 
MMP-3 activity and higher MMP-1 activity was similarly seen in tendinopathic supraspinatus 
tendon compared to a healthy controls (Riley et al., 2002). A number of differences were 
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identified in human Achilles tendons by Jones et al. (2006), including lower MMP-3 and TIMP-3 
expression and elevated ADAM-1 and MMP-11 in both ruptured and painful tendons compared 
to healthy tendons. Increased ADAMTS-4, MMP-1, MMP-14 and TIMP-1 was also reported in 
ruptured tendons (Jones et al., 2006). IL-6 expression levels have also been shown to differ in 
Achilles tendinopathy and patellar tendinopathy, showing dependence on both the tendon 
location and tendinopathy type (Legerlotz et al., 2012).  
The function of nitric oxide (NO) has also been explored in tendons. Nitric oxide synthase (NOS) 
gene expression has been found to increase in rat rotator cuff tendons after overuse, suggesting 
a role in the development of tendinopathies (Szomor et al., 2006). Interestingly, in human 
tenocytes derived from ruptured rotator cuff tissue, NO has also been found to regulate 
collagen synthesis, with increased NO availability up-regulating synthesis, while inhibition of 
inducible NOS (iNOS) down-regulates synthesis (Xia et al., 2006). More holistically, elevated NO 
levels have been proposed to alter the balance between the anabolic and degenerative 
catabolic response in tendons, as NO is also involved in the activation of MMPs and TGFβ (Scott 
and Bahr, 2009; Szomor et al., 2006; Xia et al., 2006).  
Recent research has also suggested that some individuals may be genetically prone to 
developing tendinopathies, with polymorphisms in ECM related genes COL-5A1, TIMP-2 and 
ADAMTS-14 being associated with Achilles tendinopathy (Abrahams et al., 2013; El Khoury et 
al., 2013; Morrey et al., 2013).  
The schematic in Figure 9 briefly summarises potential mechanisms involved in developing 
tendinopathies as described by Shearn et al. (2011). It is clear that the pathology, although 
initiated by various means, ultimately results in altered cellular metabolism and subsequently 
ECM changes, such as decreased collagen fibril diameters and increased collagen III gene 
expression and content (Corps et al., 2012; Pingel et al., 2014), eventually leading to the 
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symptoms associated with tendinopathies. A summary of these tendinopathic changes is also 
presented in Table 13 towards the end of this chapter. 
 
Figure 9: Schematic indicating possible mechanisms for degenerative tendinopathy (Shearn et al., 2011).  
1.3.2 Tendinopathy Treatment 
The consequences of tendinopathies vary depending on the site and degree of symptoms; they 
can range from simple swelling and slight pain to complete immobilisation of the affected area. 
As the exact mechanisms leading to tendinopathies are not known, treatment is delivered 
progressively depending on the symptoms shown and the extent of disability. Treatment first 
attempts to reduce inflammation and pain, followed by the restoration of flexibility and 
function. This can be attempted in many ways, usually starting with rest and use of non-
steroidal anti-inflammatory drugs which, upon failure, are then followed by physical therapy, 
corticosteroid injections, deep ultrasound therapy or muscle stimulation (Cucurulo et al., 2009; 
Metzl et al., 2008; Speed, 2001; Woo et al., 2007).  
The treatments suggested differ from clinician to clinician but ultimately do not resolve the 
underlying problem. For example, eccentric exercises commonly used to reduce pain in chronic 
Achilles tendinopathy have been shown to fail in completely eliminating pain after a 5 year 
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follow-up, with 60.3% of patients still exhibiting pain to some degree (de Vos et al., 2007; van 
der Plas et al., 2012).  
Corticosteroid injections are typically used to treat inflammation. However inflammation does 
not occur in all tendinopathies, and any inflammation is usually related to the healing process, 
thus this approach may not be ideal (Speed, 2001). Corticosteroid injections have also been 
linked to adverse side effects such as inhibiting collagen synthesis, reducing tendon mass, 
reducing biomechanical integrity and overall delaying of tendon healing, which is why use is 
cautioned with tendons (Speed, 2001; Woo et al., 2007). Other injection therapies for 
tendinopathies include: sclerosing injections where agents (such as polidocanol) are used to 
reduce vascular and neural ingrowth to reduce pain; platelet rich plasma injections which 
potentially introduce necessary growth factors directly into the pathological site; and 
autologous blood injections to induce healing (Hoksrud and Bahr, 2011).   
If it is deemed necessary, surgical repair is utilised for treatment (Cucurulo et al., 2009; Khan et 
al., 1999; Nixon et al., 2012). This involves excision of the tendinopathic area and is termed a 
tenotomy. Tenotomies can be performed in a variety of ways including openly exposing the 
tendon or percutaneously along the longitudinal axis and either with or without paratenon 
stripping (Cucurulo et al., 2009; Tallon et al., 2001a). Patients treated surgically for Achilles 
tendinopathies using these methods have reported success rates of more than 70%, although 
later complications are not uncommon (Roche and Calder, 2013; Tallon et al., 2001a).The 
physical act of performing surgery on tissue is known to produce a strong healing response, 
therefore it is difficult to differentiate between the effects of the surgical procedure and the 
healing response itself (Woo et al., 2007).  
It is evident that effective tendinopathy treatments are lacking, particularly due to the absence 
of pathology understanding, resulting in pain reducing therapies taking dominance rather than 
rectification. 
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1.4 Tenocyte Behaviour 
Tenocytes maintain the ECM by producing the main components such as collagen type I and 
PGs, and are responsible for collagen assembly and turnover. To better understand 
tendinopathy development, an understanding of tenocyte behaviour during physiological 
function is necessary. The structure of tendons, as described earlier, provides a complex and 
mechanically stimulating cellular environment.  As tenocytes reside both on the collagen fibres 
and between fascicles in the IFM, tenocytes are exposed to both tension and shear during 
tendon loading. Many studies have looked into characterising tenocyte behaviour to elucidate 
the mechanisms of mechanotransduction and the loading conditions which could promote 
anabolic and catabolic states.  
1.4.1 Mechanotransduction Mechanisms 
The use of mechanical stimulants, such as shear pressure, to alter cell behaviour is considered 
a mechanotransduction pathway. Mechanotransduction is defined as a series of dynamic 
processes that allow cells to convert biomechanical stimuli into biochemical activity (Kamkin 
and Kiseleva, 2008). The process of mechanotransduction can be divided into four distinct 
stages; force transmission, mechanotransduction, signal propagation and cellular response 
(Atala et al., 2008). Force transmission requires the application of a force to the tissue or ECM 
which can then be detected and converted into a local stimuli, i.e. deformation of the ECM, 
changes in hydrostatic pressure and other structural changes to the local cell environment. The 
local stimuli is then detected by the cell as a deformation, where integrins, ion channels and 
other receptors on the cell surface act as sensors and convert the local stimuli into intracellular 
signals (Atala et al., 2008; Schwartz, 2010). Signal propagation can then occur as the intracellular 
signal produced travels through the cell and ultimately results in a cellular response.  
Integrins are key transmembrane receptors involved in mechanotransduction as these are used 
by cells to adhere to a substrate surface, thus sensing mechanical changes. They possess a 
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heterodimer structure, with 24 possible combinations from 18 α- and 8 β-subunits in mammals 
(Arnaout et al., 2007). The extracellular portion of integrins binds to a variety of ligands 
depending on the combination of subunits, while the intracellular portion binds to the 
cytoskeleton. This bridging across the cell membrane results in the ability of cells to react 
bidirectionally (Figure 10), thus allowing cells to adhere, migrate, grow and differentiate 
(Arnaout et al., 2007; Qin et al., 2004). Integrin activation and cytoskeleton attachment is 
achieved through actin-binding proteins such as talin, α-actinin and filamin at the cytoplasmic 
tail end (intracellular portion), which additionally recruits F-actin localised to focal adhesion 
points (Giannone et al., 2003; Liu et al., 2000; Schwartz, 2010). At the transmembrane region 
(extracellular portion) multiple ligands can bind to a given α-β combination, and equally 
different α-β combinations can bind to the same ligand (Campbell and Humphries, 2011). For 
example the proteins laminin and collagen can both attach to integrins α1β1 and α2β1, or 
fibronectin which is recognised by α2β1, α3β1, α4β1, α4β7, α5β1, α8β1, αvβ1, αvβ3, αvβ5, 
αvβ6, αvβ8 and αIIbβ3 although with different affinities (Askari et al., 2009; Campbell and 
Humphries, 2011; Plow et al., 2000). Thus the rearrangement, recruitment and remodelling of 
integrins and the cytoskeleton in response to mechanical changes show that these structures 
are heavily involved in mechanotransduction pathways (Chiquet, 1999; Schwartz, 2010).  
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Figure 10: Model of integrin conformational changes and bidirectional signalling. Integrins in A) Inactive, B) primed 
and C) ligand bound state, while D) and E) show formation of focal adhesion points through external force (Askari 
et al., 2009). 
Direct deformation of the nucleus has also been implicated in mechanotransduction; the 
presence of nuclear actin, lamins and lamin-binding transmembrane proteins, all of which 
contribute to connections between the cytoskeleton and the nucleus, provide a mechanism for 
mechanotransduction (Dahl et al., 2008). This connection was also explored by Arnoczky et al. 
(2002a) wherein tenocytes within rat tail tendons were observed during loading and found to 
show a correlation between applied strain and nuclear deformation.  
Mechanotransduction is critical to homeostasis in tendons. However, injuries and changes in 
tendon properties can result in an altered cellular environment, and thus produce an altered 
mechanotransduction signal. 
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1.4.2 ECM Turnover  
As collagen is the most abundant ECM protein present in tendons, collagen synthesis can be 
correlated with tendon ECM synthesis. Collagen synthesis starts with polypeptide α-chain (pre-
procollagen) mRNA transcription within the cell nucleus like other cellular proteins. The mRNA 
moves into the cytoplasm where it is translated by ribosomes, producing the N-terminus of the 
pre-procollagen chain first. This portion is recognised by the rough endoplasmic reticulum 
(RER), allowing the pre-procollagen chain to be directed into the RER itself as the ribosome 
completes translation (Ishikawa and Bachinger, 2013). Different genes code for the different 
types of procollagen chains, with 3 procollagen chains needed to form a procollagen molecule 
and a number of different chain combinations possible (known collagen types and their chain 
combinations are listed in Table 2 to Table 6). When a combination of 3 procollagen chains are 
present in the RER, the chains are aligned and stabilised through disulphide bonds and 
glycosylated, resulting in a procollagen molecule with a characteristic triple helix. The 
procollagen molecules are then transported extracellularly via the Golgi apparatus where 
procollagen N-proteinase and procollagen C-proteinase (also known as propeptidases) cleave 
the N- and C- terminus, respectively, resulting in collagen molecules (tropocollagen) with the 
ability to aggregate and covalently crosslink to form collagen fibrils. The propeptidases are 
therefore vital in collagen synthesis as they are necessary to process procollagen into 
tropocollagen molecules (Canty and Kadler, 2002; Gelse, 2003; Kadler et al., 1996).  
With the collagen biosynthesis processed detailed, it is evident the gene expression of pre-
procollagen chains can be used to determine which collagen type a cell is promoting for 
synthesis. The mRNA transcription and subsequent translation by ribosomes is similar for other 
proteins, thus gene expression investigation can also be used to monitor other proteins 
promoted for synthesis.  
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Matrix metalloproteinases (MMPs) are key enzymes involved in the degradation, and thus 
remodelling, of the ECM. They are similar to ADAM (a disintegrin and metalloproteinase)  and 
ADAMTS (a disintegrin and metalloproteinase with thrombospondin motif) in structure, with all 
three protease types characterised by a catalytic Zn2+ domain and a hydrophobic cleft of 
variable depth (Klein and Bischoff, 2011; Nagase et al., 2006). In addition to ECM processing, 
these proteases are also involved with the release of membrane bound cytokines, growth 
factors and chemokines (Klein and Bischoff, 2011; Visse and Nagase, 2003).  
There are over 20 distinct MMPs identified in humans, each having different substrate 
specificity (summarised in Tables 7 to 10). MMPs have traditionally been categorised as 
collagenases, gelatinases, stromelysins or matrilysins (Visse and Nagase, 2003). However, this 
classification is often considered a hindrance in portraying their function, as each MMP can 
process multiple substrates, with different substrates indicating different roles. An example of 
this is depicted in Figure 11 where the multiple downstream effects of MMP-2 are reviewed 
(Butler and Overall, 2009; Butler, 2000; McCawley and Matrisian, 2001). 
 
 
 
Figure 11: Schematic 
summarising the variety of 
MMP-2 interactions. A) and b) 
demonstrate the role at any 
given time is dependent on the 
substrate upon which it is acting, 
while C) summarises which 
substrates are linked to which 
roles (Adapted from Butler and 
Overall (2009)). 
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MMPs can be regulated in 4 ways: gene expression, compartmentalisation, activation and 
inhibition. Transcription control and post-transcription modification via mRNA stability and 
microRNA constitutes regulation at the gene expression level. MMPs are synthesised as pre-
proenzymes, released as proenzymes and therefore MMP activation from proMMPs is another 
key method for regulation (Chung et al., 2004; Nagase et al., 2006). MMP activation is achieved 
by removal of a propeptide-domain, which otherwise blocks and prevents interactions by the 
Zn+ ion, and can be achieved through proteinases such as trypsin and other MMPs, or chemicals 
such as thiol-modifying agents, detergents and reactive oxygen species (Klein and Bischoff, 
2011; Loffek et al., 2011; Nagase et al., 2006; Sela-Passwell et al., 2010). This is usually a 
stepwise process, whereby once part of the obstructing propeptide is removed, the remaining 
portion likely becomes unstable and is removed via partially activated MMPs or other MMPs 
(Visse and Nagase, 2003). For example, MMP-3 has been shown to be involved in the activation 
of MMP-1 and MMP-13 (Klein and Bischoff, 2011). Compartmentalisation of secreted MMPs to 
pericellular zones creates a focused response and thus localises their release, in addition to 
providing a store for quick release (Loffek et al., 2011). Finally, there are 4 tissue inhibitors of 
metalloproteinases (TIMPs), each of which functions to obstruct MMP activity. This is achieved 
by directly blocking the substrate recognition site, via chelation of the Zn+ ion with the TIMP N-
terminal in a 1:1 molar ratio – typically described as the wedge shaped TIMP molecule slotting 
into and occupying the active MMP site (Nagase et al., 2006). Alterations which detrimentally 
affect the chelating ability of TIMPS inactivate their MMP inhibition (Sela-Passwell et al., 2010). 
TIMPs have a broad specificity resulting in each TIMP being able to inhibit a wide variety of 
MMPs, with all four collectively covering the known MMPs (Klein and Bischoff, 2011; Sharabi et 
al., 2014). 
MMP-1, MMP-8, and MMP-13 have typically been considered collagenases in humans, along 
with the membrane type MMP-1 (also known as MMP-14). This is due to their ability to initiate 
degradation in fibrillar collagens, arising from their hemopexin prodomain, which locally 
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unwinds the structure of collagen such that the catalytic Zn+ domain can cleave collagen into ¾ 
and ¼ fragments (Chung et al., 2004; Nagase et al., 2006; Sarkar et al., 2012). Once broken, 
other MMPs can also recognise the fragments as substrates and aid degradation further. 
Although MMP-1, MMP-8 and MMP-13 can all cleave collagen type I, II and III, their substrate 
specificity differs. MMP-1 is seen to preferentially cleave collagen type III, MMP-8 preferentially 
cleaves collagen type I and MMP-13 preferentially cleaves collagen type II (Howes et al., 2014; 
Manka et al., 2012; Mitchell et al., 1996; Ricard-Blum, 2011). 
Gelatinases MMP-2 and MMP-9, as the names suggests, digest gelatins. This includes degraded 
collagens (i.e. compromised triple helix) and laminin (Visse and Nagase, 2003). Thus their 
activity extends to fibrillar collagens once they have been processed by the aforementioned 
collagenolytic MMPs. Controversially, MMP-2 has been demonstrated to cleave fibrillar 
collagens into ¾ and ¼ fragments similar to MMP-1 (Aimes and Quigley, 1995; Patterson et al., 
2001) and stated to do so in reviews (Klein and Bischoff, 2011; Nagase et al., 2006; Visse and 
Nagase, 2003). However, this is hotly debated, with opponents suggesting that the collagen 
used in this study was not native, and damage to the triple helix facilitated degradation by 
MMP-2 (Seltzer and Eisen, 1999). This is also reinforced by a further study where MMP-2 had 
no collagenolytic effect on triple helical type I collagen unlike MMP-1 and MMP-14 (MT-MMP-
1) (Ohuchi et al., 1997). However a subsequent study showed that, although MMP-2 possesses 
a hemopexin domain, it can bind to native collagen type I using its fibronectin like domain and 
could possess weak collagenolytic behaviour towards fibrillar collagen type I (Tam et al., 2004). 
A more recent study took extra care to source intact collagen type I which could form its native 
triple helical structure when gelled and found MMP-2 unable to accomplish any digestion while 
MMP-1 did (Christiansen et al., 2007). 
There are 19 human ADAMTS which are generally similar to MMPs in that they are secreted as 
proenzymes, inhibited by TIMPs with varying affinities and digest numerous substrates, many 
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of which are currently unidentified or of unknown function (Porter et al., 2005). A list of 
ADAMTS, their structure and known substrates are shown in Table 11 and Table 12. One key 
difference between MMPs and ADAMTS is the ability for the latter to bind to the ECM (Porter 
et al., 2005). Some ADAMTS, notably ADAMTS-2, ADAMTS-3 and ADAMTS14, act as procollagen 
peptidases, thus are involved in the regulation of collagen fibril synthesis.  
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Table 2: Summary of Collagen structures, and their involvement in tendinopathies and response to loading. (Information from Ricard-Blum (2011) and Shoulders and Raines (2009) unless 
stated otherwise). Part 1 of 5. 
Type Individual Chain Structures Chain Arrangements Formation type and Associations 
Changes with Loading or 
Tendinopathy 
I 
α1[I]: 
 
α2[I]: 
 
α1[I]3 
α1[I]2.α2[I] 
-Fibrillar  
-The homotrimer α1[I]3 is resistant to all 
MMP collagenases and found in foetal tissue, 
fibrosis and cancerous cells (16). 
Increased in tendinopathy 
(3,11,12). Increased expression 
in pathological PTT (9). 
Increased expression with 
loading (4,7,8,14,15). Increased 
content with loading (5,8).  
II 
α1[II]: 
 
α1[II]3 -Fibrillar 
 
III 
α1[III]: 
 
α1[III]3 
-Fibrillar 
-Forms heterotypic fibrils with collagen type 
I 
Increased in tendinopathy 
(3,10,11). Increased expression 
in pathological PTT (9). 
Increased collagen content 
with loading (5,8). Increased 
expression with loading (6,15). 
IV 
α1[IV] and α2[IV]: 
 
α3[IV], α4[IV], α5[IV] and α6[IV]: 
 
α1[IV]2.α2[IV] 
α3[IV].α4[IV].α5[IV] 
α5[IV]2.α6[IV] 
-Network 
 
 
 
Collagen formation types: 
FACIT – Fibril associated collagen with interrupted triple helices. 
MACIT – Membrane associated collagen with interrupted triple helices. 
Multiplexin – Multiple triple helix domains and interruptions. 
 
Key: 
1 = Corps et al., 2008. 2 = Jones et al., 2006. 3 = Riley, G., 2008. 4 = Jones et al., 2013. 5 = Maeda et al., 2007. 6 = Maeda et al., 2009. 7 = Legerlotz et al., 2013. 8 = Huisman et al., 2014. 9 = Corps et al., 2012. 10 = Riley et al., 1994. 
11 = Ireland et al., 2001. 12 = Fu et al., 2002. 13 = Riley et al., 2002. 14 = Zhang and Wang, 2010. 15 = Sun et al., 2010. 16 = Han et al., 2010. 17 = Canty and Kadler, 2005. 18 = Fitzgerald et al., 2008. 19 = Wu and Eyre, 1995. 
. 
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Table 3: Summary of Collagen structures, and their involvement in tendinopathies and response to loading. (Information from Ricard-Blum (2011) and Shoulders and Raines (2009) unless 
stated otherwise). Part 2 of 5. 
Type Individual Chain Structures Chain Arrangements Formation type and Associations 
Changes with Loading or 
Tendinopathy 
V 
α1[V]: 
 
α2[V]: 
 
α3[V]: 
 
α1[V]3 
α1[V]2.α2[V] 
α1[V]2.α4[V] 
α1[V].α2[V].α3[V] 
α1[XI].α1[V].α3[XI] 
-Fibrillar 
-Isoform exists with type XI chain. 
-Forms heterotypic fibrils with collagen type 
I (17). 
Increased with long term 
loading (15). 
VI 
α1[VI]: 
 
α2[VI]: 
 
α3[VI]: 
 
α4[VI]: 
 
α5[VI]: 
 
α6[VI]: 
 
α1[VI].α2[VI].α3[VI] 
α1[VI].α2[VI].α4[VI] 
-Network 
-Other chains include α4[VI], α5[VI] and 
α6[VI] (18). 
Increased expression in both 
degenerate and ruptured 
human Achilles tendon (11). 
VII α1[VII]: 
 
α1[VII]3 
α1[VII]2.α2[VII] 
-Anchoring fibril 
 
 Collagen formation types: 
FACIT – Fibril associated collagen with interrupted triple helices. 
MACIT – Membrane associated collagen with interrupted triple helices. 
Multiplexin – Multiple triple helix domains and interruptions. 
 
Key: 
1 = Corps et al., 2008. 2 = Jones et al., 2006. 3 = Riley, G., 2008. 4 = Jones et al., 2013. 5 = Maeda et al., 2007. 6 = Maeda et al., 2009. 7 = Legerlotz et al., 2013. 8 = Huisman et al., 2014. 9 = Corps et al., 2012. 10 = Riley et al., 1994. 
11 = Ireland et al., 2001. 12 = Fu et al., 2002. 13 = Riley et al., 2002. 14 = Zhang and Wang, 2010. 15 = Sun et al., 2010. 16 = Han et al., 2010. 17 = Canty and Kadler, 2005. 18 = Fitzgerald et al., 2008. 19 = Wu and Eyre, 1995. 
. 
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Table 4: Summary of Collagen structures, and their involvement in tendinopathies and response to loading. (Information from Ricard-Blum (2011) and Shoulders and Raines (2009) unless 
stated otherwise). Part 3 of 5. 
Type Individual Chain Structures Chain Arrangements Formation type and Associations 
Changes with Loading or 
Tendinopathy 
VIII 
α1[VIII]: 
 
α2[VIII]: 
 
α1[VIII]3 
α2[VIII]3 
α1[VIII]2.α2[VIII] 
α1[VIII].α2[VIII]2 
-Network 
Increased expression in both 
degenerate and ruptured 
human Achilles tendon (11). 
IX 
α1[IX]: 
 
α2[IX]: 
 
α3[IX]: 
 
α1[IX].α2[IX].α3[IX] 
-FACIT 
-Associated with collagen type II fibrils (17). 
 
X 
α1[X]: 
 
α1[X]3 -Network 
 
XI 
α1[XI]: 
 
α2[XI]: 
 
α1[XI].α2[XI].α3[XI] 
α1[XI].α1[V].α3[XI] 
-Fibrillar 
-Isoform with collagen type V chain exists. 
-Forms heterotypic fibrils with collagen type 
II (17). 
-The α3[XI] chain is the same sequence as 
α1[II], however post-translation 
modifications and cross linking differ (19). 
 
 
 
Collagen formation types: 
FACIT – Fibril associated collagen with interrupted triple helices. 
MACIT – Membrane associated collagen with interrupted triple helices. 
Multiplexin – Multiple triple helix domains and interruptions. 
 
Key: 
1 = Corps et al., 2008. 2 = Jones et al., 2006. 3 = Riley, G., 2008. 4 = Jones et al., 2013. 5 = Maeda et al., 2007. 6 = Maeda et al., 2009. 7 = Legerlotz et al., 2013. 8 = Huisman et al., 2014. 9 = Corps et al., 2012. 10 = Riley et al., 1994. 
11 = Ireland et al., 2001. 12 = Fu et al., 2002. 13 = Riley et al., 2002. 14 = Zhang and Wang, 2010. 15 = Sun et al., 2010. 16 = Han et al., 2010. 17 = Canty and Kadler, 2005. 18 = Fitzgerald et al., 2008. 19 = Wu and Eyre, 1995. 
. 
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Table 5: Summary of Collagen structures, and their involvement in tendinopathies and response to loading. (Information from Ricard-Blum (2011) and Shoulders and Raines (2009) unless 
stated otherwise). Part 4 of 5. 
Type Individual Chain Structures Chain Arrangements Formation type and Associations 
Changes with Loading or 
Tendinopathy 
XII 
α1[XII]: 
 
α1[XII]3 -FACIT 
Increased with long term 
loading (15). 
XIII 
α1[XIII]: 
 
α1[XIII]3 -MACIT 
 
XIV 
α1[XIV]: 
 
α1[XIV]3 -FACIT 
 
XV 
α1[XV]: 
 
α1[XV]3 -Multiplexin 
 
XVI 
α1[XVI]: 
 
α1[XVI]3 -FACIT 
Increased expression in both 
degenerate and ruptured 
human Achilles tendon (11). 
XVII 
α1[XVII]: 
 
α1[XVII]3 -MACIT 
 
XVIII 
α1[XVIII]: 
 
α1[XVIII]3 -Multiplexin 
 
XIX 
α1[XIX]: 
 
α1[XIX]3 -FACIT 
 
XX α1[XX]: 
 
α1[XX]3 -FACIT 
 
 Collagen formation types: 
FACIT – Fibril associated collagen with interrupted triple helices. 
MACIT – Membrane associated collagen with interrupted triple helices. 
Multiplexin – Multiple triple helix domains and interruptions. 
 
Key: 
1 = Corps et al., 2008. 2 = Jones et al., 2006. 3 = Riley, G., 2008. 4 = Jones et al., 2013. 5 = Maeda et al., 2007. 6 = Maeda et al., 2009. 7 = Legerlotz et al., 2013. 8 = Huisman et al., 2014. 9 = Corps et al., 2012. 10 = Riley et al., 1994. 
11 = Ireland et al., 2001. 12 = Fu et al., 2002. 13 = Riley et al., 2002. 14 = Zhang and Wang, 2010. 15 = Sun et al., 2010. 16 = Han et al., 2010. 17 = Canty and Kadler, 2005. 18 = Fitzgerald et al., 2008. 19 = Wu and Eyre, 1995. 
. 
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Table 6: Summary of Collagen structures, and their involvement in tendinopathies and response to loading. (Information from Ricard-Blum (2011) and Shoulders and Raines (2009) unless 
stated otherwise). Part 5 of 5. 
Type Individual Chain Structures Chain Arrangements Formation type and Associations 
Changes with Loading or 
Tendinopathy 
XXI 
α1[XXI]: 
 
α1[XXI]3 -FACIT 
 
XXII 
α1[XXII]: 
 
α1[XXII]3 -FACIT 
 
XXIII 
α1[XXIII]: 
 
α1[XXIII]3 -MACIT 
 
XXIV 
α1[XXIV]: 
 
α1[XXIV]3 -Fibrillar 
 
XXV 
α1[XXV]: 
 
α1[XXV]3 -MACIT 
 
XXVI 
α1[XXVI]: 
 
α1[XXVI]3 -FACIT 
 
XXVII 
α1[XXVII]: 
 
α1[XXVII]3 -Fibrillar 
 
XXVIII 
α1[XXVIII]: 
 
α1[XXVIII]3 -Multiplexin 
 
 
  
 
Collagen formation types: 
FACIT – Fibril associated collagen with interrupted triple helices. 
MACIT – Membrane associated collagen with interrupted triple helices. 
Multiplexin – Multiple triple helix domains and interruptions. 
 
Key: 
1 = Corps et al., 2008. 2 = Jones et al., 2006. 3 = Riley, G., 2008. 4 = Jones et al., 2013. 5 = Maeda et al., 2007. 6 = Maeda et al., 2009. 7 = Legerlotz et al., 2013. 8 = Huisman et al., 2014. 9 = Corps et al., 2012. 10 = Riley et al., 1994. 
11 = Ireland et al., 2001. 12 = Fu et al., 2002. 13 = Riley et al., 2002. 14 = Zhang and Wang, 2010. 15 = Sun et al., 2010. 16 = Han et al., 2010. 17 = Canty and Kadler, 2005. 18 = Fitzgerald et al., 2008. 19 = Wu and Eyre, 1995. 
. 
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Table 7: Summary of Human matrix metalloproteinases, and their involvement in tendinopathies and response to loading. (Information collated from reviews Klein and Bischoff (2011), 
McCawley and Matrisian (2001) and Nagase et al. (2006) unless indicated. Schematics of structures from Loffek et al. (2011). Part 1 of 4. 
Name (Traditional Name) General Structure Known Substrates Changes with Loading or Tendinopathy 
MMP-1 (Collagenase-1) 
 
 
Collagen types I, II, III, VII, VIII, X and XI, gelatin, 
vitronectin, α2-macroglobulin, fibronectin, IL-1β, 
aggrecan, versican, perlecan, nidogen, serpins, 
Tenascin-C, IGFBP-3, IGFBP-5, Pro-MMP-1, Pro-MMP-2 
and Pro-MMP-9. 
Increased expression in ruptured human 
Achilles tendon (2). Increased in 
tendinopathy (3,12). Reduced expression 
with loading (4). Increased in ruptured 
human tendons (13). 
MMP-2 (Gelatinase-A) 
 
Collagen types I, III, IV, V, VII, X and XI, and gelatin, 
aggrecan, tenascin, decorin, substance P, fibronectin, 
laminin, IL-1β, elastin, vitronectin, Pro-MMP-1, Pro-
MMP-2 and Pro-MMP-13. 
Increased in tendinopathy (3). Increased 
expression in pathological PTT (9). 
Increased expression in both degenerate 
and ruptured human Achilles tendon 
(11). Increased with long term loading 
(15). 
MMP-3 (Stromelysin-1) 
 
Collagen types III, IV, V, IX, X and XI, gelatin, aggrecan, 
elastin, vitronectin, α2-macroglobulin, tenascin, 
decorin, fibronectin, laminin, E-cadherin, plasminogen, 
perlecan, IL-1β, laminin, Pro-MMP-1, Pro-MMP-3, Pro-
MMP-7, Pro-MMP8, Pro-MMP-9 and Pro-MMP-13. 
Reduced expression in both pathological 
(2,11) and ruptured human Achilles 
tendon (2). Reduced expression in 
pathological PTT (9). Increased in 
ruptured human tendons (13). Reduced 
in tendinopathy (3). Reduced expression 
with loading (4,15). 
 
 
 
 
 
Key: 
1 = Corps et al., 2008. 2 = Jones et al., 2006. 3 = Riley, G., 2008. 4 = Jones et al., 2013. 5 = Maeda et al., 2007. 6 = Maeda et al., 2009. 7 = Legerlotz et al., 2013. 8 = Huisman et al., 2014. 9 = Corps et al., 2012. 10 = Riley et al., 1994. 
11 = Ireland et al., 2001. 12 = Fu et al., 2002. 13 = Riley et al., 2002. 14 = Zhang and Wang, 2010. 15 = Sun et al., 2010. 16 = Han et al., 2010. 17 = Canty and Kadler, 2005. 18 = Fitzgerald et al., 2008. 19 = Wu and Eyre, 1995. 
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Table 8: Summary of Human matrix metalloproteinases, and their involvement in tendinopathies and response to loading. (Information collated from reviews Klein and Bischoff (2011), 
McCawley and Matrisian (2001) and Nagase et al. (2006) unless indicated. Schematics of structures from Loffek et al. (2011). Part 2 of 4. 
 
Name (Traditional Name) General Structure Known Substrates Changes with Loading or Tendinopathy 
MMP-7 (Matrilysin-1) 
 
Collagen types III, IV, V, IX, X and XI, gelatin, aggrecan, 
tenascin, fibronectin, plasminogen, decorin, E-
cadherin, gelatin, laminin, elastin, tenascin, TNF-α, 
IGFBP, Pro-ADAM-28, Pro-MMP-1, Pro-MMP-2, Pro-
MMP-7 and Pro-MMP9. 
Reduced expression in ruptured human 
Achilles tendon (2). 
MMP-8 (Collagenase-2) 
 
Collagen types I, II, III, VII and X, gelatin, tenascin, 
aggrecan and Pro-MMP-8. 
 
MMP-9 (Gelatinase-B) 
 
Collagen types IV, V, VII, XI and XIV, elastin, aggrecan, 
decorin, laminin, Plasminogen, IL-1β, IL-8 and TGF-β. 
Increased expression in ruptured human 
Achilles tendon (2,11). 
MMP-10 (Stromelysin-2) 
 
Collagen types III, IV, V, IX, X and XI, gelatin, fibronectin, 
vitronectin, elastin, tenascin, aggrecan, laminin, Pro-
MMP-1, Pro-MMP7, Pro-MMP-8, Pro-MMP-9 and Pro-
MMP-10. 
Reduced expression in painful human 
Achilles tendon (2). Reduced in 
tendinopathy (3). Increased expression 
with loading (4). 
MMP-11 (Stromelysin-3) 
 
Collagen type VI, gelatin, fibronectin, laminin, aggrecan 
and IGFBP-1. 
Increased expression in both painful and 
ruptured Human Achilles Tendons (2). 
Reduced expression with loading (4). 
MMP-12 (Macrophage 
Elastase) 
 
Collagen type IV, elastin, gelatin, fibronectin, laminin, 
vitronectin, aggrecan and plasminogen.  
Increased expression in painful human 
Achilles tendon (2). Reduced in 
tendinopathy (3). 
 
 
 
Key: 
1 = Corps et al., 2008. 2 = Jones et al., 2006. 3 = Riley, G., 2008. 4 = Jones et al., 2013. 5 = Maeda et al., 2007. 6 = Maeda et al., 2009. 7 = Legerlotz et al., 2013. 8 = Huisman et al., 2014. 9 = Corps et al., 2012. 10 = Riley et al., 1994. 
11 = Ireland et al., 2001. 12 = Fu et al., 2002. 13 = Riley et al., 2002. 14 = Zhang and Wang, 2010. 15 = Sun et al., 2010. 16 = Han et al., 2010. 17 = Canty and Kadler, 2005. 18 = Fitzgerald et al., 2008. 19 = Wu and Eyre, 1995. 
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Table 9: Summary of Human matrix metalloproteinases, and their involvement in tendinopathies and response to loading. (Information collated from reviews Klein and Bischoff (2011), 
McCawley and Matrisian (2001) and Nagase et al. (2006) unless indicated. Schematics of structures from Loffek et al. (2011). Part 3 of 4. 
Name (Traditional Name) General Structure Known Substrates Changes with Loading or Tendinopathy 
MMP-13 (Collagenase-3) 
 
Collagen Types I, II, III, IV, VII, IX, X and XIV, gelatin, 
aggrecan, perlecan, biglycan, tenascin-C, fibrinogen, 
IGF-I, IGF-II, PDGF, BFGF, TGF-β1, IL-1, IL-6, TNF-α, Pro-
MMP-9 and Pro-MMP-13. 
Reduced expression with loading (4,6,15). 
Increased expression in pathological PTT 
(9). 
MMP-14 (MT1-MMP) 
 
Collagen types I, II and III, gelatin, CD44, laminin, 
fibronectin, vitronectin, tenascin, nidogen, aggrecan, 
fibrin, fibrinogen, E-cadherin, N-cadherin, integrins, 
proteoglycans, Pro-MMP-2, Pro-MMP-8 and Pro-
MMP-13. 
Increased expression in ruptured human 
Achilles tendon (2,11) and degenerate 
human Achilles tendon (11). Reduced 
with long term loading (15). 
MMP-15 (MT2-MMP) 
 
Laminin, fibronectin, tenascin, aggrecan, perlecan and 
Pro-MMP-2. 
 
MMP-16 (MT3-MMP) 
 
Aggrecan and Pro-MMP-2. Increased expression in painful human 
Achilles tendon (2). 
MMP-17 (MT4-MMP) 
 
Fibrin, fibrinogen, gelatin, TNF-α, Pro-MMP-2 and Pro-
ADAMTS-4. 
Reduced expression with loading (4). 
MMP-19 (RASI) 
 
Collagen type IV, gelatin, tenascin-C, fibronectin, 
COMP, aggrecan and laminin. 
Increased expression ruptured human 
Achilles tendon (2). 
MMP-20 (Enamelysin) 
 
Aggrecan, COMP and amelogenin.  
 
 
Key: 
1 = Corps et al., 2008. 2 = Jones et al., 2006. 3 = Riley, G., 2008. 4 = Jones et al., 2013. 5 = Maeda et al., 2007. 6 = Maeda et al., 2009. 7 = Legerlotz et al., 2013. 8 = Huisman et al., 2014. 9 = Corps et al., 2012. 10 = Riley et al., 1994. 
11 = Ireland et al., 2001. 12 = Fu et al., 2002. 13 = Riley et al., 2002. 14 = Zhang and Wang, 2010. 15 = Sun et al., 2010. 16 = Han et al., 2010. 17 = Canty and Kadler, 2005. 18 = Fitzgerald et al., 2008. 19 = Wu and Eyre, 1995. 
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Table 10: Summary of Human matrix metalloproteinases, and their involvement in tendinopathies and response to loading. (Information collated from reviews Klein and Bischoff (2011), 
McCawley and Matrisian (2001) and Nagase et al. (2006) unless indicated. Schematics of structures from Loffek et al. (2011). Part 4 of 4. 
Name (Traditional Name) General Structure Known Substrates Changes with Loading or Tendinopathy 
MMP-23 (Femalysin) 
 
Gelatin and Pro-MMP-23. Increased expression in painful human 
Achilles tendon (2). Increased in 
tendinopathy (3). Increased expression in 
pathological PTT (9). 
MMP-24 (MT5-MMP) 
 
Gelatin, fibronectin, vitronectin, aggrecan and Pro-
MMP-2. 
Reduced expression in ruptured human 
Achilles tendon (2). Increased expression 
with loading (4). 
MMP-25 (MT6-MMP) 
 
Collagen type IV, fibrin, fibrinogen, fibronectin, 
proteoglycans, TNF-α and Pro-MMP-2. 
Increased expression in ruptured human 
Achilles tendon (2). 
MMP-26 (Matrilysin-2) 
 
Collagen type IV, fibronectin, fibrinogen, gelatin, 
aggrecan, tenascin and Pro-MMP-9. 
 
MMP-27 
 
Unknown Reduced expression in painful human 
Achilles tendon (2). Reduced in 
tendinopathy (3). 
MMP-28 (Epilysin) 
 
Unknown Reduced expression in ruptured human 
Achilles tendon (2). 
 
 
 
 
 
Key: 
1 = Corps et al., 2008. 2 = Jones et al., 2006. 3 = Riley, G., 2008. 4 = Jones et al., 2013. 5 = Maeda et al., 2007. 6 = Maeda et al., 2009. 7 = Legerlotz et al., 2013. 8 = Huisman et al., 2014. 9 = Corps et al., 2012. 10 = Riley et al., 1994. 
11 = Ireland et al., 2001. 12 = Fu et al., 2002. 13 = Riley et al., 2002. 14 = Zhang and Wang, 2010. 15 = Sun et al., 2010. 16 = Han et al., 2010. 17 = Canty and Kadler, 2005. 18 = Fitzgerald et al., 2008. 19 = Wu and Eyre, 1995. 
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 Table 11: Summary of the structure and substrates of the ADAMTS family, and their relevance in tendinopathies and response to loading. (Information from Lin and Liu (2009) and Porter 
et al. (2005) unless stated otherwise). Part 1 of 2. 
Name  
(Other Names) 
Structure Known Substrates Changes with Loading or Tendinopathy 
ADAMTS-1 
(Aggrecanase-3)  
Aggrecan and versican  
ADAMTS-2 
(Procollagen I N-
proteinase) 
 
Procollagen I, II and III N-propeptides Higher expression in painful human Achilles 
tendon (2). Increased in tendinopathy (3). 
Increased expression with loading (4). 
ADAMTS-3   
Procollagen II N-propeptide Higher expression in painful human Achilles 
tendon (2). Increased in tendinopathy (3). 
ADAMTS-4 
(Aggrecanase-1)  
Aggrecan, brevican, versican, decorin, 
fibromodulin and COMP 
Higher expression in ruptured human Achilles 
tendon (1,2). Increased expression with 
loading (4). 
ADAMTS-5 
(Aggrecanase-2)  
Aggrecan and brevican Lower expression in painful human Achilles 
tendon (2). Reduced in tendinopathy (3). 
Reduced expression in pathological PTT (9). 
Increased expression with loading (4). 
ADAMTS-6   Increased expression with loading (4). 
ADAMTS-7  
COMP, α2-macroglobulin Lower expression in ruptured human Achilles 
tendon (2). 
ADAMTS-8  Aggrecan and Versican  
ADAMTS-9  Aggrecan and Versican  
 
 
 
 
Signal peptide 
Pro domain 
Metalloproteinase domain 
Disintegrin domain 
Thrombospondin type I motif 
Cysteine-rich domain 
Protease and lacunin motif 
Gon-I-like motif 
Cubilin motif 
Spacer region 
Mucin-like domain 
Key: 
1 = Corps et al., 2008. 2 = Jones et al., 2006. 3 = Riley, G., 2008. 4 = Jones et al., 2013. 5 = Maeda et al., 2007. 6 = Maeda et al., 2009. 7 = Legerlotz et al., 2013. 8 = Huisman et al., 2014. 9 = Corps et al., 2012. 10 = Riley et al., 1994. 
11 = Ireland et al., 2001. 12 = Fu et al., 2002. 13 = Riley et al., 2002. 14 = Zhang and Wang, 2010. 15 = Sun et al., 2010. 16 = Han et al., 2010. 17 = Canty and Kadler, 2005. 18 = Fitzgerald et al., 2008. 19 = Wu and Eyre, 1995. 
. 
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Table 12: Summary of the structure and substrates of the ADAMTS family, and their relevance in tendinopathies and response to loading. (Information from Lin and Liu (2009) and Porter 
et al. (2005) unless stated otherwise). Part 2 of 2. 
Name 
(Other Names) 
Structure Known Substrates Changes with Loading or Tendinopathy 
ADAMTS-10   Increased expression with loading (4). 
ADAMTS-12  Aggrecan, COMP and α2-macroglobulin  
ADAMTS-13  Von Willebrand factor  
ADAMTS-14   Procollagen I and II N-propeptides Increased expression with loading (4). 
ADAMTS-15  Aggrecan  
ADAMTS-16  α2-macroglobulin Increased expression with loading (4). 
ADAMTS-17    
ADAMTS-18    
ADAMTS-19  Aggrecan  
ADAMTS-20  Aggrecan  
 
 
 
 
 
Signal peptide 
Pro domain 
Metalloproteinase domain 
Disintegrin domain 
Thrombospondin type I motif 
Cysteine-rich domain 
Protease and lacunin motif 
Gon-I-like motif 
Cubilin motif 
Spacer region 
Mucin-like domain 
Key: 
1 = Corps et al., 2008. 2 = Jones et al., 2006. 3 = Riley, G., 2008. 4 = Jones et al., 2013. 5 = Maeda et al., 2007. 6 = Maeda et al., 2009. 7 = Legerlotz et al., 2013. 8 = Huisman et al., 2014. 9 = Corps et al., 2012. 10 = Riley et al., 1994. 
11 = Ireland et al., 2001. 12 = Fu et al., 2002. 13 = Riley et al., 2002. 14 = Zhang and Wang, 2010. 15 = Sun et al., 2010. 16 = Han et al., 2010. 17 = Canty and Kadler, 2005. 18 = Fitzgerald et al., 2008. 19 = Wu and Eyre, 1995. 
. 
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1.4.3 Tenocyte Response to Loading  
Tendons, as a result of mechanotransduction, respond to mechanical stimuli by changing their 
structure, composition and mechanical properties (Wang, 2006). Given the content of collagen 
type I in tendons and its structural importance, collagen synthesis rates following exercise has 
been explored in tendons in an attempt to understand the relationship between anabolic and 
catabolic triggers. An in vitro study by Maeda et al. (2007) showed that the duration of the time 
that a rat tail tendon undergoes cyclic loading affects the synthesis of collagen by tenocytes 
within. Tendons which experienced 86400 cycles had increased collagen production compared 
to those which underwent 600 cycles (Maeda et al., 2007). Similar results were obtained by 
another study, (Goodman et al., 2004), which observed collagen production changes were 
dependant on age and loads experienced, with more collagen produced in immature tendon 
samples. A study by Miller et al. (2005) investigated collagen synthesis in human tendons after 
1 hr of one-legged kicking exercise and found fractional protein synthesis to increase after 6 
hours, peak at 24 hours and remain elevated after 72 hours (Miller et al., 2005). This is similar 
to the previous experiment by Langberg et al. (1999) where a decrease in Procollagen I C-
terminal peptide (PICP), a collagen type I synthesis marker, was seen during the initial rest 
period after acute exercise, followed by an increase to more than the basal amount after 72 
hours (Langberg et al., 1999). It is likely that during the first 24-36 hours post-acute exercise net 
collagen degradation occurs, however in the subsequent 24-36 hours net collagen synthesis 
follows (Figure 12) (Magnusson et al., 2010).  
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Figure 12: Representative graph of collagen synthesis and degradation up to 72 hours after a bout of acute exercise 
in humans. (Adapted from Magnusson et al. (2010)). 
The collagen synthesis-degradation timeline highlights the potential importance of rest in 
tendon health as continuous exercise will lead to further degradation and less synthesis 
(Magnusson et al., 2010; Reinking, 2012). This is further fortified by studies like Huisman et al. 
(2014) where including resting periods in loading studies increased collagen synthesis. In this 
study tenocytes digested from healthy human hamstring tendons were cultured onto type I 
collagen coated membranes and loaded at 0.1Hz to an average applied strain of 3-5% using the 
Flexcell system. Loading bouts of either 100 or 1000 cycles with 10s rest between bouts showed 
more collagen type I gene expression and more pro-collagen type I protein than continuous 
loading alone (Huisman et al., 2014). Similarly, Scott et al. (2011), saw increased tenocyte 
proliferation with rest periods inserted between loading bouts (Scott et al., 2011).  
TGFβ-1 has been associated with collagen synthesis in tendons, being capable of directly 
inducing collagen type I and collagen type III expression (Heinemeier and Kjaer, 2011). The role 
of TGFβ-1 has more specifically been implicated in the mechanotransduction signalling pathway 
of human tenocytes as the addition of TGFβ-1 seems to invoke a similar gene expression 
response to that created by the application of strain (Jones et al., 2013). This was particularly 
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evident with ADAMTS-5 where combining both loading and TGFβ supplementation increased 
expression more than loading alone. A previous study by Goodman et al. (2004), interestingly 
found the effect of TGFβ differed depending on the type of equine tendon the tenocytes were 
sourced from, i.e. from the energy storing SDFT or the positional CDET. The cultured mature 
CDET tenocytes showed increased proline incorporation and up-regulation of type I and type III 
collagen proteins with the addition of TGFβ-1 whereas the mature SDFT tenocytes only showed 
increased proline incorporation with the addition of TGFβ-1 (Goodman et al., 2004). Further 
studies using TGFβ inducible early gene (TIEG) knockout mice found that after tendon damage 
collagen type I expression was initially reduced in the knockout relative to the wild type, 
however expression became similar after 3 days (Tsubone et al., 2006). Therefore, although 
TGFβ is found to be related to collagen and the mechanotransduction signalling pathway, its 
involvement in tenocyte behaviour is still unclear.   
Scleraxis expression is often used as an indicator for the tenocyte phenotype (Busch et al., 2013; 
Fong et al., 2013; Morita et al., 2013; Qiu et al., 2013; Schulze-Tanzil et al., 2004; Scott et al., 
2011; Wagenhauser et al., 2012) and may be required for embryonic tendon differentiation 
(Schweitzer et al., 2001), although its specificity to tendons has been questioned (Benjamin et 
al., 2008; Scott et al., 2011). Other proposed tendon markers include tenomodulin, tenascin-C 
and Mohawk (James et al., 2008; Scott et al., 2011). Scleraxis has been reported to regulate 
collagen type I expression (Fong et al., 2013; Lejard et al., 2007), and knocking down scleraxis 
in tenocytes within collagen gels has shown reduced collagen density, while applying load 
maintains scleraxis expression (Scott et al., 2011) or causes up-regulation (Huisman et al., 2014).  
Fatigue testing of tendon fascicles has shown microdamage and altered fascicle 
micromechanics (Thorpe et al., 2014). Studies replicating fatigue loading with rat patellar 
tendons have observed an up-regulation of collagen type III and collagen type V expression and 
down-regulation of collagen type I expression, which in combination signifies a possible 
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catabolic response (Andarawis-Puri and Flatow, 2011; Sun et al., 2010). Bovine and equine 
tendon fascicles tested with in vitro overload models have shown inflammatory markers IL-6 
and COX-2 are expressed by tenocytes post loading, along with up-regulation of MMP-13 
(Spiesz et al., 2015; Thorpe et al., 2015a). IL-6 has also been suggested to regulate TGFβ activity 
in a dose dependent manner (Zhang et al., 2005) and possess other roles in addition to both 
pro- and anti-inflammatory functions (Heinemeier and Kjaer, 2011; Scheller et al., 2011). Bovine 
tenocytes have been seen to increase IL-6 expression (Langberg et al., 2002; Legerlotz et al., 
2013) while IL-6 itself has seen to stimulate collagen synthesis (Andersen et al., 2011). 
Studies such as Jones et al. (2013) have focused on metalloproteinase expression in tenocytes 
as a response to loading, to identify instigators for anabolic or catabolic behaviours and those 
involved in tendinopathies. In a collagen gel system with human tenocytes, 5% cyclic strain 
down-regulated MMP-1 and MMP-13 gene expression after 24 hours loading while COL-1A1 
was up-regulated (Jones et al., 2013). Tenocytes seeded on stiffer substrates have also been 
shown to down-regulate MMP-1 gene expression although no change in collagen type I 
expression was observed (Maeda et al., 2013a). Increase in collagen type 1 expression has been 
seen when loading fascicles from bovine extensor tendons (Legerlotz et al., 2013) and human 
tenocytes in a flexcell system (Huisman et al., 2014). Collagen type III expression has been seen 
to increase with cyclic loading of rat tail fascicles for 6 hours, up regulation of MMP-3 if loaded 
for 10 minutes and down regulation of MMP-13 if loaded continually for up to 24 hours (Maeda 
et al., 2009). Other studies have seen very little to no change with loading but could likely be 
attributed to differences in methods (Steiner et al., 2012). 
The changes with loading and chemical stimuli discussed in this section, along with changes 
seen in tendinopathies, are summarised in Table 13. This information emphasises the 
complexity of interactions and uncertainty of roles of gene expression and protein level changes 
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observed during tendon loading. Therefore there is a need for further systematic investigation 
of tenocyte behaviour under physiological conditions to better understand these changes. 
Table 13: Summary of changes seen due to tendinopathy, loading or chemical stimuli. 
Tendinopathy 
Loading 
Chemical 
Stimulus 
In Vivo In Vitro  
Cellularity increased 1,2,3,4  
Matrix degeneration 1,2,3,4  
Neovascularisation 1,2,3,4  
Collagen type I increased 5,6,10 
Collagen type III increased 5,12 
Aggrecan increased 5,6 
Biglycan increased 5,6 
MMP-2 increased 5,6 
MMP-13 increased 5,6 
MMP-3 decreased 5,6 
ADAMTS-5 decreased 5,6 
Versican decreased 7  
Tenascin-C increased 8 
MMP-1 increased 3 
TIMP-1 decreased 3 
TIMP-3 decreased 9 
ADAM-1 increased 9 
MMP-11 increased 9 
IL-6 increased 10 
NO increased 11 
Collagen synthesis 
increased 13 
Collagen type I 
increased 14 
Collagen type III 
increased 18,19  
Collagen type V 
increased 18,19 
 
Proliferation 
increased 17 
Collagen synthesis 
increased 16,30 
Collagen type I 
increased 15,16,22,23 
Collagen type III 
increased 16,24  
IL-6 increased 20,21,29 
COX-2 increased 20,21 
MMP-1 decreased 22 
MMP-13 decreased 
22,24  
MMP-3 increased 24   
Scleraxis increased 
15,17  
 
Effect of NO:  
Increased collagen 
synthesis 25 
 
Effect of TGFβ:  
Increased collagen 
type I 16,26, collagen 
type II 16,26, 
ADAMTS-5 22, and 
cell proliferation 16. 
Collagen synthesis 
also initially 
decreased 27. 
 
Effect of IL-6: 
Increased collagen 
synthesis 28 
 
1) Busch et al. (2013), 2) Tallon et al. (2001b), 3) Fu et al. (2002), 4) Khan et al. (1999), 5) Corps et al. (2012), 6) Corps 
et al. (2006), 7) Corps et al. (2004), 8) Ireland et al. (2001), 9) Jones et al. (2006), 10) Legerlotz et al. (2012), 11) Szomor 
et al. (2006), 12) Riley et al. (1994b), 13) Miller et al. (2005), 14) Langberg et al. (1999), 15) Huisman et al. (2014), 16) 
Goodman et al. (2004), 17) Scott et al. (2011), 18) Sun et al. (2010), 19) Andarawis-Puri and Flatow (2011), 20) Spiesz 
et al. (2015), 21) Thorpe et al. (2015a), 22) Jones et al. (2013), 23) Legerlotz et al. (2013), 24) Maeda et al. (2009), 25) 
Xia et al. (2006), 26) Yang et al. (2004), 27) Tsubone et al. (2006), 28) Andersen et al. (2011), 29) Langberg et al. 
(2002), 30) Maeda et al. (2007). 
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1.5 Platforms for Tenocyte Study 
The behaviour of tenocytes in response to loading and chemical stimuli discussed in the 
previous section were investigated by researchers using a number of different in vitro and in 
vivo systems. This in itself has been one of the underlying problems in characterising tenocyte 
behaviour under physiological conditions and is discussed here.  
One common in vitro platform currently used is the Flexcell system. This commercial system 
combines a flexible membrane and a vacuum to provide a means for applying tension to cells 
(depicted in Figure 13). Flexcell culture plates, custom 6 well plates containing flexible bottom 
membranes, are first coated with a protein of choice. This is usually collagen type I in the case 
of Flexcell studies performed with tenocytes (Arnoczky et al., 2002b; Backman et al., 2011; 
Goodman et al., 2004; Huisman et al., 2014). Plates can be seeded with cells and positioned on 
top of loading posts (Figure 13a). Strain is applied via a programmable computer controlled 
vacuum under the cell seeded membranes. Generating a vacuum stretches and pulls the 
membrane down around the loading post, which in turn strains the cells attached to the 
membrane surface. Cyclic loading can be performed by modulating the vacuum to release and 
re-stretch the membrane. The mode of strain can be changed depending on the shape of the 
loading post; an equibiaxial strain can be applied using round posts or a largely uniaxial strain 
can be applied using rectangular (Arctangle®) loading posts. 
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Figure 13: a) Flexcell system components including loading posts and custom culture plates with flexible 
membrane bases. b) Equibiaxial strain is applied to cells by controlling a vacuum which stretches the cell seeded 
membrane around a circular loading post. Uniaxial strain is applied by using rectangular (Arctangle®) loading 
posts. (Adapted from Frazer et al. (2009) and Backman et al. (2011)). 
Although the Flexcell system is highly controllable and conditions reproducible, one obvious 
problem with this method is the limitation to a 2D mechanical environment. As cells are 
essentially a monolayer on the surface of the membranes, only strain is experienced by cells 
while shear is completely absent. Consequently, the cellular environment becomes significantly 
different to the 3D cellular environment of tendons, leading to reduced suitability of such 
systems in tendon research. 
a) 
b) 
Gasket BioFlex Culture Plate 
BioFlex Loading Stations 
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Indeed, due to the above limitation, a more 3D environment has been incorporated into the 
Flexcell system through the use of collagen gels on the surface of the membrane (schematic 
shown in Figure 14). Collagen constructs are fabricated within moulds in a 6 well plate. The 
mould is placed under the membrane and a vacuum applied to pull the membrane into the 
mould. A solution of collagen and cells can then be injected into the depression created and 
polymerised to form a 3D collagen gel. The vacuum is then released and the mould replaced 
with a loading post to allow strain application to the construct as described previously.  
 
 
Figure 14: Flexcell system for 3D collagen gels (Tissue Train® Culture System). A trough loader is used as a mould 
around which the flexible membrane can be pulled. The collagen and cell solution is then added to the trough bay 
created, which can then be polymerised to create a collagen gel anchored into the Flexcell system. Uniaxial loading 
is then performed using the Arctangle® loading post. (Adapted from Banes et al. (2009)). 
Mould (Trough loader) 
Collagen gel construct 
Arctangle loading post 
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This system has been used in tendon related research (Garvin et al., 2003; Jones et al., 2013). 
However, although a 3D cellular environment is created, it is not necessarily the same as that 
found in tendons due to the nature of collagen gels produced. The properties of simple collagen 
gels made in vitro, such as fibril diameter, length and density can be altered by changing 
parameters such as gelation temperature, collagen concentration and solution pH (Yang et al., 
2009; Yang et al., 2010). However, collagen fibres made in this manner still remain randomly 
orientated and thus present cells with a microenvironment starkly different to that found in 
tendons. Although some degree of fibre orientation can be induced through strain application 
(Vader et al., 2009), the lack of controlled fibre orientation in simple collagen gels leads to 
varying levels of tension transferred to cells during loading and an uncontrolled cellular shear 
environment.  
The application of controlled shear has been achieved in some studies through the use of fluid 
shear. Maeda et al. (2013b) developed a system to apply controllable amounts of shear and 
tension to tenocytes (Figure 15). The system applied tension to a flexible cell seeded 
microgrooved membrane, with the microgrooves present to keep cells isolated in rows. Fluid 
was then moved across the surface of the cells at a controlled speed, with both tension and 
fluid flow applied in a uniaxial direction. However, this system was aimed at investigating 
interstitial fluid flow (Maeda et al., 2013b) and hence does not replicate the physiological shear 
generated by the movement of collagen fibres and fascicles in tendons.  
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Figure 15: Tension and fluid shear strain system developed by Maeda et al., (2013). a) A Cell seeded microgroove 
membrane is placed within a concealed flow chamber. b) Fluid shear is created through moving medium from the 
inlet to the outlet, and cyclic strain is simultaneously created through stretching the membrane. (Adapted from 
Maeda et al. (2013b)). 
Explants and in vivo models have been used in studies as an alternative to in vitro systems, 
overcoming the inability of current in vitro systems to appropriately recreate the physiological 
cellular environment in terms of tension and shear. For example, Fung et al. (2010) and 
Andarawis-Puri and Flatow (2011) employed a rat model (Figure 16) to investigate fatigue 
damage response in rat patellar tendons. However, although having the correct physiological 
environment, there are many difficulties with such systems. Firstly, it is extremely difficult to 
translate such methods into human models with ethical approval. The use of biological tissue 
also causes challenges as natural variations in structure and composition cannot be accounted 
for, reducing the reproducibility of experiments. Moreover, the use of biological tissue limits 
the amount of control a researcher has on the shear condition; the tissue provides the 
physiological tendon environment but the extent of cellular shear cannot be altered easily. 
Consequently the effect of varying magnitudes of shear on cellular behaviour cannot be 
investigated methodically. Other systemic changes also make it almost impossible to unravel 
exactly how the cells respond to a certain load condition. 
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Figure 16: In vivo model used to fatigue load rat patellar tendons. The patellar tendons of anesthetised rats are 
connected to a load cell while the tibia is connected to a fixed clamp. (Adapted from Fung et al. (2010)). 
Overall, there is currently no sufficiently controlled in vitro environment in which the cell 
response to precise, known levels of shear and tension can be investigated. The primary aim of 
this project was to address this need and provide a platform from which a host of physiologically 
representative mechanobiology questions can be addressed. Specifically, by developing a 
system more representative of physiological tendon conditions and with the ability to control 
the amount of tension and shear, tenocyte behaviour can be investigated more closely in a 
reproducible manner, helping to better understand the aetiology of tendinopathy.Aim, 
Objectives and Hypothesis 
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1.6 Project aim, objectives and hypothesis 
1.6.1 Aim 
To develop a system able to create and tightly control cellular shear-tension ratios, allowing the 
investigation of shear-tension ratio effects on tenocyte gene expression, particularly genes 
related to matrix turnover. 
 
1.6.2 Objectives 
 Create a system capable of controlling cellular shear and tension. 
 Confirm the system can incorporate and maintain viable cells. 
 Characterise the micromechanics and gross mechanics of the system to establish the 
range of shear-tension ratios producible. 
 Ensure local mechanisms can recapitulate the physiological shear-tension ratio found 
in tendons (~40% of the applied strain transferred to fibre strain), as well as non-
physiological high tension and high shear conditions. 
 Test the effects of the shear-tension ratios on tenocyte gene expression. 
 
1.6.3 Global Hypothesis 
It is hypothesised that the shear-tension ratio is a mechanical cue sensed by tenocytes, involved 
in regulating tenocyte gene expression. Shear-tension ratios above and below those found 
physiologically in tendons will affect matrix related gene expression in tenocytes, and play a 
role in tendon homeostasis and tendinopathy development. 
Chapter 2   
 
Section 2.1 - Biocompatible Materials 72 
 
 
Fibre Composite System Development 
: Fibre Composite System Development 
 
This chapter will focus on the development of the fibre composite system used to expose cells 
to both shear and tension. First some conventional materials used with cells will be briefly 
reviewed to provide context for the materials adapted in this study. This is followed by the 
concept of fibre composites, a review of a fibre composite system previously published and 
finally its further development into a functional system.  
 
2.1 Biocompatible Materials 
A simple method to narrow down potential materials for use with cells is to focus in on materials 
typically used for tissue engineering associated scaffolds as these have already been identified 
as biocompatible, avoiding material derived toxic effects. Scaffolds are defined as structures 
that provide mechanical support in addition to promoting cellular infiltration (O'Brien, 2011). 
Materials currently used for scaffolds range from synthetic to naturally available degradable 
and non-degradable materials which can be used in vivo and in vitro. Materials currently used 
in clinical treatments tend to be resorbable as non-resorbable scaffolds lead to poor clinical 
performance (Ma and Elisseeff, 2005).  
In addition to mechanical and chemical stimuli, cellular activity is also affected by the material 
surface. Hence, although a material may have the required gross mechanical properties, if the 
surface does not provide the relevant surface to promote cellular activity or provides incorrect 
strains at cellular level then the material becomes inadequate. This problem can in some cases 
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be addressed through surface modification which can be achieved through protein coating, 
peptide attachment, micro-patterning, or plasma (glow discharge) treatment.  
 
There are two main categories of scaffold materials; natural and polymers. Both materials have 
their individual advantages and disadvantages due to the way they can be produced and their 
components, some of which will now be reviewed. 
 
2.1.1 Natural Materials 
The purpose of this section is to provide a feel for some natural materials available and their 
advantages and disadvantages. Hence a full materials review is not provided and only the two 
most commonly used natural scaffolds are discussed: a distinctive form of extracellular matrix 
(ECM) and different forms of collagen. 
Extracellular Matrix (ECM) 
The extracellular matrix (ECM) is the material surrounding cells and is frequently used for tissue 
engineering in altered states. ECM typically consists of fibrillar proteins (mainly collagen and 
fibronectin), GAGs, and glycoproteins. A common form of ECM used as a scaffold is 
decellularised xenogeneic ECM. This form is typically used for skin grafts and has very good 
biocompatibility since the cellular antigens are removed in the decellularising process, thus 
eliminating a foreign body response (De Boer et al., 2008). ECM also degrades over time and 
due to its composition can also be resorbed by the body. The rate of degradation varies 
depending on the presence of chemical cross links, with fewer cross links resulting in quicker 
degradation.  
An ECM scaffold is prepared by decellularising the matrix through a combination of mechanical, 
physical and enzymatic processes and results in the removal of cellular and nuclear material (De 
Boer et al., 2008). Although ECM can be available with many different mechanical properties, 
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their load bearing capabilities are inadequate when it comes to replicating tendon function and 
therefore one layer of ECM is not enough for any purpose which is mechanically demanding. 
One solution for this inadequacy is through the use of multiple layers of ECM which is achieved 
by laminating hydrated sheets of the ECM under a vacuum (Badylak et al., 2005).  
Another problem associated with using ECM or other natural materials in cellular studies is the 
remodelling capability of the material. ECM is considered a dynamic material as cells are able 
to extensively remodel it, consequently causing changes to the mechanical properties of the 
ECM over time (Gattazzo et al., 2014). This is beneficial for tissue engineering approaches as 
cells can help recreate the target tissue composition and structure, however this aspect also 
means the mechanical conditions of experimental samples cannot be kept constant for 
mechanotransduction studies, making the use of ECM for such studies unsuitable. 
Collagen gels and sponges 
The close arrangement of the polypeptide chains and the helices in collagen give rise to high 
tensile strength of collagen networks as stated previously in Chapter 1.  
Collagen matrices have been used extensively in medical applications such as wound dressing 
and artificial skin due to the minimal inflammatory and antigenic response by the body. 
However the clinical applications of these matrices have been limited, due to their relatively 
low mechanical properties, fast degradation and the risk of viral infection when implanted into 
the human body (De Boer et al., 2008). Although there are disadvantages in using collagen, 
there are many collagen scaffolds still being used. 
Collagen platforms are limited in their manufacturing methods due to the low thermal stability 
resulting from the proteins. Hence they cannot be processed via melt-based techniques and 
rely on solvent based techniques. One common form of collagen used is gel. Collagen gels do 
not have a pre-defined shape due to their high water content and therefore can be made into 
Chapter 2 Fibre Composite System Development  
 
Section 2.1 - Biocompatible Materials 75 
 
any desired shape by using a mould. This allows them to provide a flexible environment and 
allows the possibility for the encapsulation of isolated cells. Due to their gel nature and non-
orientated collagen fibres they are usually applied in conditions where initial mechanical 
function is not a requirement (Dumitriu, 2001), hence are commonly used in drug and cell 
delivery. This is done by mixing the required chemicals or cells with the gel which can then be 
either injected or implanted into the intended tissue site. The gels allow the steady release of 
encapsulated contents (the drugs or cells) through degradation. The release rate is therefore 
directly proportional to the degradation rate and requires the structure of the collagen gels to 
be customised to attain suitable degradation rates.  
Sponges are another form of collagen with better mechanical stability, hence are often applied 
in more mechanically demanding situations. Collagen sponges have been seen to promote 
collagen production by cells (Ma and Elisseeff, 2005). One factor which affects cell growth and 
migration is the pore size. The pore sizes are regulated by controlling the manufacture 
techniques, such as freeze-drying, or by the degree of cross linking. Similarly the mechanical 
properties have also been seen to improve if the cross linking is conducted in a de-hydrothermal 
process (Lewandrowski et al., 2002). Generally, an increase in the intermolecular cross links 
results in an increased degradation time, since the collagen becomes less vulnerable to 
enzymatic attack, and also reduces the absorption capacity of water and increases its tensile 
strength (Lanza et al., 2000).  
Both collagen sponges and gels have been used in a wide variety of scaffolds for various 
applications including cardiovascular valves, bone, cartilage, skin and periodontal ligaments 
connected to teeth (guided tissue regeneration). For these different applications, different 
methods are needed when processing the collagen. This is another advantage of collagen based 
systems as there are many side groups such as carboxylic, amino and hydroxylic groups, which 
consequently result in a wide range of possible chemical modifications. The processing of 
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collagen for the situations stated above include freeze-drying, with crosslinking occurring by 
thermal-dehydration, or by crosslinkers such as hexamethylenediisocyanate, carbodiimides and 
1,6-diisocyanatohexane, gelation at various temperatures and solvent evaporation. 
Although natural materials are biocompatible and used in some medical applications as 
described above, the mechanical properties are generally poor for load bearing situations. For 
the composite system specifically, there is a need for a material where its mechanical properties 
can be altered and are homogenous. This is a problem for the natural materials described, with 
collagen gels known to have problems with reproducibility and homogeneity (Plant et al., 2009). 
Additionally, optical transparency of the material is a beneficial aspect not provided by either 
ECM or collagen based gels. A transparent system would allow characterisation and 
investigation of cells encapsulated within, thus providing extra versatility for the system where 
future studies can investigate cell loading in conjunction with morphological changes or explore 
load mediated pathways such as calcium signalling (Wall and Banes, 2005). In summary, the 
limited fabrication options alongside the mechanical malleability and inhomogeneity in 
common natural materials leave them unsuitable for the current application. 
 
2.1.2 Synthetic Polymers 
Similar to the Natural Materials section, the purpose of this section is to touch on advantages 
and disadvantages of some synthetic polymers. Hence a full materials review is not provided, 
but a few common polymers reviewed. 
Synthetic polymers are commonly used as scaffold materials due to their ease of fabrication 
and reproducibility compared to natural materials, which is especially valuable when scaffolds 
are made in large scales. 
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Poly (lactic-co-glycolic acid) (PLGA) 
Poly (lactic-co-glycolic acid) (PLGA) is a commonly used biodegradable copolymer with good 
biocompatibility and biodegradability. The degradation rate of PLGA can be controlled by 
altering the content ratio of polyglycolic and polylactic acid (PGA and PLA) and hence allows the 
possibility to create PLGA for specific applications. The rate control mechanism is mainly due to 
the methyl group in PLA making it more hydrophobic than PGA and hence more resistant to 
hydrolytic attack; hence a higher ratio of PLA results in a slower rate of degradation (Laurencin 
and Nair, 2008). The properties of PLGA also differ depending on composition, but they typically 
possess a Young’s modulus between 2-7 GPa (De Boer et al., 2008). 
Although the control of degradation is beneficial in PLGA, it also surfaces as a disadvantage due 
to the nature of the resulting products. Lactic and glycolic acids are released when PLGA is 
hydrolysed; acids also present in metabolic pathways. The bulk degradation of PLGA results in 
the deposition of large quantities of both acids and causes the immune system to respond with 
local inflammation (De Boer et al., 2008). Another disadvantage of PLGA scaffolds is the low 
cellular adhesion. This is once again partly due to the hydrophobic nature of PLA which causes 
the surface of PLGA to also be hydrophobic and hence does not promote cell attachment. 
However, there are methods to overcome this in the form of surface treatments which are 
discussed later. 
There are different ways to produce a PLGA scaffold such as using a mould or through the use 
of computer controlled micropositioner systems. Both these methods have been used in the 
construction of microfabricated scaffolds (Vozzi et al., 2002). The micropositioner with micro-
syringe deposition method can be used with a number of different polymers and utilises a three 
axis micropositioner connected to a computer. A micro-syringe provides an extremely fine tip 
and hence the whole computer based system can achieve a precision of about 0.1 µm. The 
second method uses ‘soft lithography’ approaches. A poly-dimethylsiloxane (PDMS) mould is 
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soaked in a PLGA solution, put in a vacuum to allow the PLGA to displace any air present and 
then exposed to UV light (Vozzi et al., 2002). Both methods produce usable PLGA scaffolds but 
approach the problem differently. The micro-syringe method produces scaffolds with high 
precision and the procedure allows the production of exact duplicate scaffolds. However, with 
the use of a machine and computer designed scaffolds, this method becomes expensive and 
takes time to produce large batches. The second micro mould technique has the advantage of 
creating a mould quickly which can be used repeatedly for a faster turnover as compared to the 
previous method. However, with the increase in speed and decrease in cost, there is a loss in 
accuracy; the scaffolds produced will not be exactly the same as the mould or to the 
next/previous scaffold produced. 
Poly (2-hydroxyethylmethacrylate) (PHEMA) 
Poly (2-hydroxyethylmethacrylate) (PHEMA) is a thermoset hydrogel with good 
biocompatibility which has been used in a variety of medical applications in the past. PHEMA is 
also a non-degradable material and hence it cannot be broken down by the mechanisms of 
hydrolysis (even in the presence of strong acids and alkali) or by enzymatic activity (Schiraldi et 
al., 2004). However, through the use of different crosslinkers, such as those based on divinyl-
functionalised acetal, it is possible to produce degradable PHEMA (Bulmus et al., 2007). 
Although PHEMA is considered biologically inert, it is still permeable to metabolites meaning it 
can be used to serve many roles, thus leading to it popularity as a biomaterial. 
The synthesis and polymerisation of PHEMA was first conducted in the early 1960’s by Otto 
Wichterie and Drahoslav Lim which was followed by great interest and many experiments. One 
of the more successful uses of PHEMA is in contact lenses, with the first commercial contact 
lenses being sold in 1971 by Bausch and Lomb (De Boer et al., 2008). PHEMA is still currently 
being used in some contact lenses with its success due to the transparent nature of the hydrogel 
and its permeability. 
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The properties of PHEMA gels can change depending on how they are prepared, the polymer 
volume fraction and the temperature. For example, if HEMA monomers are polymerised in a 
waterless environment, the resulting PHEMA has a glassy look and hardness comparable to that 
of bone (Filmon et al., 2002), whereas if the PHEMA is swollen in water they become softer 
depending on the water content and can have an opaque appearance (De Boer et al., 2008). 
The first PHEMA scaffolds which used this opaque variant were termed ‘sponges’ and were seen 
to allow cells to penetrate into their pores. They also had the added advantage of withstanding 
autoclaving and the ability to be formed into different shapes (ideal for soft tissue 
replacements). Clinical trials were conducted where PHEMA variants were used as a breast 
implant material. However, the scaffolds were found to undergo calcification in long term in 
vivo environments preventing further development in this area (De Boer et al., 2008). 
The effect of cross linking agents in PHEMA polymerisation have been explored previously by 
studies such as that by Mabilleau et al. (2006). It was seen that the Young’s modulus of hydrated 
PHEMA can vary from 1.83 ± 0.07 MPa to 18.03 ± 1.36 MPa while the dehydrated state gave a 
Young’s modulus ranging from 696.44 ± 5.55 MPa to 923.77 ± 5.00 MPa. These samples were 
prepared using benzoyl peroxide as the initiator, adding ascorbic acid as an accelerator and 
heating to 50°C for 2 hours (Mabilleau et al., 2006). There are a few methods to polymerise and 
make PHEMA scaffolds along with many choices of cross linkers. These cross linkers include 
ethylene glycol dimethacrylate, 3-oxapentamethylene dimethacrylate, 2,3-
dihydroxytetramethylene or trimethylolpropane trimethacrylate (Salamone, 1996).  
One method to prepare PHEMA is phase separation. Thermally induced phase separation (TIPS) 
has been used in tissue engineering to produce many scaffolds including those consisting of 
PHEMA. This technique uses the lowering of the temperature to reduce the solubility of the 
polymer and hence produce the scaffolds. There are two types of TIPS which are known as 
liquid-liquid phase and solid-liquid phase separation.  
Chapter 2 Fibre Composite System Development  
 
Section 2.1 - Biocompatible Materials 80 
 
The liquid-liquid phase method is a result of the heated homogenous polymer solution 
separating into two polymer concentrations, high and low, as it cools. These two regions result 
in different structures with the high concentration area crystallising to create dense foams while 
the less concentrated region forms a highly porous material. The result of varying 
concentrations can be seen in Figure 17. The solid-liquid phase technique is similar to the 
aforementioned phase separation method except it is used when the freezing point of the 
polymer is higher than the liquid-liquid phase separation temperature, and hence the polymer 
solidifies whilst in the homogenous state when the temperature is lowered (Ma and Elisseeff, 
2005). 
 
Figure 17: Illustration of the resulting three fabrication types with phase separation. a) Powder. b) Continuous 
networks. c) Foam with closed pore. (Adapted from Ma and Elisseeff (2005)). 
Another method to polymerise HEMA is by photopolymerisation. There are three requirements 
in photopolymerisation; electromagnetic radiation, chromophore-containing photoinitiators 
and monomers containing groups such as styrene, acrylate or methacrylate (vinyl groups) 
(Wnek and Bowlin, 2004). Specific wavelengths of visible light (400-800nm) and ultraviolet light 
(190-400nm) can be used in the polymerisation, with the required wavelength depending on 
the photoinitiator used. The role of the photoinitiator is to create reactive free radicals to 
initiate the polymerisation of the monomers. As light is needed, this method requires 
Chapter 2 Fibre Composite System Development  
 
Section 2.1 - Biocompatible Materials 81 
 
transparent moulds/surfaces in the fabrication process to allow light to pass through with 
sufficient intensity. 
The mechanical properties of PHEMA can be customised to be suited for different applications 
with different structural requirements (e.g. requirements differ when used in contact lenses 
and bone scaffolds). The different methods described for manufacturing PHEMA based 
materials also provides a degree of manufacture flexibility. For example, if any toxic or 
unwanted side effects are encountered due to the additives, a different method for production 
can be used. 
Poly (ethylene glycol) (PEG) 
Poly-(ethylene glycol) (PEG), also known as Poly-(ethylene oxide) (PEO), is another commonly 
used hydrogel and consists of two hydroxyl group terminals. PEG is readily soluble in water and 
many organic solvents, and the hydrophilic nature of PEG has commonly led to its use as a 
dehydrating agent in studies (Rigozzi et al., 2013). The end groups of PEG can be easily modified 
allowing the possibility for many synthetic reactions such as acryloyl chloride or methacryloyl 
chloride with triethylamine to produce photoreactive vinyl group (Ifkovits and Burdick, 
2007).The properties of PEG itself differ depending on its molecular weight. For example, the 
compressive modulus is seen to be around 34.2 ± 3.3 kPa for 4600 g/mol PEG where as a 
molecular weight of 10000 g/mol reduces the compressive modulus to 18.6 ± 2.4 kPa (Ostroha, 
2006). 
Two common techniques to produce cross linked PEG networks are chemical cross linking and 
radiation cross linking (Ratner and Bryant, 2004). Chemical cross linking can be achieved using 
the hydroxyl groups present. For example, PEG can be mixed with a triol and a diisocyanate to 
produce the polymers in a dehydrated state. Catalysts such as tin can also be used for the cross 
linking process but the toxic affects need to be taken into account when considering this 
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method for biological use (Harris, 1992). Radiation cross linking is a method which produces 
water swollen polymers and is a preferred technique as the addition of potentially toxic cross 
linking agents are not required.  
PEG is usually used in producing polymer blends or copolymers. This is done to increase the 
hydrophilicity, biocompatibility or softness of the resulting material. These hydrogels have very 
different properties depending on the type of blend made. For example, poly (propylene 
fumerate-co-ethylene glycol) has been used for cardiovascular applications but, with further 
modifications using pore forming agents and cell adhesive ligands, the resulting porous scaffold 
can be used for bone tissue engineering. Degradable PEG based polymers can also be produced 
similar to oligo (polyethylene glycol) fumerate which has been used in guided tissue 
regeneration (Ratner and Bryant, 2004). 
Many different PEG based hydrogels can be made, and its extensive use in cell based 
applications ensures PEG is viewed as a versatile material in the medical field especially since it 
can be used to alter biocompatibility of other materials (i.e. through PEG coating), allows 
nutrient diffusion and has a wide range of possible chemical modifications including the 
coupling of proteins and peptides (Leslie-Barbick et al., 2009; Roberts et al., 2002). 
In summary, the customisable chemistry and mechanical properties of synthetic polymers 
provide an advantage over natural based materials. The synthetic materials can also be made 
with varying degrees of optical transparency which many natural materials lack. The 
biocompatibility benefit of natural materials can be matched with some synthetic polymers as 
described above, therefore overall some synthetic polymers, such as PHEMA and PEG, are ideal 
versatile materials which can be used in the fibre composite system. 
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2.2 Fibre Composite Concept 
A composite material is known as a “material made by dispersing particles of one or more 
materials in another” (Piggott, 2002), hence forming a continuous network.  Although the 
properties of the individual materials involved in a composite material remain unchanged, in 
some instances the overall material property may be considerably different. Composites can be 
characterised into two main categories; Particulate Composites and Fibrous Composites. The 
mechanical properties of fibrous composites tend to be better than particulate composites due 
to their long fibre like components and some polymer-fibre composites are known to have 
stiffness and strength equivalent to metals (Ratner and Bryant, 2004).  The different types of 
classifications and sub-classifications are illustrated below in Figure 18.  
 
Figure 18: The different classifications of composite materials with the branch best describing tendons indicated 
in green. (Adapted from Ratner and Bryant (2004)). 
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Tendons can be classified as a composite material at the molecular and micro-structural level 
(Ratner and Bryant, 2004). More specifically, tendons can be described as natural multilevel 
fibre composites classified as a fibre-reinforced composite with discontinuous fibres in a 
preferred orientation (Figure 18). Therefore an ideal way to imitate their behaviour is by the 
use of such fibre composites.  
 
2.2.1 The effect of Fibre Orientation 
 
The organisation of the collagen fibres and their bonds (both inter and intramolecular), play a 
vital role in providing the known tensile strength of tendons. The effect of fibre organisation is 
also seen in fibrous composite constructs.  
The theoretical curve in Figure 19 for the Young’s modulus in composites depends on the angle 
(θ) at which the fibres are orientated with respect to the direction of load - the difference 
between the principle fibre direction and the stress direction.  
 
 
 
 
 
  
Figure 19: Graph and schematic drawing showing the effect of fibre orientation. The graph shows the change in 
Young’s modulus against the angle 𝛉, while the diagram depicts how 𝛉 is measured. (Adapted from Hancox 
(1981)). 
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It can be seen that as the fibre orientation changes, the Young’s modulus exhibited by the 
material also changes, with the peak modulus occurring when both the load and fibre 
orientation are in the same direction. Hence the material property can be customised through 
the orientation of the fibres and the effect of the orientation on the Young’s modulus can be 
modelled using the related equations (Hancox, 1981). 
The actual forces on the individual fibres can be found using the simple stress relationship: 
σ =
F
A
 
Where σ is stress, F is force and A is cross sectional area. This can be simplified for fibres such 
that; 
σ =
F
πr2
     or     F = πr2σ   
 
2.2.2 The Shear Lag Model 
There are two common models used to estimate the shear stresses within fibre composite 
materials. The first model was derived by Cox (1952) and is known as the shear lag model. This 
model assumes that the load applied to the construct is transferred from the matrix to the short 
fibres by shear (Soboyejo, 2002). This model also assumes that the displacement in a fibre in 
the composite material is proportional to the displacement in the fibre and the matrix of the 
material. The longitudinal Young’s modulus is therefore given by the equation (when it is 
assumed that the stresses at the end of the fibres are zero, σ0 = 0); 
Ec = VfEf [1 −
tanh (
βl
2 )
(
βl
2 )
] + EmVm 
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Also; 
β =
Gm2π
EfAfln (R/Rf)
 
Where: 
Gm = Shear modulus of the matrix 
R = The mean separation of the fibres 
Rf = Radius of the fibres 
 
The shear lag model, whilst a simple model of fibre behaviour and used to model tendons 
(Ahmadzadeh et al., 2013), has been hypothesised to not produce accurate stress distributions, 
and hence other methods could be used to provide alternative modelling (Lee and Suh, 2006). 
 
2.2.3 The Tyson Critical Length 
 
To load short uniaxial fibres embedded within a matrix to their maximum strength, the matrix 
must be able to sustain the shear deformation. When short fibres are subjected to tensile stress, 
stress build up occurs at the edges of the fibres and, if the fibre is long enough, plateaus to a 
constant maximal value (Hancox, 1981). This is demonstrated in figure 10 where three different 
fibre lengths are compared and once the fibre length reaches a critical value, the normal stress 
reaches its maximum value.  
 
Where: 
Ec = Modulus of elasticity of composite 
Ef = Modulus of elasticity of fibre 
Em = Modulus of elasticity of matrix 
 l = Length of fibre 
Vf = Fibre Volume fraction ( Where Vf =
Af
Ac
) 
Vm = Matrix Volume fraction ( Where Vm =
Am
Ac
) 
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Figure 20: Graphs comparing the stress distribution against three distinct different fibre lengths using the Tyson 
model. Where 𝐥𝐢 = 𝐥𝐜 = 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐥𝐞𝐧𝐠𝐭𝐡 and 𝐱 denotes the fibre length.  (Adapted from Lee and Suh (2006)). 
If the fibres are shorter than this critical length the fibre will fail due to its inability to withstand 
the shear and not due to fracturing as the fibres will not reach their fracture stress. The equation 
for the critical length is given as: 
lc =
Dσ
2τ
=
Rσ
τ
 
 
 
 
 
 
 
 
This leads to a simple force balance described using the formula; 
τ = σf
R
4lc
 
 
 
 
The critical length and fibre strain depend on the fibre stiffness and shear strength of the 
interface between the matrix and the fibres, two parameters which can be manipulated to alter 
the local mechanics of the composite. 
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Where:                                                                                                                                                    
lc = Critical length 
D = Fibre diameter 
R = Fibre radius 
σf =Tensile stress on fibre 
τ = Shear stress 
 
Where: 
τ = Shear stress on fibre 
σf = Tensile stress on Fibre 
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2.3 Fibre Composite Development 
The hierarchical structure of tendons, with multiple fibres making up fascicles and fascicles 
grouped together to make tendons, creates a complex cellular environment. When a tendon is 
stretched the fibres within both stretch and slide (Rigozzi et al., 2013; Sasaki and Odajima, 
1996a; Shepherd et al., 2014; Thorpe et al., 2013b). Studies have found the fibres to stretch by 
approximately 40% of the applied strain in physiological tendons (Shepherd et al., 2014). This 
consequently creates both tension and shear for the cells within tendons. The purpose of 
developing a fibre composite system is to be able to reproduce this cellular shear and tension 
environment seen in tendons. Achieving this would allow tenocyte mechanotransduction 
studies under tightly controlled reproducible conditions. Studies targeted for investigation 
using this system include the matrix related gene expression of tenocytes, derived from both 
healthy and tendinopathic tissue, and the gene expression changes in response to different 
shear/tension ratios. This will help address the implications of shear in tendon matrix turnover 
and tendinopathy.  
The requirements for such a system primarily include the ability to both create and control 
cellular shear and tension ratios. Without being able to control this, the effects of varying 
magnitudes of shear and tension, including physiological equivalents, cannot be investigated 
and compared. The system must be able to support the incorporation of cells and maintain their 
viability. Subsequently, the system must also be able to permit diffusion of nutrients and other 
solutes from encompassing media. This aspect also provides versatility to the system, allowing 
use in future studies where response to additives such as growth factors can be investigated. 
Similarly, optical clarity of the system is another requirement providing a more useful system 
as encapsulated cells and components can be imaged and monitored easily. 
The first fibre composite system designed for exposing cells to shear and tension was initially 
developed by Screen et al. (2010). This system was based on two hydrogels; poly (2-
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hydroxyethyl methacrylate) (PHEMA) and poly (ethylene glycol dimethacrylate) (PEGDM). To 
manufacture the composites, fibres of PHEMA were made using a photopolymerisable solution 
consisting of 80% 2-hydroxyethyl methacrylate (HEMA), 2 mol % tetraethylene glycol 
dimethacrylate (TEGDM) and 1.5% Irgacure 651 (a photoinitiator) in ethylene glycol and water 
(1:1.33). This solution was injected into a mould and exposed to UV light (~4 mW cm-2 of 365nm 
wavelength light) to produce fibres averaging 2.80 mm in length and 0.36 mm in diameter when 
swollen. Collagen was then immobilised on the surface of these fibres via the use of the coupling 
agent 1,1’-carbonyl diimidazole (CDI) which creates carbamate groups able to react with amines 
present in collagen. This process essentially changes the fibre surface to promote cell 
attachment. These fibres were then seeded with cells and encapsulated in a PEG matrix made 
by mixing 10 wt% PEGDM with 0.05% Irgacure 2959 (a photoinitiator) and polymerising under 
UV light (365nm wavelength at ~4 mW cm-2).   
The study by Screen et al. (2010) characterising this composite without cells found mechanical 
properties of the system could be customised through altering the fabrication process: 
increasing the time PHEMA fibres were left to dry and soak in PEG solution prior to 
polymerisation resulted in higher moduli and ultimate tensile strength (UTS). This study also 
demonstrated cell attachment onto collagen type I coated PHEMA fibres. A comparison of 
fibroblasts in the composite under loading to that in 2D culture and unorganised 3D 
encapsulation showed a significant increase in collagen type I gene expression in the composite.  
Although the properties of the individual components of the above system could be customised 
and cellular shear created, a couple of significant limitations were present. The first was the 
system using fibre ‘drying’ as a method to change micromechanics: a combination of drying 
PHEMA fibres and leaving them to soak in PEG was required to increase the extent of matrix 
integration into fibres, which in turn changed the composite micromechanical properties and 
consequently the shear/tension ratio. However, the process of drying fibres would kill the cells 
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attached to the surface of the fibre. Thus, the only viable composite type created by this system 
would be one where the fibres are not dried, resulting in only one composite type: a high shear-
low tension environment. The second problem seen with this system was an observation of the 
composite fragility seen personally by Dr Screen and Dr Bryant. Composites were seen to readily 
tear at the fibre/matrix interface once the fibres were coated in collagen, indicating a poor 
matrix-fibre interface. 
Therefore further development of the above fibre composite system was performed to address 
these limitations and achieve the desired system as described at the beginning of this section. 
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2.3.1 Characterising Collagen Coupling via 1-1’-Carbonyl Diimidazole (CDI) 
 
 
The system described by Screen et al. (2010) was used as the basis for development. The limited 
feasible shear/tension properties produced by this system were first addressed by using an 
additional PHEMA fibre stiffness. This was done by using 65% PHEMA, resulting in less stiff fibres 
compared to the original 80% PHEMA. A less stiff fibre would theoretically stretch more than a 
stiff fibre when the composite is stretched and consequently result in less matrix sliding against 
it. Further characterisation of the matrix-fibre interface was also performed to determine the 
cause of the weak interface following collagen immobilisation. Collagen immobilisation is 
performed in two stages, first PHEMA modification via CDI (CDI reaction), then coating with 
collagen type I (collagen coating), with the contribution of either to the interface weakness 
unknown.  Therefore both steps involved in collagen immobilisation were investigated to 
determine their individual effect on the extent of matrix-fibre integration.  
 
Experimental Overview 
 
Figure 21: Flow diagram for studying the effect of CDI coupling and collagen coating on the matrix-fibre interface. 
 
Composites polymerised and 
imaged
Soaked in PEG solution for 0, 
30, 60, 90 and 120 minutes.
Fibres made from 65% and 
80% PHEMA.
PHEMA 
fibres
Plain,
20% PEG 
Matrix
CDI 
Reaction
20% PEG 
Matrix
Collagen 
Coating
20% PEG 
Matrix
20% PEG Matrix 
PHEMA Fibre 
CDI coupled collagen type I 
Chapter 2 Fibre Composite System Development  
 
Section 2.3 - Fibre Composite Development 92 
 
Methods 
Note 1: Procedures performed at room temperature (RT) unless stated otherwise. 
Note 2: Further details of all chemicals used, including supplier details, are present in Table 35 
and Table 36, in Appendix B: Chemicals and Materials List. 
 
PHEMA Fibre Production 
Fibres of two degrees of stiffness were made by preparing pre-polymer solutions of 65% and 
80% PHEMA. The pre-polymer solutions were made by combining 2 mol% TEGDM and 1.5% w/v 
Irgacure 651 in ethylene glycol and deionised water (1:1.33) with either 80% v/v HEMA for an 
80% PHEMA solution or 65% v/v HEMA for a 65% PHEMA solution. This was done in 5 mL vials 
and the solution vortexed to ensure the Irgacure 651 was fully dissolved. The solutions were 
then labelled fluorescently by adding 0.1% w/w fluorescein methacrylate. This entire solution 
was wrapped in foil to protect from light and stored at 4ᵒC. 
The pre-polymer solutions were polymerised into fibres by using Teflon moulds containing 
holes of 0.3 mm diameter and 4 mm length (Figure 22). The outer mould edges were first lightly 
smeared with silicon grease and placed on top of a glass slide (75 mm x 25 mm x 1 mm) to 
create a liquid tight seal. The PHEMA pre-polymer solution was then pipetted into the holes and 
another glass slide placed on top once full. Bulldog clips were used to hold the glass slides and 
mould together. The solution was then polymerised by placing under 365nm UV light (~4 
mW/cm2) and leaving for 10 minutes with the entire assembled mould turned over after the 
first 5 minutes to ensure the UV light penetrated and polymerised the whole fibre. Resulting 
fibres were termed 65% or 80% PHEMA. 
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Figure 22: CAD drawing of Teflon mould used for creating fibres. Mould contains 36 holes of 0.3 mm diameter and 
4 mm length. 
Once polymerised, fibres were extracted from the mould by peeling away the glass slides. Most 
fibres remained attached to the bottom of the glass slide and could be cut away at the base. 
The fibres remaining in the mould were retrieved using a thin wire (diameter <0.3 mm) to push 
them out of the holes. The PHEMA fibres were stored in 70% ethanol until ready for the fibre 
treatment stage. 
 
Fibre Treatment 
To assess the stages involved in collagen immobilisation PHEMA fibres were either kept plain 
(i.e. untreated), coupled with CDI (stage 1) or coupled with CDI and coated with collagen (stage 
2).  
Fibres to be reacted with CDI were stored in 50% methanol and 50% water for at least 1 hour, 
after which they were transferred into clean vials with 70% ethanol and left for a minimum of 
2 hours. Vials containing fibres were covered with parafilm which was perforated using a syringe 
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needle to allow the ethanol to evaporate. These vials were placed in a vacuum oven to speed 
up the drying process. Once dried, vials were transferred into a sterile hood with the integrated 
UV lights on to sterilise the fibres. From this point forward the fibres were treated as sterile. 
After 30 minutes the parafilm was removed and the vial half filled with 100% dry acetone. With 
the lids placed back on, the vials were sonicated for 30 minutes after which the dry acetone was 
replaced while in a sterile hood and then re-sonicated. This sonicated rinse process was done 
for a total 3 times.  
Acetone was removed from the vials after the final rinse and the fibres left to air dry in a sterile 
hood. A 20 mM CDI acetone solution was created and added to the vial containing fibres and 
left to react for 5 minutes on an orbital shaker. The CDI solution was removed following the 
reaction and 3 more sonicated rinses were performed with acetone. After the third rinse the 
acetone was removed, fibres left to air dry for 1 minute and then stored in phosphate buffered 
saline (PBS) at 4°C. These fibres were labelled as ‘CDI reacted’. 
For collagen coated fibres a 0.3 mg/mL sterile collagen solution was made by mixing Type I rat 
tail collagen with a sodium bicarbonate buffer, prepared by mixing sodium bicarbonate in 
deionised water and adjusting the pH to 10.4. Taking CDI reacted fibres after their final 
sonicated rinse and air drying, rather than transferring to PBS, 2 mL of the prepared collagen 
solution was added to each vial. This was left for 48 hours at 4°C on an orbital shaker after which 
the fibres were rinsed in PBS, labelled as ‘Collagen coated’ and stored in cold PBS at 4°C. 
 
Matrix PEGDM Solution 
The procedure for making a stock quantity of PEGDM can be summarised as two procedures; 
methacrylation followed by purification. 
Chapter 2 Fibre Composite System Development  
 
Section 2.3 - Fibre Composite Development 95 
 
Methacrylation consisted of weighing a known quantity of 3000 molecular weight polyethylene 
glycol (PEG) in a microwaveable 20 mL glass vial and adding trace amounts of hydroquinone. 
This was microwaved for 5 minutes at 400W and left to cool for another 5 minutes. Depending 
on the quantity of PEG weighed, a 10 fold molar excess of methacrylic anhydride was added, 
the vial purged with argon and then briefly vortexed to mix the solution. This was microwaved 
for a total of 10 minutes at 400W, with a cooling period of 10 minutes after the first 5 minutes.  
Following methacrylation, polyethylene glycol dimethacrylate (PEGDM) was precipitated and 
purified to remove reaction by-products and unreacted methacrylic acid. First the vials were 
left to cool for at least 30 minutes after methacrylation. The supernatant liquid was removed 
and enough dichloromethane added to each vial to dissolve the PEGDM (~25% w/v). The 
PEGDM was then precipitated in cold diethyl ether (10:1 v/v to dichloromethane used) and the 
solution kept moving using a magnetic stir bar and plate. Using a vacuum flask, pump, Buchner 
funnel and Whatman Grade 1 filter paper the solution was filtered and collected in a beaker 
shielded from light. The collected PEGDM was re-dissolved in dichloromethane and re-
precipitated in diethyl ether to further purify the product; a process repeated a total of 3 times. 
After the final collection, the PEGDM was protected from light and left to air dry for a few days. 
The percentage methacrylation was confirmed by performing 1H nuclear magnetic resonance 
(NMR) spectroscopy. 
For the composite matrix a 20% PEGDM solution was made by first preparing a stock solution 
of the photoinitiator Irgacure 2959 at 0.006 g/mL in PBS. This solution was left in a water bath 
at 37ᵒC for a week until the photoinitiator had fully dissolved. A mixture of 20% w/v PEGDM, 
0.05% w/v Irgacure 2959 and PBS was then prepared in a 5 mL vial and vortexed until the 
PEGDM had dissolved. This solution was labelled fluorescently by adding 0.02% w/w Rhodamine 
methacrylate and protected from light. 
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Composite Production 
Composites were made by surrounding the different types of PHEMA fibres in PEG solution and 
then polymerised to make the final composites.  
For initial studies of the integration of PEG into PHEMA fibres, simple cylindrical moulds for the 
PEG solution were adapted by trimming the ends off 1 mL syringes (Figure 23). The fibres were 
placed in these trimmed syringes and 100 µL 20% PEGDM solution pipetted in slowly to 
submerge fibres without bubbles. Two fibres were present in each syringe and left to soak in 
this solution for 0, 30, 60, 90 or 120 minutes before proceeding to the polymerisation step. 
When ready for polymerisation, filled syringes were placed under 365nm UV light at 4mW/cm2 
for 10 minutes after which they were collected and rinsed in PBS. 6 repeats were made of each 
test condition.  
 
 
 
 
 
 
 
 
 
Figure 23: Circular moulds. 1 mL syringes were cut at the nozzle end and used as moulds for cylindrical composites. 
A pipette tip holder from a 200 µL pipette box was used as a base plate to hold multiple trimmed syringes vertical. 
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Confocal Imaging and Analysis 
Composites were imaged via confocal microscopy and the fluorescent fibres and matrix excited 
using Argon and He-Ne lasers. The extent of fibre-matrix integration was calculated by 
measuring the distance Rhodamine labelled PEG matrix (red) was present past the boundaries 
of the fluorescein labelled PHEMA fibres (green) using ImageJ. Two PHEMA fibres were analysed 
in each composite, with three measurements taken on either side of each fibre. Thus each gel 
provided 6 measurements. An example of the measurements is shown in Figure 24.                
 
 
 
 
 
 
 
Figure 24: Example of image analysis method performed on a composite with 80% PHEMA fibre reacted with CDI 
and 90 min soak. Intensity profiles are plot along 3 lines running across the fibre (only one line shown) for the red 
(matrix) and green (fibre) channels separately. The green channel is used to define the boundaries of the fibre. 
The distance the red fluorescence is seen past these boundaries, i.e. interpenetration into the fibre, is measured 
and taken as the integration distance. 
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Results 
Figure 25 shows a positive trend between soak time and interpenetration distance for plain 65% 
and 80% PHEMA fibres. Both percentages of PHEMA fibres show no difference in integration 
when soaked for 0 and 30 minutes, with the average integration distance being 74.4 µm and 
86.2 µm for 80% PHEMA and 72.7 µm and 86.2 µm for 65% PHEMA, respectively. However at 
60, 90 and 120 minutes a significant difference (p<0.05) is seen between the two fibre types 
suggesting these longer soak times can be used to adjust the matrix-fibre interface. 
 
 
 
Figure 25: Summary of average PEG integration into 65% and 80% PHEMA fibres in composites as either plain 
untreated fibres (Plain), CDI reacted fibres (Stage 1) and collagen coated fibres (Stage 2) (n = 6). Increasing soak 
time can be seen to increase the integration distance for 65% PHEMA fibres. However, after reacting PHEMA fibres 
with CDI, integration is significantly inhibited. * = P<0.05. 
Figure 25 also demonstrates that performing the CDI reaction on PHEMA fibres results in a 
significant decrease in integration of the matrix into the fibres. Since collagen coating requires 
the CDI reaction it was not surprising that the collagen coated fibres also exhibited little to no 
integration.  
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Discussion and Conclusion 
The system originally described by Screen et al. (2010) was limited in the ability to generate 
varying shear/tension ratios and was found to have fragile a matrix-fibre interface following 
collagen immobilisation. The data obtained after further characterising these PHEMA/PEG 
composites provides an insight into the matrix-fibre interface, specifically that changes to the 
permeability of the PHEMA occur during the stages involved in coating fibres with collagen. It 
was found performing the CDI reaction on PHEMA fibres significantly prevented the PEG matrix 
from penetrating into the fibres (Figure 25). This also meant reacting fibres with type I collagen 
resulted in little matrix-fibre integration as the CDI reaction was a prerequisite. Therefore the 
fragile composites observed by Dr Screen and Dr Bryant, where composites readily tore at the 
matrix-fibre interface, can be attributed to this weak interface. It was noted that fibres post CDI 
reaction appeared more rigid when handled than those not reacted. As a result it is thought 
that CDI cross links with itself during the reaction to form a layer on the surface of PHEMA fibres, 
thus restricting the integration of PEG matrix. This is reinforced by the fact that hydroxyl groups 
activated with CDI, i.e. the intermediate state, can react with neighbouring hydroxyl groups 
while still maintaining reactivity towards amines (Everaerts et al., 2007; Hermanson, 2008). As 
such, although matrix integration is not seen, the fibres retained their amine reactivity allowing 
successful collagen type I coating and, consequently, cell attachment (Screen et al., 2010). 
The matrix-fibre interface is an important aspect of the composite as this allows bulk strain to 
be transferred to the fibres. Without integration it is not possible to control this interface and 
therefore only a high shear cellular environment can be created. This makes this system 
unsuitable for exploring the effects of different tension and shear ratios on cellular metabolism. 
Hence, it was necessary to find an alternative method to achieve this goal. 
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2.3.2 N,N’-Dissucinimidyl Carbonate (DSC) and Collagen System 
 
Following the results from the CDI integration experiment, an alternative coupling agent was 
investigated to allow collagen to be conjugated with PHEMA. The requirement once again was 
to have a reaction modifying the hydroxyl group of PHEMA and allowing addition of contacting 
amines.  
N,N’-Discuccinimidyl Carbonate (DSC) is a cross linking agent which contains N-
hydroxysuccinimidyl (NHS) esters and has been widely used for the conjugation of peptides 
(Huang et al., 2002; Huang et al., 2001; Lahiri et al., 1999; Miron and Wilchek, 1993). Similar to 
the CDI method, DSC can be used to convert hydroxyl groups into amine reactive groups. 
Therefore this can be used with PHEMA as an alternative method to produce collagen coated 
fibres for the fibre composite system. 
 
2.3.2.1. DSC Protocol Optimisation 
Experimental Overview 
Adapting the protocol from Hermanson (2008), a method optimised for use with PHEMA fibres 
was established. The method is similar to that in the previous section using CDI where the plain 
PHEMA fibres are first reacted with the coupling agent (DSC) and then reacted with collagen 
(stages summarised in Figure 26).  
20% PEG Matrix 
PHEMA fibres 
DSC coupled collagen type I 
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Previous observations with the CDI method found cracks running along the length of some 
fibres and therefore an additional objective was introduced to reduce the extent of cracking 
through different preparation methods. To reduce fibre cracking the necessity of drying fibres 
within the protocol (Stage 1) was evaluated in addition to the effectiveness of ‘graded’ solutions 
when transferring fibres to acetone. The analysis compared direct transfer to acetone with a 
graded transfer (Stage 2) as outlined below: 
i. Ethanol : Water (50:50) 
ii. Ethanol : Water : Acetone (33:33:33) 
iii. Water : Acetone (50:50) 
iv. Water : Acetone (25:75) 
v. Acetone (100%) 
Fibres in all groups were then reacted with DSC, a coupling agent which introduces NHS esters 
into PHEMA fibres (Stage 3), and then collagen coated (Stage 4) for the final comparison, giving 
4 treatment groups as outlined in Table 14. Collagen conjugated fibres were analysed via Raman 
Spectroscopy to check for the presence of collagen and the success of the reaction. 
 
Figure 26: Flow diagram detailing the stages involved in achieving collagen coated PHEMA fibres via DSC. The four 
protocol variables are dried fibres straight to acetone (DFSA), dried fibres through graded solutions (DFGS), non-
dried fibres straight to acetone (NDSA) and non-dried fibres through graded solutions (NDGS). 
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Methods 
Note: Procedures performed at room temperature (RT) unless stated otherwise. 
Note 2: Further details of all chemicals used, including supplier details, are present in Table 35 
and Table 36, in Appendix B: Chemicals and Materials List. 
 
PHEMA Fibre Preparation 
80% PHEMA fibres were prepared as described in the previous section and stored in 70% 
ethanol. Enough fibres were made for all 4 of the procedures shown in Table 14. 10 plain 80% 
PHEMA fibres were taken and set aside as non-modified controls. 
Table 14: Summary of variations and abbreviations of protocols tested. 
Condition Abbrev. Dried 
Acetone 
Transfer 
No. 
Fibres 
Dry 
Weight (g) 
Dried fibres straight to acetone DFSA Yes Acetone only 91 0.033 
Dried fibres in graded solutions DFGS Yes Acetone only 98 0.038 
‘Not dried’ fibres straight to acetone NDSA No Graded 100 0.039 
‘Not dried’ fibres in graded solutions NDGS No Graded 95 0.037 
 
Considering the groups with dried fibres, the ethanol was removed from the glass vials 
containing sterile fibres designated as DFGS and DFSA and fibres left to air dry for 10 minutes 
in a sterile hood. These were then placed in a lyophiliser for 2 hours to completely dry. Non-
dried fibres, NDSA and NDGS, remained in 70% ethanol. NDSA and DFSA were then immediately 
immersed in 100% dry acetone and three 30 minute sonicated rinses performed, with the 
solution being replaced after each sonication. NDGS and DFGS were transferred through graded 
solutions, with three 30 minute sonicated rinses performed with each solution. After the final 
rinse all fibres types were kept in 100% dry acetone. 
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NHS Ester Addition via N,N’-Discuccinimidyl Carbonate (DSC) 
NHS ester addition was performed by creating two solutions of molar concentrations 6 times 
that of HEMA (i.e. using dry weight from Table 14); 6x DSC in 10 mL dry acetone and 6x 4-
(dimethylamino) pyridine catalyst in 10 mL dry acetone. 
When ready, acetone was removed from the fibre vials and the 6mmol DSC solution added with 
a magnetic stir bar to keep the mixture stirring. The catalyst solution was then slowly poured 
in. The magnetic stir bars were then removed and the vials left on a shaker for 6 hours. 
After the reaction the solutions were removed and fibres rinsed by performing three 30 minute 
sonicated rinses with dry acetone. 20 fibres were taken from each vial at this point to perform 
Raman spectroscopy in the ‘post reaction’ state. 
Collagen Immobilisation 
12 mL of a cold sterile 0.3 mg/mL collagen reaction solution was made using 3 mg/mL stock rat 
tail type I collagen solution and a sodium bicarbonate buffer prepared to pH 10.4. The dry 
acetone was removed from all fibres and 3 mL of this collagen solution was added to each vial 
and left to react overnight on a shaker at 4°C. These fibres were then stored in PBS and labelled 
as ‘collagen coated’. 10 collagen coated fibres from each protocol were allocated for Raman 
spectroscopy analysis. 
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Results 
Visual assessment of PHEMA fibres in each of the 4 treatment groups, looking for signs of 
cracking, showed drying had little effect on crack formation (Table 15). Fibres transferred 
through different graded solutions, DFGS and NDGS, appeared to be more prone to cracks. 
PHEMA fibres that weren’t dried and transferred straight into acetone, NDSA, produced no 
visible cracking probably due to the least amount of ‘processing’ and handling. 
Table 15: Summary of the visual assessment of fibres in each of the 4 treatment groups, alongside the unreacted 
PHEMA control fibres. The number of separate distinct cracks were counted on each fibre and then averaged by 
the total number of fibres counted to produce the data for each fibre type and the standard deviation (SD) (n=6 
for all fibre types). 
Protocol Type Average No. Cracks SD 
Control 0.0 0.0 
NDSA 0.0 0.0 
NDGS 0.8 0.8 
DFSA 0.3 0.5 
DFGS 1.5 1.0 
 
   
  
Figure 27: Representative bright-field microscopy images at x10 magnification of a) a plain fibre (control), b) NDSA 
fibre, c) NDGS fibre, d) DFSA fibre and e) DFGS fibre. Locations of cracks indicated by red arrows. Fibres that 
underwent the NDSA protocol showed the least amount of fibre cracking once processed. 
a) b) c) 
d) e) 
Chapter 2 Fibre Composite System Development  
 
Section 2.3 - Fibre Composite Development 105 
 
Raman spectroscopy was performed at the three stages of the protocol; unreacted PHEMA 
fibres (control), post NHS addition reaction for each protocol version and post collagen coating. 
Results were consistent between repeats and therefore it was possible to show a reliable 
representative spectra for each condition. Figure 28 shows that the spectra for all 4 treatment 
groups (DFSA, DFGS, NDSA and NDGS) post NHS addition were the same in relation to peak 
locations. This provides confidence in the different protocol versions having little or no effect 
on the NHS addition reaction. Subsequently, comparisons with plain PHEMA fibres and collagen 
coated fibres were carried out using only the spectrum produced from NDSA as this condition 
also reduced cracking, therefore being the ideal protocol for further experiments. 
 
Figure 28: Comparison of representative Raman spectra of DFSA, DFGS, NDSA and NDGS treatment groups post 
NHS addition. All protocols can be seen to have the same spectral profile, thus all methods create the same 
modifications. 
Raman spectroscopy showed there were a few distinct changes after NHS ester addition to 
PHEMA fibres (Figure 29); notably a large peak appears at 797 cm-1 along with additional small 
peaks at 395 cm-1, 535 cm-1 and 1230 cm-1. Peak shifts were also seen from 1105 cm-1 to 1080 
cm-1, 1720 cm-1 to 1710 cm-1 and 2945 cm-1 to 2935 cm-1. Peak shifts and widening between 
1700-1800 cm-1 have been linked to changes in NHS ester formation (Deckert et al., 2004). 
Following collagen coating some peaks disappear such that they resume the same appearance 
as that of the control spectrum. This is particularly noticeable with the peaks at 797 cm-1 and 
535 cm-1 which are associated with nitrogen-carbon rings (Carcamo et al., 2012; Krishnakumar 
and Balachandran, 2004). 
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Figure 29: Raman Spectra for plain PHEMA (control), PHEMA after DSC reaction (‘NHS addition’) and after collagen 
coating (Collagen). Graph intensity separated for each spectra to allow easier comparison of peaks. Red numbers 
indicate peaks found in the control samples, blue indicates peaks which change with NHS addition and green 
indicate changes with collagen addition. Possible peak assignments were identified from literature and indicated 
as grey text (Carcamo et al., 2012; Krishnakumar and Balachandran, 2004; Mabilleau et al., 2008; Movasaghi et al., 
2007; Qin et al., 2006; Taddei et al., 2005). 
 
Discussion and Conclusion 
As the original method for creating collagen coated fibres presented a problem with matrix-
fibre integration, an alternative method for coating PHEMA fibres with collagen was explored. 
This new method used DSC to couple collagen type I to PHEMA fibres. The results from 4 
different DSC reaction protocols found that drying PHEMA fibres was not a necessary step and 
fibres can be transferred straight to 100% dry acetone from 70% ethanol with no discernible 
cracks. Transferring fibres gradually from ethanol to acetone was attempted to try reduce the 
rate of swelling, however this method increased crack prevalence. This is likely due to increased 
handling and the need for better optimisation in the order and ratio of graded solutions. As 
drying and graded solutions are not needed, the ideal protocol is also the shortest and simplest. 
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Raman Spectroscopy analysis of the hydrogel found peaks similar to other studies which 
examined PHEMA based polymers, with peaks at 1275 cm-1, 1205 cm-1, 1088 cm-1, 1026 cm-1, 
896 cm-1 and 830 cm-1 (Mabilleau et al., 2008; Taddei et al., 2005), thus providing a reliable 
control spectrum. Comparisons of the chemical structure of PHEMA fibres at the three stages 
involved in collagen immobilisation showed distinct new peaks after NHS ester addition (Figure 
29). These additional and changed peaks are attributed to the change in structure, namely the 
addition of a nitrogen-carbon ring, which also brings additional C=O species. Since the spectra 
are similar for all 4 protocols (DFSA, DFGS, NDSA, NDGS), it can be concluded that drying fibres 
or using graded solutions during fibre rinses does not affect the NHS reaction.  
Performing the collagen reaction is seen to change the Raman spectra of the specimens again; 
however, the resulting spectra appear almost identical to the control spectrum, particularly the 
loss of peaks 797 cm-1 and 535 cm-1, and minor changes at 1320 cm-1, 901 cm-1, 862 cm-1 and 
367 cm-1. This change is not surprising as any unreacted NHS activated hydroxyl groups will 
revert back to the original hydroxyl state through hydrolysis, while collagen reacted hydroxyls 
will also lose the additional nitrogen-carbon ring (Hermanson, 2008), thus giving a similar bulk 
structure to normal PHEMA. The Raman spectrum for collagen has been documented previously 
(Carcamo et al., 2012; Sun et al., 2008). It was not possible to distinguish these peaks in the 
spectra obtained for collagen coated fibres. However, as the collagen is essentially confined to 
a monolayer on the surface of the fibre, there will be a very small amount present, making it 
difficult to distinguish any small collagen peaks amongst the overshadowing hydrogel peaks.  
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2.3.2.2. Cell attachment 
Experimental Overview 
In order to establish if collagen coating had been successful, an alternative assessment method 
was required, and cell attachment to the fibres was investigated. The method outlined by 
Screen et al. (2010) was adapted for use with the new collagen coating method. Plain, DSC 
reacted and collagen coated fibres were covered with cells and the extent of cell attachment 
was compared between the groups to determine whether collagen coating was successful. 
Additionally, the effect of agitating cells during fibre seeded was investigated to determine the 
optimal conditions for seeding, exploring whether keeping fibres static or allowing fibre 
movement and rotation increased cell coverage. Static seeding of fibres was compared to 
agitation using either a roller or a shaker for up to 48 hours after an initial 24 hours static culture 
(Figure 30). 
 
Figure 30: Flow diagram detailing the variables and time points investigated for optimising cell seeding. The 
diagram represents two experiments, one looking at static culture for up to 96 hours, and the other looking at 
agitation for up to 48 hours using either a roller or a shaker after the initial 24 hours static culture. 
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Method 
Note 1: Procedures performed at room temperature (RT) unless stated otherwise. 
Note 2: Further details of all chemicals used, including supplier details, are present in Table 35 
and Table 36, in Appendix B: Chemicals and Materials List. 
Bovine Tenocyte Explant Culture 
Fresh surplus bovine joints were obtained from the local abattoir, from which digital extensor 
tendon (DET) explants were used to culture bovine tenocytes. Briefly, small sections of DET 
were cut and collected in sterile conditions, taking care to remove as much tendon sheath as 
possible. Central portions of these sections were then extracted to further eliminate the 
possibility of tendon sheath culture and diced into smaller pieces of ~3mm3. A tissue culture 
treated 6 well plate was filled with 3 diced pieces per well, each submerged in a small drop of 
50% fetal bovine serum (FBS) culture medium (medium components detailed in Table 16). This 
was incubated for 48 hours at 37°C with 5% CO2, after which an additional 1mL of culture 
medium was added, taking care not to detach the explants from the culture plate surface.  After 
a further 2 days of incubation, 0.5 mL of the medium was replaced with fresh medium, an 
activity repeated every 3 days. At the end of the second week the explants were removed and 
media in all wells changed to culture medium containing 10% FBS. The medium was then 
changed every 2-3 days and cells left to proliferate until the wells were 70-80% confluent, at 
which stage the cells were trypsinised using 1mL 1X Trypsin-EDTA and seeded into T25 flasks 
labelled as passage 1 (P1). The cells were then grown, repeating the trypsinisation and seeding 
process when confluent, until the cells reached P3 and spare cells frozen down until needed. 
Note: every increase in P indicates splitting of cells from 1 culture flask into two flasks (i.e. a 
doubling of area). 
Cells were frozen by re-suspending cells in media containing 5% dimethyl sulfoxide (DMSO) and 
no FBS at 1 million cells/mL and transferring 1 mL of this solution into cryovials. The vials were 
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then placed in an isopropyl bath and moved in to a -80°C freezer for 24 hours after which they 
were transferred into the cryobank until needed. 
Table 16: Bovine Tenocyte culture medium components and quantity 
Component 50% FBS 
Medium 
10% FBS 
Medium 
Dulbecco’s Modified Eagle Medium (DMEM) with low glucose 100 mL 500 mL 
Fetal Bovine Serum 50 mL 50 mL 
HEPES (1M) 2 mL 10 mL 
L-Glutamine (200mM) 1 mL 5 mL 
Penicillin/Streptomycin (10000U/10mg per mL) 1 mL 5 mL 
Non-essential amino acids 1 mL 5 mL 
 
Cell Seeding 
For the first part of the experiment which focused on looking at cell attachment over time in 
static culture, plain PHEMA (80%), DSC reacted and Collagen coated fibres were produced using 
the NDSA protocol as described in section 151.2490538.0. Bovine primary tenocytes, P3, were 
resuscitated by retrieving a cell vial from the cryobank and briefly opening in a sterile hood to 
release pressure. The vial cap was then closed firmly and thawed quickly by dipping in a 37ᵒC 
water bath for 2-3 minutes. Once completely thawed the cell suspension in the vial (1 mL) was 
transferred into 10 mL of 10% FBS media. This was then centrifuged as 2000rpm for 5 minutes, 
after which the media was aspirated and the cell pellet re-suspended in 5 mL 10% FBS media 
(Table 16). A T150 flask was filled with 20 mL 10% FBS media and the 5 mL cell suspension was 
added. This was then incubated at 37ᵒC and 5% CO2. The cells were grown and passaged until 
P5 before use. 
The fibres were transferred into a 24 well plate using sterile forceps. A total of 3 wells were 
used, with the different types of fibres kept in separate wells and each well containing 152 fibres 
with 1 mL 10% FBS media. This was temporarily placed in an incubator to warm up and displace 
the ethanol while the cells were prepared for seeding.  
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Cells were harvested from flasks by first rinsing with warmed sterile PBS and then adding 4 mL 
Trypsin-EDTA (1X concentration). This was left in the incubator for ~5 minutes. Once the cells 
detached, the cell/trypsin solution was transferred into a 50 mL conical tube containing 10 mL 
10% FBS media. The tube was then centrifuged at 2000 rpm for 5 minutes to pellet the cells. 
Once centrifuged, the supernatant was aspirated and fresh 10% FBS media was added (5 mL) 
to re-suspend the cells. The cells were then counted using a haemocytometer and trypan blue; 
15 µL cell suspension was mixed with 15 µL trypan blue (dilution factor 2), 10 µL of stained cells 
pipetted into haemocytometer on either side (total 20 µL), cells in the 4 corner grids on each 
side counted (total 8 sub-grids counted), and the total cell number determined by averaging 
the count and multiplying by the dilution factor (2), haemocytometer volume factor (10000) 
and total cell suspension volume (5 mL). The cell suspension was then diluted with 10% FBS 
media to make a solution of ~4 million cells/2.5 mL. The well plate containing fibres was 
retrieved from the incubator and the media aspirated carefully using a 250 µL pipette to avoid 
discarding any fibres. Fibres were covered with 2.5 mL of the cell suspension (~4 million cells) 
slowly, and the plates were incubated for the cells to attach for 3 hours. Fibres were then 
transferred into a 6 well plate containing 10% FBS media using sterile forceps and cell 
attachment inspected at 3, 24, 48, and 96 hours of culture using Calcein AM (n=6 per time 
point). 
A second experiment investigated agitation within the protocol (static, roller or shaker) for 
effectively seeding cells. An additional set of plain 50% PHEMA fibres, DSC modified fibres and 
Collagen coated fibres (n = 100 per group) were prepared and seeded with ~4 million cells per 
well as just described. After the initial 24 hours static culture, the fibres were placed into their 
respective modified culture conditions for up to 48 hours and imaged as described (Figure 30). 
Fibres (n=3) were taken for analysis after the initial 24hrs of static culture, and then additionally 
at 48 hours and 72 hours after spending the additional time in their secondary seeding 
condition.  
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Florescent Cell Staining  
Cells for Exp. 1 were visualized by adding 5 µM Calcein AM and incubating fibres at 37°C for 30 
minutes. These were then imaged via a Perkin-Elmer spinning disk confocal microscope at the 
designated time points (3, 24, 48 and 96 hours, n=6 per time point).  
The cells on fibres in Exp. 2 were imaged at 24 and 48 hours post seeding (n=3). Images were 
taken on a Leica SP2 confocal microscope after fixing samples in 4% paraformaldehyde for 30 
minutes, permeabilising cells with 0.1% Triton-X100 for 4 minutes and then staining with 
Phalloidin (Alexa Fluor 488) diluted 1:40 in PBS with 1% bovine serum albumin (BSA) for 30 
minutes at room temperature.  
In both experiments, an estimate of cell coverage was calculated using ImageJ (National 
Institutes of Health, Abramoff (2004)) to measure the area of the fibre fluorescently covered 
with cells as a percentage of the total fibre area. 
 
Results 
Figure 31 reviews the data from Experiment 1 in which static culture of cells on plain PHEMA 
fibres and fibres after the DSC and collagen reactions were compared. As expected, there was 
no cell attachment on plain fibres. However, cell attachment after treatment indicates the 
successful coating of fibres. It can be seen that DSC reacted fibres which are not coated with 
collagen still allowed cell attachment, although to a lower extent. It was also notable that these 
cells remained more spherical in appearance with increasing culture time, suggesting cells were 
less well attached. In collagen coated and DSC reacted fibres the density of attached cells 
appeared to reduce after the initial 24 hours.  
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Figure 31: Representative images from Experiment 1 comparing plain, DSC reacted and collagen coated fibres after 
3, 24, 48 and 96 hours static seeding. Calcein AM dye used and images taken using Perkin-Elmer at X10 
magnification. Both DSC reacted and collagen coated fibres allowed cell attachment unlike plain PHEMA rods. The 
DSC reacted fibres, although not coated with collagen, still allowed cell attachment due to proteins in the culture 
medium binding to reactive NHS esters. However, DSC reacted fibres generally showed less cell attachment and 
more spherical cells compared to collagen coated fibres.  
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Agitating the well plates for as little as 24 hours resulted in cells detaching from fibres in all 
cases (Figure 32). An estimate of the percentage cell coverage in some samples (n=6 for static 
and n=3 for other methods) in Figure 33 confirms static culture for 24 hours as the optimal cell 
seeding method. 
 
   
          
Figure 32: Representative images of collagen coated fibres after 24 hours static culture; 48 hours static culture; 24 
hours static culture and 24 hours agitation on a shaker; and 24 hours static culture and 24 hours agitation on a 
roller. Cells were stained with Phalloidin (Alexa Fluor 488) and imaged using a Perkin-Elmer spinning disk confocal 
microscope at X10. 24 hours static culture is observed as the superior cell attachment protocol 
 
Figure 33: Percentage cell coverage calculated over half the fibre surface (surface closest to microscope lens), 
calculated as fluorescent area relative to the total fibre area (n=3). ST = static, SHK = shaker and ROL = roller. Note: 
Although cells were seen to encompass the entire fibre surface, only the top half of fibres were analysed due to 
fluorescence obstruction. Therefore the % coverage over the visible half of the fibre was doubled to provide an 
estimate of overall coverage. 
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Discussion and Conclusion 
In order to determine if collagen had attached to fibres using the DSC-collagen modification 
process, the ability of cells to attach to the fibre surface was addressed; tenocytes should not 
attach to plain PHEMA while collagen coated fibres would allow attachment. It was established 
that bovine tenocytes did indeed attach to treated fibres in comparison to plain PHEMA fibres, 
demonstrating the collagen attachment protocols were successful. However, Figure 31 showed 
that DSC reacted fibres, although not coated with collagen, still allowed some cell attachment. 
This can be attributed to the NHS esters still being reactive when culture medium (containing 
serum) is present and thus any protein within the medium would be immobilised and create a 
potential site for cell attachment. The cells attached to DSC reacted fibres without collagen 
appeared more spherical in appearance, suggesting they had not attached as well as to collagen 
coated fibres. 
The results in Figure 32 and Figure 33 show 24 hours static culture as the most suitable condition 
for cell attachment, reaching an average of 75% fibre coverage. Any agitation of fibres knocked 
cells off. After 24 hours, regardless of culture condition, there was a significant decrease in cell 
coverage as cells migrated away from fibres again. 75% coverage is an ideal starting point for 
studies using the fibre composite; there must be areas of the fibre without cells to enable 
integration of surrounding PEG into the PHEMA fibre for appropriate composite mechanics. 
However, if cellular coverage is too high, integration will be limited and result in a weak 
composite. 75% coverage provides sufficient fibre surface area for integration whilst ensuring 
total cell numbers are sufficient for later gene expression techniques.  
As no cell attachment is seen with plain PHEMA fibres, it can be concluded that fibre 
modification and collagen coating can be achieved with DSC and the described techniques. 
Using a culture period of 24 hours allows a quick, simple and repeatable seeding protocol to 
carry forward in studies. 
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2.3.2.3. Matrix-Fibre Integration 
With the protocol for collagen immobilisation using the coupling agent DSC established and cell 
attachment confirmed, investigation of the extent of matrix-fibre integration was attempted 
using the same method as detailed in Section 2.3.1. The PEG matrix and PHEMA fibres were 
labelled fluorescently with Rhodamine methacrylate and fluorescein methacrylate respectively 
and soak times of 0, 30, 60, 90 and 120 used when making composites. 
 
Methods 
Note 1: Procedures performed at room temperature (RT) unless stated otherwise. 
Note 2: Further details of all chemicals used, including supplier details, are present in Table 35 
and Table 36, in Appendix B: Chemicals and Materials List. 
The integration of the matrix into fibres was investigated using a similar method to that 
described in section 2.3.1. Fluorescent pre-polymer solutions of 65% and 80% PHEMA were first 
prepared. The pre-polymer solutions were made by combining either 65% v/v HEMA or 80% 
HEMA with 2 mol% TEGDM and 1.5% w/v Irgacure 651 in ethylene glycol and deionised water 
(1:1.33). This was done in 5 mL vials and vortexed to ensure Irgacure 651 was fully dissolved. 
The solutions were then labelled green fluorescently by adding 0.1% w/w fluorescein 
methacrylate. The vial was then protected from light by wrapping in foil and stored at 4ᵒC. 
Both pre-polymer solutions were polymerised into fibres using the Teflon moulds described 
previously containing holes of 0.3 mm diameter and 4 mm in length. The mould edges were 
lightly covered with silicon grease and placed on top of a glass slide (75 mm x 25 mm x 1 mm). 
The PHEMA pre-polymer solution was then pipetted into the holes with another glass slide 
placed on top and secured with bulldog clips. The solution was polymerised by placing the entire 
mould under UV light (365 nm, ~4mW/cm2) for 10 minutes, with the entire mould being turned 
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over after the first 5 minutes. This was done for the 65% and 80% PHEMA solutions separately. 
Fibres were extracted from the mould and stored in 70% ethanol until ready for the fibre 
treatment stage. 
A 20% PEG solution for the composite matrix was made by mixing 20% w/v PEGDM, 0.05% w/v 
Irgacure 2959 and PBS in a 5 mL vial. This was fluorescently labelled by adding 0.02% w/w 
Rhodamine methacrylate.  
Composite cylinders were made as described previously, placing 2 fibres into a trimmed 1 mL 
syringe and filling with 100 µL 20% PEG matrix solution (shown previously in Figure 23). The 
designated soak time was waited and then composites polymerised under UV light 
(~4mW/cm2) for 10 minutes. Soak times were 0, 30, 60, 90 and 120 minutes. Three gels were 
made for each time point, with 2 fibres encapsulated per gel (total fibre n=6 per time point). 
The polymerised composites were then washed in PBS over 2 hours, with the PBS changed every 
30 minutes, to remove excess dye.  
The composites were imaged by confocal microscopy as described in section 2.3.1. Images were 
analysed via ImageJ, plotting fluorescence profiles across 6 spots on each fibre for 3 composites 
for each soak group  as described previously (total n for measurements = 36 per group). The 
distance the matrix had penetrated past the fibre edge, i.e. the distance the matrix fluorescence 
was seen inside the fibre, was used as the integration distance. 
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Results 
The integration of matrix into plain 65% and 80% PHEMA fibres was seen to increase as the soak 
time was increased (Figure 34). Unfortunately, similar to the matrix-fibre integration patterns 
seen after the CDI reaction, the DSC reaction also significantly restricted integration of the 
matrix into the fibres. The consequences were particularly evident in images where the fibres 
had pulled away from the matrix (Figure 35). It was noted that PHEMA fibres and other larger 
PHEMA specimens tested separately exhibited an increase in stiffness post the DSC reaction. 
Thus crosslinking on the surface of PHEMA fibres could have occurred similar to that seen in the 
CDI method. Studies have seen similar unintended non-specific crosslinking from DSC coupling 
agents where binding occurs with non-amine functional groups, such as hydroxyls, or multiple 
side chains on proteins (Everaerts et al., 2007; Lane et al., 2011). 
 
Figure 34: Summary of matrix integration in fibres after the different stages of PHEMA modification and fibre soak 
times of up to 120 minutes (fibre n=6). Data shown as average distance PEG matrix present past the boundaries 
of PHEMA fibres, and error bars represent standard deviation. ‘Plain’ = plain PHEMA fibres, ‘DSC’ = DSC reacted 
fibres, ‘Collagen’ = collagen coated fibres, and ‘Cells’ = cell seeded fibres. Plain 65% and 80% PHEMA fibres allow 
matrix integration, which also increases with soak time. However, modification with DSC, and consequently 
collagen coating and cell coating, limited the extent of integration dramatically. * = P<0.05. 
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Figure 35: Confocal image of composite made from collagen coated 65% PHEMA fibres in 20% PEG matrix after 
150 min soak period. Matrix labelled fluorescently red with Rhodamine methacrylate and fibres labelled green 
with fluorescein methacrylate. Note a complete lack of matrix-fibre integration indicated by the separation of the 
fibres from the matrix. 
Discussion and Conclusion 
After successfully coating PHEMA fibres with collagen type I, the matrix-fibre interface was 
characterised once fibres were incorporated in a 20% PEG matrix. The matrix-fibre integration 
distance was measured as the distance the matrix (labelled red fluorescently) had penetrated 
past the edge of the fibres (labelled green fluorescently). This integration was found to be 
lacking following the NHS addition reaction with PHEMA fibres. Consequently both collagen 
coated and cell covered fibres also showed little or no PEG integration as NHS modification is 
required to achieve both. The consequences of this lack of integration can also be seen in Figure 
35 where a collagen fibre has pulled away from the PEG matrix. As stated previously, the lack 
of matrix-fibre integration is undesirable due to the inability in providing different cell shear-
tension environments; if there is no matrix-fibre integration, the only cellular shear/tension 
Region where the fibre has 
pulled away from the 
matrix indicating a weak 
matrix-fibre interface. 
Matrix 
Fibre 
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environment producible is one of high shear as the matrix will slide against the fibres and not 
transfer tension when the composite is stretched.  
Both methods used to functionalise PHEMA to enable cell attachment altered the chemistry 
such that no integration was possible. Since these coupling reactions are the source of the 
problem, it was decided to move away from this method and introduce a new system. 
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2.3.3 PEG-Peptide System 
 
As described previously, PEG is a versatile material due to the large number of modifications 
and conjugations that can be performed. One such conjugation is that of peptides to enable cell 
attachment via acrylate reactive groups. This modification of PEG differs to the coupling 
reaction needed to modify PHEMA, as peptide sequences are directly incorporated into the PEG 
network during polymerisation and therefore eliminates the secondary crosslinking problem 
seen in previous attempts at making fibres for the composite. 
Any primary amine containing peptide sequence can be used and conjugated with PEG, 
however for the fibre composite system, one which mimics the attachment site found in 
proteins is required to allow cell attachment on the otherwise bioinert PEG. A common cell 
attachment peptide used in studies is Arg-Gly-Asp (RGD) (DeLong et al., 2005; Dettin et al., 
2009; Lynn et al., 2011; Steinmetz and Bryant, 2011; Yang et al., 2005). Although this sequence 
is commonly associated with the attachment site found on fibronectin, it is also present in many 
other protein cell adhesive sites including vitronectin, fibrinogen, laminin, and tenascin 
(Ruoslahti, 1996). RGD is also found in collagen type I, however it is only accessible once the 
collagen is partially degraded and hence not the intended motif for cell attachment in this case 
(Taubenberger et al., 2010). A number of integrins bind to RGD; α5β1, α8β1, αVβ1, αVβ3, αVβ5, 
αVβ6, αVβ8 and αIIbβ3 (Ruoslahti, 1996). 
Collagen type I mimetic peptides have been identified and characterised by their ability to be 
recognised by the β1 integrins; α1β1, α2β1, α3β1, α10β1 or α11β1 (Luo and Tong, 2011; 
20% PEG Matrix 
PEG-Peptide fibres 
Conjugated protein mimetic peptide 
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Taubenberger et al., 2010). Gly-Phe-Hydroxyproline-Gly-Glu-Asp (GFOGER) is a sequence found 
on the α1 chain of collagen type I and known to bind to integrin α2β1 (Knight et al., 2000). The 
shortest collagen type I mimetic peptide sequence is Asp-Gly-Glu-Ala (DGEA) and binds to α2β1 
integrin (Mizuno et al., 2000). Such peptides haves been used in studies looking for either 
alternatives to RGD (Culpepper et al., 2010; Weber et al., 2007) or to enhance surfaces with 
collagen specific motifs (Blewitt and Willits, 2007; Connelly et al., 2011; Culpepper et al., 2010; 
Hennessy et al., 2009; Wojtowicz et al., 2010). 
DGEA, as it is one of the shortest collagen type I mimetic peptides, and YRGDS as it has been 
used extensively in PEG based hydrogels, with the RGDS variant having better cell attachment 
activity than RGD (Hirano et al., 1993), were selected for investigation as potential alternative 
materials to PHEMA within the fibre composite system.  
 
Experimental Overview 
The peptides were incorporated into PEG by first combining commercially available acrylate-
PEG-NHS monomers with either DGEA or YRGDS to create acrylate-PEG-DGEA or acrylate-PEG-
YRGDS monomers, respectively. These were then added to a solution of PEGDM. The monomers 
contained an acrylate group, the same crosslinking chemistry used in PEGDM, becoming 
incorporated into the PEG network when the solution was polymerised.  
Conjugation of DGEA and YRGDS to acrylate-PEG-NHS monomers was first characterised, after 
which fibre composites made using the two peptide types were characterised in terms of cell 
attachment, gross mechanics and micromechanics (Figure 36).  
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Figure 36: Flow diagram summarising different aspects of characterisations performed. 
Methods 
Note 1: PEG-YRGDS fibres are referred to as PEG-RGD fibres from here onwards. 
Note 2: Procedures performed at room temperature (RT) unless stated otherwise. 
Note 3: Further details of all chemicals used, including supplier details, are present in Table 35 
and Table 36, in Appendix B: Chemicals and Materials List. 
PEG-Peptide Synthesis 
PEGDM was synthesised as described previously (section 2.3.1). YRGDS and DGEA were 
purchased from Genscript, USA, using their custom peptide synthesis service. Both YRGDS and 
DGEA were conjugated to PEG using the same technique, therefore both are referred to as 
‘peptide’ unless specific steps unique to either sequence were required. 
Sufficient sodium bicarbonate buffer, pH 8.4, was first prepared and the desired quantity of 
peptide weighed in a micro-centrifuge tube (40mg YRGDS or 30mg DGEA). A 20mL amber vial 
was filled with 9mL buffer while a further 1 mL of buffer was added to the peptide in the micro-
centrifuge tube. The peptide solution was mixed and then transferred to the amber vial (total 
Types of 
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PEG-Peptide System
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solution now 10mL) along with a magnetic stir bar. A sample of this solution (66uL) and a sample 
of the buffer (1500uL) were taken, labelled as ‘pre-reaction’ and stored at 4°C to perform a 
conjugation assay later.  
Commercially available acrylate-PEG-NHS monomers were used to create acrylate-PEG-peptide 
monomers. The quantity of Acrylate-PEG-NHS was first calculated to ensure the final mix had a 
peptide excess of 10%: 
For 40mg YRGDS: 
YRGDS MW = 596.59 
Acrylate-PEG-NHS MW = 3500 
 
40mg YRGDS: 
𝑛 =
40 ÷ 1000
596.59
= 6.705 × 10−5 𝑚𝑜𝑙 
10% excess: 
6.705 × 10−5 ÷ 110 × 100 = 6.095 × 10−5 𝑚𝑜𝑙 
Therefore, mass of acrylate-PEG-NHS needed: 
6.095 × 10−5 × 3500 × 1000 = 213.3𝑚𝑔 
 
For 30mg DGEA: 
YRGDS MW = 390.35 
Acrylate-PEG-NHS MW = 3500 
 
30mg YRGDS: 
𝑛 =
30 ÷ 1000
390.35
= 7.69 × 10−5 𝑚𝑜𝑙 
10% excess: 
7.69 × 10−5 ÷ 110 × 100 = 6.99 × 10−5 𝑚𝑜𝑙 
Therefore, mass of acrylate-PEG-NHS needed: 
6.99 × 10−5 × 3500 × 1000 = 244.54𝑚𝑔 
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With the quantity calculated, the acrylate-PEG-NHS bottle (stored at -20°C) was quickly brought 
to room temperature and the calculated amount weighed. The bottle was then purged with 
nitrogen and returned to the -20°C freezer. The weighed Acrylate-PEG-NHS was added to 
peptide containing amber vial and left to react for 2 hours on a stir plate protected from light.  
30 minutes before the end of the reaction, dialysis membranes (molecular weight cut off 500-
1000 daltons) were cut and rinsed in deionised water, and the bottom ends of the dialysis 
membranes were folded and secured with dialysis clips to prevent liquid from leaking out of the 
membranes. At the end of the reaction period, a sample of solution (130 µL) was taken, labelled 
as ‘post-reaction’ and stored at 4°C for the conjugation assay performed later. The remaining 
reacted peptide solution was pipetted into the dialysis membrane tube and the opening folded 
and secured with another set of dialysis clips. The filled membranes were left in a 1 L beaker 
containing deionised water, with the water changed every 30 minutes for at least 4 hours after 
which they were left overnight. Amber vials were half filled with the solutions from the 
membranes and placed in the -80°C freezer for 2 hours. These were then lyophilised for 2 days 
and the final product weighed. 
 
Conjugation Assay 
A conjugation assay was performed with the samples taken from the PEG-peptide synthesis to 
confirm the peptide had attached to the acrylate-PEG-NHS monomers. 
The conjugation assay used Fluoraldehyde O-phthalaldehyde (OPA) which binds to proteins and 
peptides, with linear results over a wide range of concentrations. The excitation and emission 
wavelengths for Fluoraldehyde OPA are 340 nm and 455 nm, respectively. 
Based on the amount of peptide initially weighed, a series of dilutions of known concentrations 
(detailed in Table 17) were performed to create a standard curve. Dilution was done using the 
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‘pre-reaction’ and buffer samples taken during the PEG-peptide synthesis. 40 µL of the standard 
curve samples were then plated out in triplicates on a white opaque 96 well plate followed by 
the unknown samples and buffer only blanks. 160 µL of the Fluoraldehyde OPA reagent was 
then added to each well and placed in a FLUOstar microplate reader (BMG Labtech) within 5 
minutes to measure the fluorescence intensity. 
Table 17: Standard preparation for conjugation assay. For YRGDS, Stock 1 was made by diluting the ‘pre-reaction’ 
sample by a factor of 2 using the buffer and Stock 2 made by taking 5 µL Stock 1 and adding 45 µL buffer. For DGEA, 
Stock 1 was prepared by diluting the ‘pre-reaction’ sample by a factor of 1.5 with buffer, and stock 2 made by 
adding 45 µL buffer to 5 µL Stock 1. 
Concentration (µg/mL) Stock 1 needed (µL) Stock 2 needed (µL) Buffer needed (µL) 
0.00 - 0.00 130.00 
6.15 - 4.00 126.00 
15.39 - 10.00 120.00 
29.23 - 19.00 111.00 
61.50 4.00 - 126.00 
153.90 10.00 - 120.00 
246.20 16.00 - 114.00 
492.30 32.00 - 98.00 
1000.00 65.00  - 65.00 
The results from the conjugation assay shows the quantity of free peptide still remaining in the 
‘post-reaction’ sample, which in turn indicates the amount of peptide not conjugated to 
acrylate-PEG-NHS. 
 
Matrix-Fibre Integration 
Matrix-fibre integration for effective composite manufacture was investigated by adapting the 
method described previously. PEG-RGD fibres of either 20% or 40% PEG were fluorescently 
labelled via fluorescein methacrylate and embedded in 20% PEG matrix which was labelled 
fluorescently with Rhodamine methacrylate. PEG-DGEA fibres were not used for this 
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experiment as the only difference between the PEG-RGD and PEG-DGEA fibres is the 
substitution of YRGDS with DGEA in the latter.  
The pre-polymer solutions were polymerised into fibres using the Teflon moulds containing 
holes of 0.3 mm diameter and 4 mm in length as described previously. These were placed into 
trimmed 1 mL syringe and surrounded with 100 µL 20% PEG matrix solution as before (Figure 
23). The designated soak time was waited and then composites polymerised under UV light 
(~4mW/cm2) for 10 minutes. Soak times were 0, 30, 60, 90 and 120 minutes. Three gels were 
made for each time point, with 2 fibres encapsulated per gel (total fibre n=6 per time point). 
The polymerised composites were then washed in PBS over 2 hours, with the PBS changed every 
30 minutes, to remove excess dye.  
The composites were imaged using confocal microscopy, and the distance the matrix had 
penetrated past the fibre edge calculated as previously described (section 2.3.1). 
Cell Viability and Attachment 
Additional cylindrical composites were made using the method described above, however 
without fluorescent dyes, to assess cell viability and cell attachment on PEG-RGD and PEG-DGEA 
fibres.  
Both PEG-RGD and PEG-DGEA fibres were made and seeded with cells using the 24 hour static 
culture method (2.3.2.2).  
Table 18: Serum free culture medium used for initial seeding step with bovine tenocytes. 
Components for serum free media Quantity 
Dulbecco’s Modified Eagle Medium (DMEM), low glucose 500 mL 
HEPES (1M) 10 mL 
L-Glutamine (200mM) 5 mL 
Penicillin/Streptomycin (10000U/10mg per mL) 5 mL 
Non-essential amino acids 5 mL 
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For viability analysis within the composites, the next day a 20% PEGDM solution for the 
composite matrix was made by mixing 20% w/v PEGDM, 0.05% w/v Irgacure 2959 and 10% FBS 
media in a 5 mL vial. This solution was then sterile filtered using 0.22 µM syringe filters. 
In a sterile hood, 2 cell seeded fibres were placed into a sterile cylindrical mould (a trimmed 1 
mL syringe shown previously in Figure 22) and filled with 100 µL sterile 20% PEG solution. The 
designated soak time was waited and then composites polymerised under UV light (~4mW/cm2) 
for 10 minutes. Soak times used were 0, 30, 60, 90 and 120 minutes. The polymerised 
composites were immediately placed in 6 well plates with 10% FBS media and live/dead cell 
staining performed. Three gels were made for each time point, with 2 fibres encapsulated per 
gel (total fibre n=6 per time point). 
Live/dead staining was done by placing a composite in 1 mL media and adding 4 µM Calcein AM 
and 4 µM ethidium homodimer. Composites were kept in an incubator for 30 minutes at 37°C, 
5 % CO2 after which the gels were imaged using an epi-fluorescent microscope to count live and 
dead cells. 
Cell attachment was also investigated on PEG-RGD fibres at 3 hours and 24 hours post-seeding 
to confirm cell attachment and spreading. PEG-RGD fibres (n=3) at 3 hours and 24 hours post 
seeding were fixed in 4% paraformaldehyde for 30 minutes and then cells permeabilised with 
0.1% triton X-100 for 4 minutes. The fibres were then stained with Phalloidin (Alexa Fluor 488) 
diluted 1:40 in PBS with 1% bovine serum albumin (BSA) for 30 minutes at room temperature. 
Fibres were then rinsed twice with PBS and counterstained with DAPI diluted 1:1000 in PBS for 
1 min. Fibres were rinsed once again in PBS and then imaged using a confocal microscope 
(Model SP2, Leica). 
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Micromechanics 
Composites were made using different stiffness PEG-RGD fibres and different soak times to see 
if the micromechanics of the resulting composite when subjected to tensile strain could be 
manipulated, to create different shear/tension ratios locally in the material. 
Table 19: List of fibre types and soak times use to make composites. 
Fibre Type Soak Time Abbrev. 
20% PEG-RGD 0 minutes 20-0 
20% PEG-RGD 60 minutes 20-60 
40% PEG-RGD 0 minutes 40-0 
40% PEG-RGD 60 minutes 40-60 
60% PEG-RGD 0 minutes 60-0 
60% PEG-RGD 60 minutes 60-60 
Fibres of 20%, 40% and 60% PEG-RGD were made as previously described, but without the 
inclusion of fluorescein.  
Fibres were sterilised with short wavelength UV light for 30 minutes in a sterile hood. Using 
sterile forceps the fibres were transferred into a 24 well plate containing serum free media 
(Table 18). Separate wells were used for each fibre type and the plate kept in an incubator to 
keep warm while the cells were prepared. Bovine tenocytes, P6, were harvested from flasks via 
trypsinisation and re-suspended at 3.5 million cells/mL in serum free media. Media was 
removed from the 24 well plate containing fibres, and 1 mL cell suspension (i.e. 3.5 million cells) 
was added to each well and topped up with a further 0.5 mL serum free media. The plate was 
then left in the incubator at 37°C, 5% CO2 for 1.5 hours. 0.5 mL media was then removed from 
both wells and replaced with 0.5 mL 10% FBS media (Table 16). The well plate was then left for 
a further 1.5 hours in the incubator. After a total of 3 hours sterile forceps were used to transfer 
all the fibres into new wells containing 10% FBS media and the plate left in the incubator 
overnight. 
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24 hours after seeding, the fibres were ready to make into composites. First a 20% PEGDM 
solution for the composite matrix was made as previously described. This solution was then 
sterile filtered using a 0.22 µM syringe filter. Rectangular Teflon moulds were used to make 
composites. Each mould made 3 composites as each contained 3 rectangular grooves of 
dimensions 25 mm x 2.5 mm x 1 mm (Figure 37). 7 fibres were placed within each groove and 
made into composites using a modified ‘dipping’ method (Figure 37). The ‘dipping’ method 
differs to that previously used to make composites in so far as cell seeded fibres are briefly 
immersed in a drop of 20% PEGDM matrix solution prior to positioning into the composite 
mould. This displaces media surrounding the fibre and cell surface, replacing it with PEGDM, 
thus giving a better matrix-fibre interface.  
 
 
 
 
 
 
 
 
Figure 37: Schematic showing the ‘dipping’ method used for making composites. Cell seeded fibres were picked 
up with sterile forceps individually and dipped into a drop of sterile 20% PEGDM solution. This replaced any media 
retained on the surface of the fibres with 20% PEGDM to create a better matrix-fibre interface. Fibres were then 
placed into the groove in the Teflon composite mould to make composites of 25 mm x 2.5 mm x 1 mm. Three 
composites could be made at once. 
A glass slide was placed on top of the mould and secured tightly using bulldog clips. The mould 
was slowly filled with the 20% PEGDM solution using a 5 mL syringe and 25 gauge needle. The 
Media layer 20% PEGDM layer 20% PEGDM solution 
Cell seeded fibre Cell seeded fibre  Cell seeded fibre 
Bulldog clip 
Glass slide Groove (25 mm x 2.5 mm x 1 mm) 
Teflon composite mould 
Fibres placed 
into mould 
Fibre 
20% PEGDM 
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composite mould was then left for the designated soak times of either 0 or 60 minutes. After 
soaking, the composites were polymerised under UV light (365 nm, ~4 mW/cm2) for 10 minutes 
whilst still in the sterile hood. Polymerised composites were stored in a 6 well plate containing 
10% FBS media, and 16 composites of each type made.  
A customised uniaxial strain rig (Figure 38a) was used in conjunction with brightfield microscopy 
to image composites whilst applying strain, and characterise their micromechanics. The sample 
chamber of the uniaxial strain rig was filled with 10% FBS media and the composites were 
carefully attached to the rig grips (as shown in Figure 38a). The rig grips were configured to 
create an initial test length of 10 mm by using a metal spacer. The rig grips, with composite 
attached, were lowered into the strain rig chamber and the grips secured to the rig motor arms. 
The spacer was then removed and the slack in the composite adjusted by operating the motor 
in small 0.05 mm increments whilst monitoring the edge of the composite under the 
microscope. Once the entire composite edge was at the same focus depth the composite was 
assumed to be slack free and straight. The test length was measured as the distance between 
the rig grips at this stage. Up to 10% strain was then applied to the composites at a rate of 15% 
strain/min. Images were taken at 0%, 2%, 4%, 5%, 8% and 10% applied strain. All 16 composites 
were tested, but do to some breaking during handling, n = 12-15 for each composite type. 
In order to characterise local fibre strains, the change in fibre length (fibre strain) relative to 
gross applied strain was calculated at each applied strain by analysing images in ImageJ and 
monitoring fibre length changes (Figure 38b). The fibre strain was then calculated by dividing 
the fibre length change by the original length.  
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Figure 38: a) Uniaxial strain rig and grip setup. Grips use a flexible silicon membrane to hold sample firmly in place 
without exerting too much pressure which could crush the composite. The entire assembled rig is placed on top 
of a microscope stage and images taken through the transparent sample chamber. b) Example images of fibre 
extension calculations; the change in fibre length was measured and divided by the original length to obtain fibre 
strain. This was done at each applied strain increment. 
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Gross Mechanics 
Bulk mechanical properties of fibre composites were determined using a Hounsfield tensile test 
machine and 5N load cell. Composites were made using the same method as that for the 
micromechanics with 20%, 40% and 60% PEG-RGD fibres seeded with tenocytes (3.5 million 
cells per well, each containing 100 fibres) and encapsulated in 20% PEG matrix. Plain PEG gels 
of 20%, 40% and 60% PEG were also characterised to assess the mechanical properties of the 
separate materials. 
For testing, each end of the composite was placed inside a folded piece of card using glue 
(Loctite Power Flex Control Gel) with the test length defined as the distance between the edges 
of each card (Figure 39). The specimens were then setup up into the tensile test machine and 
grips placed on the card to prevent specimen slippage and damage. Composites were then 
strained at a rate of 15% / min, with force and extension recorded (n = 9-13). 
 
 
Figure 39: Configuration for the bulk mechanical testing of composites using the Hounsfield Test Machine. 
Composite ends were glued in-between sturdy folded card pieces. These could then be gripped firmly and the 
composites tested to failure without sample slippage. The sample test length was defined as the distance between 
the top card edge and the bottom card edge, and load measured using a 5N load cell. 
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Top grip connected to load cell 
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Results 
Peptide Conjugation 
The assay showed successful conjugation of YRGDS and DGEA to acrylate-PEG-NHS, with 
conjugation values of 96% and 80% respectively (Figure 40).  
 
Peptide Intensity Peptide not conjugated (µg/mL) % Conjugation 
DGEA 1384 596.3 80 
YRGDS 413 165.3 96 
Figure 40: Graph and table summarising standards and peptide conjugation percentage for YRGDS and DGEA. 
 
Fibre integration 
The average integration distance was calculated by plotting the intensity profile of the fibre 
(green) and the matrix (red) across a line (Figure 41a). An intensity cut-off threshold was created 
for the red (matrix) channel by averaging the intensity of red at the central 25 µm of the fibre, 
essentially correcting for background fluorescence. The integration distance was then taken as 
the amount of red matrix inside the green fibre up to the threshold line. The average integration 
distance at increasing soak times was found to show a non-significant weak positive trend; at 0 
and 120 minutes the average integration distances were 43 µm and 68 µm for 40% PEG-RGD 
and 66 µm and 75 µm for 20% PEG-RGD fibres, respectively (Figure 41b). 
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Figure 41: a) Example of matrix-fibre integration calculation on a 20% PEG-RGD fibre with 0 min soak. Intensity 
profiles were plot along 3 lines running across the fibre (only one line shown) for the red (matrix) and green (fibre) 
channels separately. The green channel was used to define the boundaries of the fibre. The distance of red 
fluorescence past these boundaries was then measured up to the matrix ‘cut-off threshold’ and taken as the 
integration distance. The cut-off threshold was determined by averaging the intensity of red at the central 20 µm 
portion of the fibre, thus correcting for background fluorescence. b) Integration data from composites made from 
20% and 40% PEG-RGD fibres at varying soak times. (n=3, with 3 composites containing 2 fibres each and 6 
measurements on each fibre). Integration of the matrix into the fibre can be seen to be successful, with a weak-
positive trend as soak time is increased. 
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Cell attachment  
Figure 42 shows cells attached to the surface of fibres 3 hours after seeding possess a closely 
packed and circular morphology. However, at 24 hours, the cells were seen to spread and cover 
the surface of the fibre. 
 
      
      
Figure 42: Phalloidin (Alexa Fluor 488) and DAPI staining of PEG-RGD fibres at 3hrs and 24 hrs post seeding using 
confocal imaging at x10 and x40 magnification. Cells were seen to attach to fibres 3 hours post seeding, however 
they exhibited a spherical morphology suggesting they were not well attached. After 24 hours the cells spread 
across the surface of fibres and no longer showed the compact spherical appearance. 
 
 
100 µm 
100 µm 100 µm 
100 µm 
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The cells were seen to remain viable at all soak times used, with the final time point of 120 
minutes possibly showing slightly more dead cells (visually) (Figure 43). Dead cells were also 
visible around areas devoid of cells, however this was due the handling of fibres; areas where 
the fibres have been picked up with forceps will consequently result in crushed cells, with such 
areas identified by having viable cells on either side of the small empty region (indicated on 
Figure 43).  
The cylindrical structure of fibres resulted in cells being present at varying depths relative to 
the microscope lens and therefore at varying levels of focus. Consequently, images of fibres 
within composites had both a focused region and an out of focus region where the fibre curved. 
Nonetheless, it was still possible to get an overview of cell viability qualitatively from these 
images. It should be noted that the images in Figure 42 look clearer than those in Figure 43 
since a confocal microscope was used; as fibres for Figure 42 were not encapsulated in gels, it 
was possible to get the fibres close to the high magnification lens such that they were within 
the lens working distance, enabling the use of confocal microscopy. 
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Figure 43: PEG-RGD and PEG-DGEA fibres within 20% PEG matrix with a 0, 60 and 120 minutes soak before 
polymerisation. Cells stained with Calcein AM and Ethidium Homodimer and imaged using an epi-fluorescent 
microscope at X10 magnification. Cells remain viable after soaking in 20% PEG for 0, 60 and 120 minutes, with only 
a slight increase in dead cells seen visually at the 120 minutes time point. This is true for both PEG-RGD and PEG-
DGEA fibres. Acellular regions are seen as a result of forceps crushing cells when the fibres are picked up. 
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Gross Mechanics 
The mechanical properties of plain PEG was seen to differ with PEG concentration, confirming 
that increasing PEG concentration increased the stiffness of PEG (Figure 44). On the other hand, 
bulk mechanical properties of the composites (Figure 45) were seen to be similar for all 
composites with no significance between the groups. When looking at the data paired by fibre 
stiffness, i.e. bars of the same colour in Figure 45, it can be seen there was a trend for a small 
increase in the ultimate tensile strength (UTS) when the soak time increased; when 60 minutes 
soak was used instead of 0 minutes, the mean UTS increased by approximately 4, 13 and 7 kPa 
for 20%, 40% and 60% PEG-RGD fibres respectively. Similarly, this pattern was also seen with 
the failure strain differences of the composites and, to a lesser extent, with the modulus 
differences. Additionally, the modulus of the composites generally showed a small increase 
when the PEG percentage, i.e. the fibre stiffness, was increased (Figure 45c). 
 
Micromechanics 
Figure 46 shows the micromechanics of the composites made from 20%, 40% and 60% PEG-
RGD fibres with either a 0 or 60 minutes soak. The fibre strain was seen to change depending 
on the type of composite even though bulk mechanical properties remained the same, with 
softer 20% PEG-RGD fibres stretching more than stiffer 60% PEG-RGD fibres. Figure 47 further 
investigates this relationship, 20% PEG-RGD fibre composites with 60 minute soak creating the 
least shear while 60% PEG-RGD composites with 0 minutes soak produced the highest amount 
of shear. 
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Figure 44: Average mechanical properties of plain PEG gels made from 20%, 40% or 60% PEG. a) Shows stress-
strain curves of representative samples, b) shows the average failure strain (%), c) shows the average UTS (kPa) 
and d) shows the average modulus (kPa) of the composites (n = 10-11). The gross mechanical properties are seen 
to increase slightly with increasing soak times, but no significant differences are evident. Significance difference 
can be observed in the modulus of PEG, with higher PEG concentration resulting in a stiffer material. The failure 
strain also decreases with increasing PEG concentration.  
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Figure 45: Average gross mechanical properties of composites made with 20%, 40% and 60% PEG-RGD fibres 
seeded with cells and soaked for either 0 or 60 minutes. Samples are labelled as ‘XX-YY’, with ‘XX’ indicating the 
PEG fibre type and ‘YY’ indicating the soak time. Similarly, bars of the same colour indicate the same fibre type, 
while striped and solid colours indicate 0 and 60 minutes soak respectively. a) Shows stress-strain curves of 
representative samples, b) shows the average failure strain (%), c) shows the average UTS and d) shows the 
average modulus of the composites (n = 9-13). The gross mechanical properties are seen to increase slightly with 
increasing soak times, but no significant differences are evident. 
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Figure 46: Summary of micromechanics data obtained after image analysis of cell seeded composites (n=12-15). It 
can be seen that at any given gross applied strain, the resulting fibre extension can be changed by using a 
combination of fibre stiffness and soak time; using stiffer fibres (higher percentage PEG fibres) the magnitude of 
fibre strain is reduced, while increasing the soak time increases the magnitude of fibre strain. For example, at 5% 
applied strain, composites can be made where the fibres stretch by approximately 1.2% or up to 3%, which 
translates to a range of 24%-60% of the applied strain. 
 
Figure 47: Shear-tension ratio averaged across 2%, 4%, 5%, 8% and 10% applied strain for each composite type 
(n=12-15). As 100% tension would theoretically result in 0% shear, shear % was calculated as 100%-tension %. It 
can be seen that the different combinations of fibre stiffness and soak time create a range of shear-tension ratios, 
ranging from high shear and low tension (fibres with 60% PEG and 0 minutes soak) to low shear and high tension 
(fibres with 20% PEG and 60 minutes soak). 
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Discussion 
The new system replaces PHEMA fibres used in previous iterations of the composite with PEG-
peptide fibres. This eliminates the self-crosslinking problem seen with coupling agents used on 
PHEMA fibres that prevented matrix-fibre integration and hence reduced control over 
micromechanics. Although the matrix-fibre interface study summarised in Figure 41 confirmed 
the presence of matrix interpenetration and showed a weak positive trend with increasing soak 
times, the data obtained did not show significant differences between the different composite 
types. Moreover, it is unknown how slight changes in integration may affect mechanical 
properties of the composites at the fibre level, so having successfully achieved integration, 
micromechanical analysis of the composites was pursued to investigate the capacity to 
generate varies shear-tension ratios.  
As can be seen from Figure 46, the data obtained from micromechanics analysis reveals the 
properties of the composites more clearly, with a distinct pattern through the different groups. 
Following fibre composite theory, stiffer fibres in composites result in less fibre extension at 
any given applied strain, while increasing the soak time to increase fibre-matrix integration, 
increases the extent of fibre extension. As these micromechanical data are collected with fibres 
seeded with cells, the data obtained shows the expected properties of the composite during 
future mechanotransduction studies. Figure 46 also shows an ideal range of properties can be 
created from the composites. For example, at 5% applied strain, we can have composites where 
fibres stretch approximately 1% through to composites where the fibres stretch approximately 
3% (illustrated in Figure 48). Studies have found that the fibres within physiological tendons 
stretch by about 40% of the applied strain (or 2% for an applied strain of 5%) (Shepherd et al., 
2014). Composites made from 20% PEG-RGD fibres with 0 minutes soak, 40% PEG-RGD fibres 
with 0 minutes soak, 40% PEG-RGD fibres with 60 minutes soak and 60% PEG-RGD fibres with 
0 minutes soak all recreate shear/tension ratios similar to these physiological conditions for 
cells. Additionally, the low fibre extension composite (60% PEG-RGD with 0 minute soak) and 
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the high fibre extension composite (20% PEG-RGD with 60 minute soak) can create pathological 
conditions of high and low shear, respectively.  
  
Figure 48: Graph of average fibre strain (%) at 5% gross applied strain for all composite types (n=12-15). Fibre strain 
~40% of the applied strain is seen in physiological tendons (Shepherd et al., 2014). The graph indicates two 
composites capable of creating physiologically equivalent conditions (60% PEG fibres with 60 minute soak and 20% 
fibres PEG with 0 minute soak). A high shear - low tension condition can also be created (60% PEG fibres with 0 
minute soak) in addition to a low shear – high tension condition (60% PEG fibres with 60 minute soak). * = P<0.05. 
The gross mechanics was essentially similar for all types of composites, with only slight non-
significant differences evident in the modulus when stiffer fibres were used (Figure 45). This is 
to be expected as PEG itself is not a very stiff material when hydrated, and since a large 
molecular weight was used (PEG MW ~ 3000), the increase of PEG concentration in fibres, 
combined with the relatively low numbers of rods is likely insufficient to dramatically affect the 
bulk mechanical properties. Additionally, since cells were present, the matrix-fibre interface 
would be intermittent, consequently reducing the effect of fibre stiffness on the extension of 
the bulk material. Nonetheless, although the bulk properties remain the same, the critical 
variation in the micromechanics of the composites differ when using the different fibre types. 
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The cylindrical nature of fibres present a problematic scenario for imaging as higher 
magnification lens have a limited depth of field and the changing fibre depth blurs cells in the 
background. This is further accentuated when the fibres are encapsulated into composites as 
the matrix thickness increases the distance the fibres are from the microscope lens. Therefore 
it is difficult to image cells clearly with high clarity and magnification. However, by using x10 
magnification, it is still possible to get an overview of the viability of cells qualitatively as seen 
from Figure 43. Cell attachment was confirmed on both PEG-RGD and PEG-DGEA composites, 
with the majority of cells remaining viable after soaking fibres for up to 120 minute before 
polymerisation. This, along with the conjugation assay, demonstrates the ability to conjugate 
the desired peptide sequence group to PEG while also retaining the intended biofunctionality 
of the peptide.  
Further imaging of cell-seeded PEG-RGD fibres with Phalloidin (Alexa Fluor 488) and DAPI dyes 
showed cells attached 3 hours post seeding (Figure 42). After 24 hours the cells spread to cover 
the surface of the fibres, indeed showing results similar to that seen in the previous system 
(2.3.2.2). Therefore, the previously established cell seeding protocol was kept the same for this 
system. 
In conclusion, the new system eliminates the integration problems seen with previous 
attempts, successfully allows cell attachment through protein mimetic peptides, and creates 
controllable high and low shear cellular environments. As such, it is presented as a viable system 
to allow the exploration of shear-tension ratio effects on cells. 
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Protocols and Protocol Optimisation 
: Protocols and Protocol Optimisation 
With the final fibre composite system validated, this chapter covers the necessary protocols for 
composite manufacture with different resident cells and also outlines the optimisation of gene 
analysis protocols. 
Note 1: Further details of all chemicals used, including supplier details, are present in Table 35 
and Table 36, in Appendix B: Chemicals and Materials List. 
. 
3.1 Cell Resuscitation, Culture and Passaging 
10% FBS (section 2.3.2.2) was warmed to 37ᵒC in a water bath. A sterile hood was prepared 
along with 50 mL conical tubes, 10 mL stripettes, sterile pipette tips and a T150 flask. The cell 
vial to be resuscitated was removed from the cryobank and briefly opened under the hood to 
release pressure. The vial cap was then closed firmly and the vial thawed quickly by dipping in 
a 37ᵒC water bath for 2-3 minutes. Once completely thawed the cell suspension in the vial 
(usually 1 mL) was transferred into 10 mL of media. This was then centrifuged as 2000rpm for 
5 minutes, after which the media was aspirated and the cell pellet re-suspended in 5 mL media. 
The T150 flask was filled with 20 mL media and the 5 mL cell suspension added. This was then 
incubated at 37ᵒC and 5% CO2. 
During culture, the culture media was changed every 2-3 days until cells were more than 75% 
confluent. The cells were then passaged by detaching the cells through the use of Trypsin-EDTA 
as described previously in section 2.3.2.2, and cell culture continued until the required cell 
number was reached. 
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3.2 Fibre Composite Production 
The final version of the composite system consisted of a 20% PEG matrix, encapsulating cell 
seeded PEG-RGD fibres made of either 20% or 60% PEG. The stages of manufacture included 
the synthesis of the PEG hydrogel in a photopolymerisable format, followed by fibre production, 
cell seeding of fibres and finally encapsulation of fibres into the surrounding PEG to create 
composites ready for use as depicted in Figure 49. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49: Schematic briefly summarising the procedure to produce composites from PEG. Stages include PEGDM 
synthesis, peptide conjugation, fibre production, cell seeding, encapsulation and polymerisation. 
Cell Seeding 
Encapsulation 
 Tenocytes seeded 
 24 hours static seeding 
 Aligned in Teflon mould 
 Soak time of 0 or 60 min 
Polymerisation  10 min UV exposure 
Composite 
PEG Powder 
Fibre Production 
 PEGDM and PEG-YRGDS synthesised 
 Fibres made of either 20% or 60% PEG 
 5mM YRGDS incorporated into fibres 
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3.2.1 Material Synthesis 
PEGDM was used for making both the matrix and the fibres of the composite system. It was 
synthesised in the laboratory using a two-step, methacrylation and purification process, as 
described in section 2.3.1. 
Peptides were conjugated to PEG via a commercially available intermediate material, Acrylate-
PEG-NHS using the procedure described in section 2.3.3.  
 
3.2.2 PEG-RGD fibres 
PEG-RGD fibres were created in two different stiffness by changing the percentage of PEG; 60% 
PEG and 20% PEG were used to create stiff and ‘less stiff’ fibres, respectively.  
The solutions for both PEG % were made using a combination of PEGDM, PBS and photoinitiator 
(PI) made of Irgacure 2959 at 0.006 g/mL in PBS: 
20% PEG: 
 0.2 g PEGDM 
 83.8 µL PI 
 716.7 µL PBS 
 
The solutions of PEG were made by mixing the 3 components described in a 5 mL vial and 
vortexing to dissolve the PEGDM, particularly the viscous 60% PEG solution. 5mM of acrylate-
PEG-YRGDS was then added to the solution to incorporate the peptide, usually taking 1 mL PEG 
solution and adding 21 mg acrylate-PEG-YRGDS.  
Fibres were created by pipetting the solution into Teflon moulds (arrangement depicted in 
Figure 50). The moulds contained holes of 0.33 mm diameter and 4 mm in length as needed for 
each fibre. A glass slide (75 mm x 25 mm x 1 mm) with a thin silicon gasket (0.4 mm thick) was 
60% PEG: 
 0.6 g PEGDM 
 83.8 µL PI 
 316.7 µL PBS 
 
Chapter 3 Protocols and Protocol Optimisation  
 
Section 3.2 - Fibre Composite Production 149 
 
first placed under the mould, then the top covered with a second glass slide once the solution 
was pipetted into the mould. The edges of the Teflon moulds were covered with silicon grease 
in addition to using the gasket to create a capillary chamber to help fill the holes, efficiently 
producing fibres without wasting peptide (depicted in Figure 50). Magnets were used on the 
top and bottom of the compiled mould to keep the glass slides secures. 
The fibres were polymerised by placing the filled mould under UV light (365nm wavelength, 
~4mW/cm2) for 10 minutes, turning the mould over after the first 5 minutes. The fibres were 
then extracted as described previously, collected in a small petri dish containing 70% ethanol 
and stored at 4ᵒC until needed. The mould was cleaned with 70% ethanol, the holes cleared 
using a thin wire and re-used to create more fibres. 
 
 
 
 
 
 
 
 
 
Figure 50: Front, side, bottom and exploded view of Teflon mould setup to efficiently create fibres. Mould 
contained 36 holes of 0.3 mm in diameter (Ø) and 4 mm in length. The edges of the glass slides are lightly covered 
in silicon grease to provide a liquid tight seal. All parts excluding the top glass slide and top magnets are greased 
and assembled first, then the hydrogel solution pipetted into each hole, after which the top glass slide can be 
placed on top and secured with magnets (and bulldog clips if needed) and placed under the UV lamp. Not to scale. 
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3.2.3 Cell seeding 
Once enough fibres were made for an experiment they were seeded with cells using the static 
culture method and serum free media. 
Serum Free media (i.e. without FBS): 
 DMEM, low glucose (500 mL) 
 HEPES (1M) (10 mL) 
 L-glutamine (200mM) (5 mL) 
 Penicillin/Streptomycin (10000U/10mg per mL) (5 mL) 
 Non-essential amino acids (5 mL) 
The fibres were sterilised before seeding. This was partly done by storing the fibres in 70% 
ethanol (minimum 2 hours in ethanol before use) when made, but was further ensured by 
briefly exposing fibres to short wavelength UV light for 1 hour in a sterile hood and using aseptic 
techniques when working with them. Once sterile, the fibres were transferred into a 24 well 
plate using sterile forceps, with a single well containing between 150-200 fibres and serum free 
media. Each fibre type was kept in separate wells to enable easy identification and temporarily 
placed in the incubator to warm up and displace the ethanol while the cells were prepared.  
Cells were harvested from flasks using Trypsin-EDTA as described in section 2.3.2.2. After re-
suspending the cells in a known volume of 10% FBS media, the cells were counted using a 
haemocytometer and trypan blue and re-suspended in serum-free media such that the 
resultant solution was 3.5 million cells/mL. The well plate containing fibres was retrieved from 
the incubator and the serum free media aspirated. The fibres were then slowly covered with 1 
mL of the cell solution (i.e. 3.5 million cells) and topped up with an additional 0.5 mL serum free 
media. The plates were then incubated for the cells to attach. After 1.5 hours, 0.5 mL media 
was removed from each well and replaced with fresh 10% FBS media to introduce some serum. 
After a further 1.5 hours (i.e. total 3 hours after seeding) sterile forceps were used to transfer 
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the fibres into new wells containing 10% FBS media. Fibres were then incubated overnight to 
let the cells fully attach. 
A full 24 hours after seeding, the fibres were ready to be encapsulated. 
3.2.4 Fibre encapsulation 
Encapsulation was performed as described previously in section 2.3.3 in a sterile hood and 
required aseptic techniques similar to those for cell seeding fibres to maintain sterility. The 
quantity of 20% PEGDM solution needed to create the required number of composites was 
calculated and prepared by following the formulation described in 3.2.2. PBS was substituted 
with 10% FBS media to keep media present around cells once fibres were encapsulated, and 1 
composite required approximately 0.1 mL PEGDM solution. The solution was sterile filtered 
using 0.22 µm filters and warmed in a water bath to 37°C.  
The 24 well plate containing seeded fibres was retrieved from the incubator. A small quantity 
of PEGDM solution was drawn into a 5 mL syringe with a 25 gauge needle while the rest was 
placed back into the water bath. The composite moulds were rectangular (2.5 mm x 25 mm x 1 
mm) as shown in Figure 51, where a Teflon strip contained 3 moulds. The outer areas of the 
Teflon strips were lightly greased with silicon, taking care to avoid the area where the hydrogel 
solution would be in contact and thus reduce the possibility of contamination. A sterile glass 
slide was placed to one side and a small drop of PEGDM placed on this as a dipping agent for 
fibres, to displace any media and coat with PEGDM prior to positioning in moulds. A small drop 
of PEGDM was also placed in the centre of each individual composite mould to help fibres stay 
in place once positioned. A total of 10 fibres were placed in each composite mould and arranged 
axially. The Teflon strip allowed up to three composites to be made at once. 
Once fibres were placed in the moulds, a glass slide was placed on top of the Teflon strip, 
overhanging one edge (as depicted in Figure 51), and secured with bulldog clips. Each composite 
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mould was then filled with PEGDM solution. The solution was injected slowly to prevent fibres 
from being pushed towards the end of the mould and only filled ¾ full. At this point the mould 
was filled from the other end to push the fibres back towards the middle of the groove and 
further align them axially. The mould was then left for either 0 minutes or 60 minutes to soak 
depending on the type of composite being made and then placed under the UV (365 nm, 
~4mW/cm2) lamp for 10 minutes to polymerise. The composites produced were removed from 
the mould and stored in a petri dish containing 10% FBS media, and housed in the incubator. 
The procedure was repeated, dipping fibres in PEGDM, aligning in the mould, injecting PEGDM 
solution and polymerising until all the composites were made. 
 
 
 
 
 
 
 
 
 
Figure 51: Teflon Mould and glass slide configuration. The glass slide was left overhanging to expose one end of 
the groove allowing air to escape while filling and to enable filling from both ends. Teflon mould surface in contact 
with glass slide was lightly greased, with care taken not to clog the grooves, and the glass slides held firmly on top 
through the use of multiple bulldog clips. 
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3.3 RNA Extraction 
In order to investigate cell response to strain within composites, gene expression approaches 
were adopted. This requires the extraction of RNA from the composites, reverse transcription 
into cDNA and then cDNA amplification via polymerase chain reaction (PCR). There are a 
number of methods for sample homogenisation to extract RNA such as digestion, shearing or 
grinding, with the method selected being dependent on the sample type. The composites 
present a unique challenge with a complex structure and relatively low cell numbers per 
construct compared to other tissues. It was necessary to first optimise the RNA extraction 
procedure to produce sufficient yields of useable RNA. 
3.3.1 RNA extraction Optimisation 
Experimental Overview and Methods 
The optimisation of RNA extraction with composites followed a trial and error route starting 
from an established protocol (Ireland et al., 2001) with changes made sequentially based on the 
results. The range of protocols tested is summarised in Figure 52. 
 
Figure 52: Summary of optimisation route 
Method -
1
•Rotor stator homogenisation
•Trizol and RNA precipitation method
Method -
2
•Ball mill homogenisation
•Trizol and RNA precipitation method
Method -
3
•Pestle and mortar and QIAshredder column homogenisation
•QIAzol with MinElute Spin Columns (silica-membrane method)
Method -
4
•Ball mill and QIAshredder column homogenisation
•QIAzol with MinElute Spin Columns (silica-membrane method)
Final 
Method
•Ball mill and QIAshredder column homogenisation
•QIAzol with MinElute Spin Columns (silica-membrane method)
•2 composites combined per extraction
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Method – 1 
The first method of RNA extraction involved using Trizol, a rotor stator homogeniser for sample 
disruption and phenol-chloroform based phase separation as described by Ireland et al. (2001). 
Both 20% and 60% cell seeded PEG-RGD composites with both 0 and 60 minutes soak (total 58 
composites) were made for analysis. The composites were placed into 2 mL cryovials (each vial 
containing 1 composite) and snap frozen in liquid nitrogen either at 0 hours, 24 hours or 48 
hours after production. The samples were then stored in a -80°C freezer until ready for 
processing. To begin the extraction process the vials were retrieved from the freezer and placed 
on dry ice in a fume hood. The rotor stator homogeniser tip was first rinsed in 70% ethanol, 
followed by RNase free water, operating the device while submerged in the respective 
solutions. 1 mL ice cold Trizol was added to a vial and 3 x 30 second bursts performed using the 
homogeniser. After the third burst, the state of the sample was checked and additional bursts 
performed if the composite was not fully homogenised. The sample vial was then placed on ice 
and the homogeniser tip cleaned with 70% ethanol and RNase free water. This was repeated 
until all samples were homogenised. The vials were then placed at RT, and 125 µg glycogen 
added as an RNA carrier.  This was then incubated at RT for 5 minutes, after which 300 mL 
chloroform (~1/5 ratio) was added to each vial and shaken vigorously for 15 seconds to 
thoroughly mix the solution. The vials were incubated at room temperature (RT) for 3 minutes 
and then centrifuged for 15 minutes at 12,000g and 4°C to allow phase separation. The upper 
clear aqueous phase was transferred into a new micro-centrifuge tube with care taken not to 
transfer or touch the interphase. This was done for all the vials separately. An equal volume of 
isopropanol was added to each tube and incubated at RT for at least 10 minutes. The tubes 
were then centrifuged at 12,000g for 10 minutes at 4°C to pellet the RNA/glycogen. The 
supernatant was then discarded, with care taken not to discard the pellet, and washed by 
adding 70% ethanol and gently mixing with a pipette. The tubes were then centrifuged at 7,500g 
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for 5 minutes at 4°C and the wash step repeated with 70% ethanol and centrifuged again. After 
discarding the supernatant after the second rinse, the pellet was left to air dry for ~15-20 
minutes (i.e. until the pellet appeared transparent). Once dry, 50 µL RNase free water was 
added to each vial and incubated for ~10 minutes. The tubes were mixed gentle agitation whilst 
housed in a tube rack and then stored at -80°C until ready to measure the quantity. 
The RNA quantity is easily found by measuring the absorbance of the solution, with RNA 
absorbing strongly at a specific wavelength of 260nm. A NanoDrop spectrophotometer is an 
instrument capable of measuring the absorbance of UV wavelengths through samples as small 
as 1 µL. Hence the RNA quantity was determined using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific). Samples were retrieved from the -80°C freezer and transferred onto ice. 
The NanoDrop sample pedestal was cleaned and RNase free water used as a blank. Samples 
were thawed, briefly centrifuged to collect the solution at the bottom of the tube, and 1 µL 
taken to place on the NanoDrop pedestal to measure RNA quantity. All the samples were 
measured, with the pedestal being cleaned after every sample. 
The total RNA quantity was calculated from the implied concentration per µL given by the 
NanoDrop results and the 260/280 ratio compared. 
Denaturing formaldehyde gel electrophoresis was performed on 8 samples to check sample 
integrity. One each from a range of composite conditions were tested: 20-60-0h, 20-60-24h, 20-
60-48h, 60-60-0h, 60-60-24h and 60-60-48h (sample labels are described in the legend of Table 
20). The Sample with the lowest RNA concentration (20-10-48h) and the sample with the 
highest RNA concentration (20-60-48h) were also tested. A rectangular gel with 8 sample wells 
was first made of agarose. This was done by heating a 1% agarose in RNase free water (DEPC 
treated) in a microwave for 30-40 seconds. The solution was then cooled in a rectangular mould 
and a ‘comb’ inserted to create wells. The gel was placed into the electrophoresis tank and filled 
with 1 X 3-morpholinopropanesulfonic acid (MOPS) buffer. 5 µL of each sample was mixed with 
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2.5 µL formaldehyde loading dye in a 0.5 mL micro-centrifuge tube and heat denatured at 65°C 
for 10 minutes. These were then chilled immediately after heating and loaded into the gel ports 
and the gel electrophoresis run for approximately 1 hour at 50-60V. The gel was then removed 
and imaged on top of a UV plate. 
 
Results – 1 
Table 20: Summary of NanoDrop results of all samples, showing mean (n=3 for 0 hour samples and n=6 for 24 and 
48 hour samples) and standard deviation (SD) for the concentration, 260/230 and 260/230 ratio. Sample IDs 
indicate the composite type in the format ‘XX-YY-ZZh’ with ‘X’ indicating the type of fibre, ‘Y’ indicating the soak 
time and ‘Z’ indicating the time at which the composites were frozen after making. Total sample quantity was 50 
µL. 
No. 
Sample 
type 
Nucleic Acid 
Conc. ng/µl 
260/280 260/230 Total RNA (ng) 
Average SD Average SD Average SD Average SD 
1 20-60-0h 15.3 2.7 1.61 0.08 0.12 0.07 765 135 
2 20-60-24h 22.2 6.2 1.63 0.07 0.09 0.06 1110 310 
3 20-60-48h 41.7 58.8 1.63 0.09 0.15 0.06 2085 2940 
4 60-60-0h 21.8 5.6 1.70 0.04 0.26 0.04 1090 280 
5 60-60-24h 18.6 4.1 1.66 0.11 0.13 0.06 930 205 
6 60-60-48h 18.3 7.5 1.63 0.06 0.15 0.04 915 375 
7 60-0-0h 16.4 2.1 1.72 0.05 0.23 0.09 820 105 
8 60-0-24h 25.5 7.7 1.61 0.04 0.18 0.07 1275 385 
9 60-0-48h 19.8 9.2 1.67 0.15 0.14 0.07 990 460 
10 20-0-0h 18.3 3.2 1.66 0.11 0.17 0.10 915 160 
11 20-0-24h 18.2 4.7 1.64 0.09 0.12 0.07 910 235 
12 20-0-48h 18.8 9.8 1.61 0.06 0.12 0.06 940 490 
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Figure 53: Gel electrophoresis image for 8 selected samples; 1) 20-60-0h, 2) 20-60-24h, 3) 20-60-48h, 4) 60-60-0h, 
5) 60-60-24h, 6) 60-60-48h, 7) the individual sample with the lowest concentration (20-0-48h) and 8) the individual 
sample with the highest concentration (20-60-48h). Results show poor sample quality with only one sample (well 
4) being at all visible. 
Discussion and Conclusion – 1 
The NanoDrop results show that the RNA concentrations extracted, although low, are above 
the detection limit of 2ng/µL imposed by the instrument. The yield itself is also sufficient for 
performing PCR as 100ng is usually required. However, the purity of the sample inferred by the 
260/280 and 260/230 ratios suggests the samples are not reliable and the sample integrity is 
compromised. This is implied by the different absorbing UV wavelengths; RNA absorbs at 260 
nm whilst contaminants such as phenol absorbs strongly at 230 nm and proteins absorb at 280 
nm (NanoDrop Technologies, 2007). Hence 260/280 and 260/230 ratios are used to gauge the 
amount of possible contamination, although the effect is exaggerated at lower RNA 
concentrations and hidden at higher RNA concentrations. The 260/280 ratio is used most often 
for this purpose and RNA is said to be ‘pure’ if the 260/280 ratio is 2.0. However, since factors 
such as the composition of nucleic acids, pH of the RNA solution itself and the concentration of 
RNA are all known to affect the ratio magnitude, the ratio is used as a guideline and generally 
1    2     3     4    5     6    7      8 
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accepted to be sufficient if between 2 ± 0.3 (Thermo Fisher Scientific, 2010). Since the results 
in Table 20 show the 260/280 ratio falls outside this range consistently, the possibility of 
contamination or sample degradation arose.  
The results from the gel electrophoresis confirmed the above as the expected distinct 18S and 
28S bands were not visualised, and only 1 sample (well 4) showed any signal at all. This 
suggested there was severe degradation of the samples and the procedure used for RNA 
extraction was not suitable.  
One of the main stages where degradation could occur was during the homogenisation step as 
the samples need to be processed quickly to avoid RNases destroying the sample. Additionally, 
since the composites are tough to fully homogenise, the time required to sufficiently 
homogenise with the rotor stator may have generated too much heat and therefore degraded 
the sample. 
Thus it was decided to try another means of homogenising the sample while also taking into 
consideration steps to keep possible RNase activity minimised.  
Method – 2 
Method – 1 was adapted by substituting the rotor stator homogeniser with a ball mill based 
machine (Mikro-Dismembrator U, Sartorius) which can keep the sample cooled for longer whilst 
homogenising.  
Cell seeded composites were made with 40% PEG-RGD fibres and a 60 minutes soak, and snap 
frozen in 2 mL cryovials either as pairs (n=5) or individually (n=5) 24 hours after production and 
stored at -80°C until ready to use. On the day of RNA extraction, a small Dewar filled with liquid 
nitrogen along with a box of dry ice were prepared and a steel shaker chamber and steel 
grinding ball cooled inside the Dewar. The samples were retrieved from the -80°C freezer and 
kept on dry ice throughout the procedure except during necessary processing. Each sample was 
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removed from the vial and placed in the cooled shaker chamber along with the grinding ball, 
after which it was swiftly secured in the Mikro-Dismembrator and homogenised at 2000rpm for 
1 minute. Once homogenised, the shaker chamber was quickly moved into a fume hood and 
the chamber opened to pipette in 1 mL Trizol. Due to the chamber being made of metal and 
cooled in liquid nitrogen, the chamber remains cold when Trizol is added and therefore freezes 
on contact. As soon as the Trizol started to thaw, the mixture was thoroughly mixed by pipetting 
and transferred into a 1.5 mL micro-centrifuge tube and kept on ice. The shaker chamber and 
grinding ball were cleaned with 70% ethanol and RNase free water before being used again to 
process the rest of the samples. Once all samples were homogenised and in Trizol, the 
remaining steps described in Method – 1 were followed; glycogen was added to each tube, then 
chloroform added to perform phase separation, the supernatant collected into separate tubes 
and centrifuged to create a pellet which was then washed with 70% ethanol twice and re-
suspended in RNase free water. To create a more concentrated sample, 40 µL of RNase free 
water was used instead of 50 µL to re-suspend the RNA and then samples stored at -80°C.  
NanoDrop was used to measure the RNA quantity of the samples and denaturing gel 
electrophoresis performed to check the integrity as described in Method – 1.  
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Results – 2 
Table 21: NanoDrop results for RNA extracted from composites using the modified method. Doubling composites 
during extraction does not seem to always increase the quantity of RNA and thus seems variable (samples 6-10). 
Sample 
No 
No. of 
Composites 
Concentration 
(ng/µL) 
260/280 260/230 Total RNA 
(ng) 
1 1 6.86 1.63 0.13 274.4 
2 1 4.66 1.57 0.23 186.4 
3 1 14.93 1.84 0.05 597.2 
4 1 19.62 1.72 0.08 784.8 
5 1 18.21 1.77 0.51 728.4 
6 2 53.82 1.61 0.22 2152.8 
7 2 49.14 1.57 0.11 1965.6 
8 2 14.70 1.65 0.49 588.0 
9 2 12.14 2.07 0.03 485.6 
10 2 17.43 1.76 0.53 697.2 
 
 
Figure 54: Image of RNA samples after gel electrophoresis. Wells 1-5 are of samples extracted from 1 composite, 
while 6-10 are for samples from 2 composites. 
 
 1   2   3   4    5   6   7   8    9   10 
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Discussion and Conclusion – 2 
The NanoDrop results from the new homogenisation method showed improved 260/280 ratios, 
although data remained highly variable. The gel electrophoresis image also confirmed this as 
the samples were visible, however they were still considerably degraded with only one band 
visible. The samples with low RNA concentration in Table 21 (samples 1 and 2) did not show up 
in the gel, confirming the low RNA concentration and its highly degraded nature. Surprisingly, 
combining 2 composites during extraction did not always produce higher RNA yields. This could 
be due to loss during the pellet washing stages. 
The results from this modified homogenisation improved upon the previous method as the RNA 
was less degraded. However, quality remained insufficient for use. As the yield was extremely 
variable and the method not producing sufficient quality RNA, the method was concluded as 
insufficient. 
 
Method – 3 
An alternative method for RNA extraction is the use of silica-membrane columns to selectively 
bind RNA. The QIAgen MiRneasy micro kit (Cat no. 217084, QIAgen) is based on this technique 
and was selected for trial as, unlike other membrane based columns, it retains smaller RNA 
molecules (>18 nucleotides compared to >200 of other available columns) and thus provides a 
similar total RNA spectrum to the Trizol methods. It is designed for use with small cell numbers 
and hence ideal for the composites. Furthermore, QIAshredder columns were also used as an 
additional step for the homogenisation process. The new procedure was based off the standard 
protocol provided in the kit (miRNeasy Micro Handbook by QIAgen, 2012) and used phenol-
chloroform phase separation similar to the previous methods. 
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Cell seeded composites were made with 40% PEG-RGD fibres and a 60 minute soak (n=6), and 
snap frozen in 2 mL cryovials 24 hours post production. Buffers in the kit were reconstituted as 
instructed in the manual. The first specimen was then transferred into a 1.5 mL micro-centrifuge 
tube and held in a shallow well of liquid nitrogen in a small mortar. The sample was ground 
down as much as possible by hand using a disposable pestle, taking care not to let the sample 
thaw by keeping the bottom of the tube in the cooled mortar. 1 mL QIAzol (supplied with kit) 
was added to the tube whilst in a fume hood and pipetted vigorously. The next sample was then 
processed in the same manner using a new disposable pestle for each one.  
Once all samples were homogenised by hand and in QIAzol, 700 µL of each sample was 
transferred into individual QIAshredder columns and centrifuged at full speed for 2 minutes to 
completely lyse the cells. The flow through was collected and the remaining 300µL of each 
sample was added to the respective columns and centrifuged in the same manner. Once all the 
samples were full processed, the collected homogenate was incubated at RT for 5 minutes and 
QIAshredder columns disposed of. 200 µL chloroform (~1/5 ratio) was then added to each tube, 
shaken vigorously for 15 seconds and then incubated at RT for 3 minutes.  
Following incubation, all the tubes were centrifuged at 12,000g for 15 minutes at 4°C. The upper 
aqueous phase was then transferred to new tubes and 1.5 x the volume 100 % ethanol added. 
After mixing this solution gently by pipetting, 700 µL of each sample was transferred into 
RNeasy MinElute Spin Columns (supplied with kit) with a re-useable collection tube (to collect 
flow through) and centrifuged at 8,000g for 30 seconds at RT. After this step the RNA was bound 
to the silica membrane and therefore the flow through discarded.  
The emptied collection tube was reused, and the remaining solution added to the respective 
columns, centrifuge repeated and the flow through discarded again. The membrane bound RNA 
was then washed with the two proprietary buffers supplied in the QIAgen kit. The collection 
tubes were reused and 700 µL of the first wash buffer added to each spin column. This was 
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centrifuged at 8,000g for 30 seconds at RT and the flow through discarded. Re-using the 
collection tubes, 500 µL of the second wash buffer was pipetted onto all the spin columns and 
all tubes centrifuged at 8,000 g for 30 seconds at RT. The flow through was discarded once again 
and the collection tubes reused once more. 80% ethanol was pipetted into each spin column, 
500 µL each, then centrifuged at RT for 2 minutes at 8,000g.  
Having completed all wash-through steps, both the flow through and collection tubes were then 
discarded. The spin columns were placed in new 2 mL collection tubes and centrifuged with lids 
open at full speed for 5 minutes at RT to dry the membrane. The new collection tubes were 
discarded again after this centrifuge and spin columns placed in a smaller 1.5 mL micro-
centrifuge tube for the final collection of RNA. 14 µL RNase free water was pipetted directly 
onto the centre of the membrane and left to incubate at RT for 5 minutes. These were then 
centrifuged at full speed for 1 minute at RT and the spin columns discarded. During this final 
elution step, 2 µL water is lost in the column and therefore the final flow through containing 
RNA was 12 µL. The tubes containing RNA were stored at -80°C until ready to measure. 
NanoDrop and gel electrophoresis were performed as described previously to check the quality 
of the RNA collected. 
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Results – 3 
Table 22: NanoDrop results for third method. Sample 1 showed significantly low 260/230 ratio and was therefore 
“re-dropped” and scanned to confirm it was not an anomaly. Total of 12 µL of RNA solution was extracted from 
each sample.  
Sample ID RNA Concentration (ng/µl) 260/280 260/230 Total RNA (ng) 
1 45.43 1.86 0.21 545.16 
1 (Re-drop & scan) 45.49 1.87 0.21 545.88 
2 51.44 2.01 1.67 617.28 
3 40.05 1.91 1.77 480.60 
4 48.14 2.02 1.49 577.68 
5 44.70 1.78 1.25 536.40 
6 31.86 2.00 1.23 382.32 
 
 
Figure 55: Screenshot of absorbance spectrum created by the NanoDrop spectrophotometer. The high absorbance 
between 220 and 230 nm is not an anomalous result and a re-drop and scan creates the same profile and thus 
contamination is present in the sample. 
  Sample 1 
  Sample 1 (Re-drop & scan) 
  Sample 2 
  Sample 3 
  Sample 4 
  Sample 5 
 Sample 6 
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Figure 56: Denaturing gel electrophoresis results for RNA samples extracted using membrane column based 
method. Sample 1 and 6 were lost whilst trying to pipette into the gel wells, hence only samples 2-5 indicated. 
Bands 28S, 18S and 5S indicated with white arrows. 
Discussion and Conclusion – 3 
The new method using QIAshredder columns and silica based membranes for RNA collection 
provided improved RNA purity, with 260/280 being within the acceptable range of 2±0.3. The 
260/230 was also improved and generally over 1.2, whereas previous attempts saw a 260/230 
of less than 1. Sample 1 was seen to have a low 260/230 ratio and contamination was clearly 
observed in the absorbance spectrum (Figure 55). The gel electrophoresis results also provided 
confidence in the new technique as clear bands of 28S, 18S and 5S were seen with minimal 
smearing, thus indicating intact RNA.  
Although the concentration of RNA was higher, the procedure itself proved too time consuming 
for large sample numbers, due to the first manual homogenisation step. Large chunks of 
composite also remained stuck in the QIAshredder column meshes, suggesting the inefficiency 
of homogenisation. 
28S 
18S 
5S 
  2    3    4    5 
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Method – 4 
Successful aspects of Method – 2 were taken forward, namely the improved homogenising 
capability of the Mikro-Dismembrator U and the multi sample holder.  
Cell seeded composites made with both 20% and 40% PEG-RGD fibres and a 60 minute soak 
were snap frozen in 1.2 mL cryovials 24 hours post production and kept in a Dewar containing 
liquid nitrogen for the first homogenisation step. A steel grinding ball (9 mm chromium steel) 
was added to each tube. The new holder for the Mikro-Dismembrator U can hold 4 vials at a 
time, hence the sample vials were processed in batches of 4. The sample holder was briefly 
cooled, 4 vials placed inside, and the holder secured tightly in the homogeniser and run at 2000 
rpm for 1 minute. The tubes were then kept in another small Dewar containing liquid nitrogen 
while the rest of the vials were processed in the same way. QIAzol (700 µL) was added to each 
vial individually. The QIAzol freezes once added to the tubes due to the low temperature and 
therefore care was taken to mix the homogenate as soon as it starts to thaw, to ensure it did 
not fully thaw without being in contact with QIAzol. At this stage the samples were processed 
in the same way as described in ‘Method – 3’; the QIAzol/RNA solution was pipetted into 
QIAshredder columns to ensure the cells were completely lysed; chloroform added (~ 1:5 ratio) 
to perform phase separation; solutions diluted by adding 100% ethanol in a 1:1.5 ratio; RNA 
collected on RNeasy MinElute Spin Columns; spin columns washed sequentially with the two 
supplied buffers and then 80% ethanol; spin columns dried by centrifuging with lids open for 5 
minutes; and then the final elution performed using 14 µL RNase free water.  
Additionally, an extra elution was performed on 3 spin columns (using 14 µL RNase free water) 
to confirm how much RNA was left behind and thus whether it was necessary to perform a 
second elution.  
NanoDrop was performed on these samples using the NanoDrop 1000 spectrophotometer as 
previously described. 
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Results – 4 
Table 23: NanoDrop results for samples tried with new method using Mikro-Dismembrator U, QIAshredder 
columns and QIAgen MiRNeasy Micro Kit. Spin columns used for samples 7, 8 and 9 were eluted with RNase free 
water a second time in separate tubes and indicated as ‘second elute’ in the table. 
Sample ID Composite Type ng/µl 260/280 260/230 Total RNA (ng) 
1 40% PEG-RGD 11.17 1.77 1.77 134.04 
2 40% PEG-RGD 12.69 2.03 2.03 152.28 
3 40% PEG-RGD 24.16 1.71 1.71 289.92 
4 20% PEG-RGD 22.15 1.7 1.11 265.8 
5 20% PEG-RGD 13.28 1.76 1.03 159.36 
6 20% PEG-RGD 14.8 1.66 0.6 177.6 
7 20% PEG-RGD 34.16 1.8 1.4 409.92 
8 20% PEG-RGD 20.04 1.8 1.2 240.48 
9 20% PEG-RGD 22.65 1.75 0.19 271.8 
7 - second elute 20% PEG-RGD 5.66 1.57 1.01 67.92 
8 - second elute 20% PEG-RGD 6.73 1.48 0.84 80.76 
9 - second elute 20% PEG-RGD 6.84 1.37 0.69 82.08 
 
               
Figure 57: Screen shot of NanoDrop results from samples 7, 8 and 9 after the first and second elution. Sample 9 
shows high absorbance at 220 nm suggesting some contamination.  
  Sample 7 
  Sample 8 
  Sample 9 
  Sample 7 – Second elute 
  Sample 8 – Second elute 
 Sample 9 – Second elute 
 RNase free water 
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Discussion and Conclusion – 4 
The method combining the Mikro-Dismembrator U, QIAshredder columns and MiRNeasy Micro 
Kit (Method – 4) consistently allowed extraction of RNA with 260/280 ratios within the 
acceptable 2±0.3 range (Table 23). The 260/230 ratios are similar to the previous method, and 
much improved compared to Method – 1 and Method – 2. Sample 9 has the lowest 260/230 
and is evident in Figure 57 to be due to high absorbance at 220nm, suggesting possible 
contamination. Interestingly, the second elute of sample 9 did not have a high absorbance at 
220nm, indicating that the contaminant may have transferred from the outer edge of the spin 
column on the first elute or possibly have been present in the tube beforehand. Additionally, 
while the samples from the second elute showed low 260/280 and 260/230 ratios, there does 
not seem to be contaminants in the actual absorbance spectra obtained, emphasising the 
concentration related effect of the ratios, where at lower RNA concentrations the impurity is 
over exaggerated. This observation was incorporated into the protocol for future use wherein 
the spectral profile obtained from the NanoDrop is used more so than the 260/230 ratio alone, 
particularly at lower RNA concentrations. Consequently, samples with a high peak at the 220 
region were rejected for use.  
The yield of RNA extracted with Method – 4 still remained lower than that with Method – 1. 
However, as the first method produced highly degraded RNA, the results obtained could have 
been artefacts and therefore not reliable. A second elute was performed on the spin columns 
to investigate whether any RNA still remained and whether it could be retrieved. The results in 
Table 23 showed some RNA was indeed left behind on the membrane, with approximately 67-
82 ng RNA recovered in a second elute. Incorporating a second elute into the protocol would 
require combining two RNA solutions, however as the concentration of the second RNA solution 
is low, combining both solutions would further dilute the concentration. As 9.5 µL of sample (~ 
100 ng total) is necessary for performing reverse transcription, a concentrated solution is 
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preferable and thus a second elution step is not a suitable approach. Although the yield of RNA 
extracted is not significantly improved, the quantity obtained is still higher than 100ng and 
therefore sufficient for downstream applications. To ensure enough RNA is obtained, in future 
experiments, samples will be combined in pairs (i.e. two composites used to create one RNA 
solution) at the spin columns step, creating a higher concentration of RNA. 
The use of a multi sample holder and Mikro-Dismembrator U significantly reduced the time 
required for homogenising samples compared to the previous method and is ideal for 
performing multiple extractions at once. This improved protocol, with its consistent 260/280 
ratio and sufficient RNA yield, was therefore adopted as the final method for further 
experiments looking into gene expression. 
 
 
3.3.2 Final Optimised RNA Extraction Protocol 
The final optimised version of the RNA extraction protocol is based on Method-4. Composites 
are combined during extraction and therefore experiments require all composite conditions in 
multiples of two. For example, 2 composites are paired and extracted together to provide 1 
RNA sample, thus 6 composites are needed if 3 individual RNA samples are required for PCR. 
The rest of the procedure is the same as that described in Method-4, where composites are 
homogenised via the Mikro-dismembrator U and QIAshredder columns and RNA collected and 
purified using the QIAgen MiRNeasy micro kit. 
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3.4 Bose Strain System and Setup 
Cyclic strain was applied to the composites using a Bose ElectroForce 5500 test system with 
custom made chambers to house individual samples. This system can be used within a cell 
culture incubator, maintaining cells in a viable environment during testing. The custom 
cylindrical chambers along with their setup within the Bose system is shown in Figure 58. The 
system was used to apply 5% cyclic strain at 1 Hz for 24 hours (86400 cycles) to composites. 
 
 
 
 
 
 
 
 
 
 
Figure 58: Images showing the Bose system and custom chamber setup. Image in the centre shows the stainless 
steel chambers with a composite setup inside. The image on the left shows the chamber filled with media and 
sealed with a glass cylinder. The image on the right shows the chambers attached to a multi chamber holding plate 
and connected to the Bose system inside an incubator. 
 
Glass Cylinder 
Media filled Chamber 
Bottom Grip 
Top Grip Plate 
Grip to Actuator 
Bose System 
Multi-Chamber Holder  
Composite 
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3.4.1 Custom chamber setup 
Before setting up the samples into the chambers, the chambers themselves along with the glass 
cylinders and tools used for assembly were put into autoclave bags and sterilised by 
autoclaving. They were then transferred into a sterile hood for assembly, securing the 
composites ready for loading chambers. Handling of all parts of the chambers and the 
composites was carried out with sterile tools which included screwdrivers, hex keys, forceps 
and spatulas. This was to prevent contamination of the composites and thus ensured viability 
over the test period. 
The top grip was removed from a chamber and placed on a petri dish, acting as a sterile work 
surface. The composite was placed into the dish with a few drops of media to keep it hydrated. 
The composite was then held on the top grip and the top grip plate screwed in slowly until the 
composite was secure. This assembled piece was then carefully slid into the chamber from the 
top, being careful not to crush or damage the sample. Once in, the bottom grip was screwed 
into place to secure the composite. The glass cylinder was then placed over the chamber and 
pushed down to create a tight seal. Approximately 2 mL of media was then pipetted into the 
chamber from the top, by temporarily offsetting the top grip slightly from the centre to expose 
a small gap into which media could be injected without damaging the sample. The top gap was 
re-centred and the filled chamber labelled, and temporarily placed on a small petri dish in case 
of leaks and placed into an incubator while the next chamber was prepared.  
Once all the composites were setup, the chambers were moved into the multi-chamber holder. 
The chambers were secured in the circular base plate first, after which the top circular plate 
was placed on top and the top grips of each chamber carefully connected. The entire setup was 
then moved into the incubator and connected to the Bose actuator securely ready for use.  
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3.4.2 Stable Gene Expression 
Preliminary data (not shown) from RT-qPCR data using human tenocyte seeded composites 
showed the expression of some genes, particularly MMP-1, changed significantly after 
encapsulation and handling, remaining unstable for up to 24 hours. Therefore gene expression 
of cells within the composite was investigated over time once set up into customised Bose 
chambers to determine the ideal time point for starting strain application. 
Experimental Overview 
 
Figure 59: Overview of experimental flow and variables investigated to determine the ideal experimental start 
point. 
Method 
PEG-RGD fibres were made with 20% and 60% PEG according the previously described method. 
Human tenocytes from a healthy Achilles tendon (obtained from 76 year old male patient, 
courtesy of University of East Anglia, further cell details and ethics statement provided in 
Appendix A: Human cell source and ethics) were resuscitated and cultured until P10, at which 
Composite 
Types
•Healthy Human Achilles Tenocytes
•20% and 60% PEG-RGD fibres
•Either 0 or 60 minute soak
Bose Strain 
System
•Composites set up into custom 
chambers
Stabilisation 
Time
•Either 0, 24, 48 or 72 hours waited 
before snap freezing samples.
Gene 
Expression
•18S, GAPDH, COL-1A1, MMP-1, 
TIMP-1, ADAMTS-5, Aggrecan and 
Decorin investigated
•Taqman primer and probes used
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point enough cells were ready to create all the composites. 4 time points were investigated; 0, 
24, 48 and 72 hours after Bose setup. Composites were made using either a 0 or 60 minutes 
soak, and enough composites made for all 4 time points and 3 repeats for each variable (total 
of 48 composites created, see Table 24). These were left overnight and set up into Bose 
chambers the next day. 
Table 24: Summary of composite type, time points analysed and no of samples. 
Composite Type No. of composites for time points: 
0 hours 24 hours 48 hours 72 hours 
20% PEG-RGD, 0 minute soak 3 3 3 3 
20% PEG-RGD, 60 minute soak 3 3 3 3 
60% PEG-RGD, 0 minute soak 3 3 3 3 
60% PEG-RGD, 60 minute soak 3 3 3 3 
36 custom strain chambers were autoclaved in preparation for use along with an autoclavable 
Philips screwdriver and hex keys. The composites were set up into the chambers as previously 
described and left for the designated time points. At this time, the 12 composites for the 0 hour 
time point were simply placed in 1.2 mL cryovials and snap frozen in liquid nitrogen and stored 
at -80°C. At 24 hours 12 composites were removed from the chambers, snap frozen in liquid 
nitrogen and stored at -80°C. This was repeated at 48 and 72 hours. 
Once all the samples were obtained the RNA was extracted using the Mikro-Dismembrator U, 
QIAshredder columns and MiRNeasy Micro Kit as described previously (section3.3, Final 
Optimised RNA Extraction Protocol). Due to the limited number of chambers and the number 
of time points investigated, the composites were not doubled during extraction and kept single.  
The RNA quantity was determined using the NanoDrop 1000 spectrophotometer and samples 
were all diluted to 80 ng/9.5 µL (i.e. the lowest possible RNA quantity per 9.5 µL). 9.5 µL of each 
RNA solution was pipetted out into 0.5 mL tubes and 200ng Random Hexomers added. The 
tubes were briefly centrifuged (~2000g for 10 seconds) and then placed in a thermocycler set 
to heat the samples to 70°C for 10 minutes and then held at 4°C until opened. A stock mastermix 
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of the reverse transcriptase solution was prepared using a Superscript II kit such that there was 
enough for all 48 samples, with 9 µL required per sample. For 1 sample (i.e. 9 µL) mastermix 
contained 1 µL Superscript II, 4.5 µL 5x Sample Buffer, 2 µL dithiothreitol, 1 µL deoxynucleotides 
and 0.5 µL recombinant RNasin ribonuclease inhibitor. The tubes were retrieved from the 
thermocycler, 9 µL of this mastermix solution added and re-incubated in the thermocycler for 
60 minutes at 42°C, then 70°C for 10 minutes and finally 4°C until the thermocycler was opened.  
Table 25: List of Human TaqMan primers and probes used (Ordered from Life Technologies). References listed 
below table. 
Target 
Gene 
Primer/Probe Sequence 
Amplicon 
size (bp) 
Location 
(bp) 
Ref 
COL-1A1 
Forward 5’- CGC ACG GCC AAG AGG AA -3’ 
66 185-251 1 Reverse 5’- CAT GGT ACC TGA GGC CGT TCT -3’ 
Probe 5’- FAM - CCA AGA CGA AGA CAT CCC ACC AAT CAC C –TAMRA -3’ 
18S 
Forward 5’- GCC GCT AGA GGT GAA ATT CTT G -3’ 
45 949-994 2 Reverse 5’- CAT TCT TGG CAA ATG CTT TCG -3’ 
Probe 5’- FAM - ACC GGC GCA AGA CGG ACC AG – TAMRA -3’ 
GAPDH 
Forward 5’- TTT TAA CTC TGG TAA AGT GGA TAT TGT TG -3’ 
97 240-337 1 Reverse 5’- TGA CGG TGC CAT GGA ATT T -3’ 
Probe 5’- FAM- ATT GAC CTC AAC TAC ATG GTT TAC ATG TTC CAA TAT G -3’ 
MMP-1 
Forward 5’- AAG ATG AAA GGT GGA CCA ACA ATT -3’ 
59 587-646 4 Reverse 5’ –CCA AGA GAA TGG CCG AGT TC -3’ 
Probe 
5’- FAM – CAG AGA GTA CAA CTT ACA TCG TGT TGC GGC TC - TAMRA -
3’ 
TIMP-1 
Forward 5'- GAC GGC CTT CTG CAA TTC C -3' 
53 288-341 3 Reverse 5'- GTA TAA GGT GGT CTG GTT GAC TTC TG -3' 
Probe 5'- FAM – ACC TCG TCA TCA GGG CCA AGT TCG T –TAMRA -3' 
ADAMTS-
5 
Forward 5’- AGG AGC ACT ACG ATG CAG CTA TC -3’ 
53 
1796-
1849 
5 Reverse 5’- CCC AGG GTG TCA CAT GAA TG -3’ 
Probe 5’- FAM - TGC CCA CAT AAA TCC TCC CGA GTA AAC A – TAMRA -3’ 
Aggrecan 
Forward 5’- CCG CTA CGA CGC CAT CTG -3’ 
50 
1400-
1450 
2 Reverse 5’- CCC CCA CTC CAA AGA AGT TTT -3’ 
Probe 5’- FAM - TAC ACA GGT GAA GAC TTT GTG GAC ATC CCA – TAMRA -3’ 
Decorin 
Forward 5’- GCT GTC AAT GCC ATC TTC GA -3’ 
50 264-314 2 Reverse 5’- GGG AAG ATC CTT TGG CAC TTT -3’ 
Probe 5’- FAM - CCA GAC CCA AAT CAG AAC ACT GGA CCA - TAMRA -3’ 
 
 
1) Ireland et al. (2001), 2) Corps et al. (2006), 3) Nuttall et al. (2003), 4) Jones et al. (2013), 
5) Porter et al. (2004) 
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1 µL of each cDNA sample was collected into a single micro-centrifuge tube to act as a standard 
curve stock (SCS). The remaining cDNA samples were diluted by adding 90 µL RNase free water 
to provide a total volume of 90 µL and kept on ice. Serial dilutions were performed on SCS using 
RNase free water (1:1.5) with a total of 5 standards being produced and kept on ice. All 48 
samples, 5 serial dilutions for standards and 3 non-template controls (RNase free water) were 
plated into a 96 well plate. A stock gene mix containing TaqMan primers and probes was then 
prepared for all the samples, with 0.5 µL forward primer (10 µM), 0.5 µL reverse primer (10 
µM), 0.5 µL TaqMan probes, 8.33 µL Mastermix and 5.17 µL RNase free water needed per 
sample. A different stock gene mix was prepared for each gene, with the specific TaqMan 
primers and probes listed in Table 25. 15 µL of the stock gene mix was added to the plate and 
run on an Applied Biosystems 7500 Real-Time PCR system, setting the reporter and quencher 
to FAM and TAMARA, respectively, and the reaction volume to 25 µL. 
The threshold Ct was obtained through the software supplied with the machine (7500 Software 
V2.06, Applied Biosystems) and the expression fold change calculated relative to the 0 hour 
samples and normalised to reference genes 18S and GAPDH using the Pfaffl efficiency corrected 
method (Pfaffl, 2001): 
Fold change = 
Etarget
∆Cttarget
Ereference
∆Ctreference
 
Where: 
Etarget = Efficiency of the target gene 
Ereference = Efficiency of the reference gene 
∆Cttarget = Threshold Ct control target gene - sample target gene 
∆Ctreference = Threshold Ct of control reference gene - sample reference gene 
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Results 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60: Gene expression graphs showing average fold change relative to the 0 hours composites and normalised 
to 18S and GAPDH (n=3). Bars show mean expression and error bars indicate standard deviation. Different 
composite types are kept separate, with colours indicating the time point. Samples are labelled as XX-YY-ZZ where 
‘XX’ indicates fibre type, ‘YY’ indicates soak time and ‘ZZ’ indicates the analysis time point. The biggest gene 
expression changes occur within 24 hours setting up into chambers. The gene expression then stays relatively 
consistent for the next 72 hours, although with small variations. ‘+’ indicates significant differences compared to 
0 hour control composites (+ = P<0.05, ++ = P<0.01 and +++ = P<0.001), while ‘*’ indicates significant differences 
between other time points (* = P<0.05, ** = P< 0.01 and *** = P<0.001). 
Legend:         24 hours 
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Discussion and Conclusion 
The gene expression data obtained from leaving samples static in chambers for up to 72 hours 
(Figure 60) showed the largest gene expression changes, for genes such as COL1A1 and MMP1 
during the first 24 hours. The expression levels then stay fairly stable, either in the elevated or 
reduced state, over the next 48 hours. Although small variations were observed during these 
additional 48 hours, the changes were not as dramatic as the initial change. The initial change 
was also an interesting observation in itself, as the only differences between the 0 hour samples 
and the 24 hours samples are the handling, suggesting that this brief period of handing, 
approximately 3-5 minutes, was enough to evoke a response from the cells. Such a finding 
reflects previous studies that have shown that brief loading periods such as 100 cycles of up to 
5% cellular strain at 0.1 Hz result in changes in gene expression (Huisman et al., 2014; Scott et 
al., 2011).  
Alternatively, another difference between the two groups was the state of tension, as before 
being placed in chambers the composites were in a free swelling state, whereas once set up, 
the composites were held taut. It is possible that gripping samples and securing them in 
chambers, preventing free-swelling influenced gene expression, supported by the fact that 
initial changes observed in the current study remained for the duration of the experiment. 
Indeed, dissecting and incubating rat tail tendon fascicles (RTTFs) in culture media, i.e. stress 
deprivation, has been shown to significantly change matrix related gene expression in tenocytes 
for the first 24 hours (Leigh et al., 2008), and change the mechanical properties of RTTFs 
compared to those held taught, i.e. not stress deprived (Abreu et al., 2008).  
The aim of this investigation was to find a stable point at which strain application could be 
engaged, allowing confidence the gene expression observations would be due to the loading 
regime itself rather than other factors. The biggest changes occurred within the first 24 hours 
after composites were set into chambers, suggesting a minimum wait time of 24 hours prior to 
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loading. As leaving the composites in chambers for longer increases the risk of contamination, 
it was decided leaving the composites for 24 hours is ideal and therefore the procedure taken 
forward. 
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Healthy and Tendinopathic Tenocyte Metabolism 
: Healthy and Tendinopathic Human 
Tenocyte Metabolism 
 
This chapter focuses on the use of the newly developed fibre composite system (summarised 
in Chapter 2) for investigating the metabolism of healthy and tendinopathic human tenocytes. 
The preliminary results obtained are discussed under 3 subheadings (‘Results: Differences 
between pre-seeded tendinopathic and healthy tenocytes’, ‘Results: Substrate stiffness effects 
and differences between tendinopathic and healthy tenocytes in non-strained composites’ and 
‘Results: Shear-tension ratio effect’). These look at a baseline gene expression profile 
differences in healthy and tendinopathic tenocytes before encapsulation into composites, 
differences in gene expression after encapsulation in composites and the effect of substrate 
stiffness, and the gene expression changes in response to different shear-tension ratios, 
respectively. An overall conclusion is provided at the end of the chapter. 
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4.1 Rationale and Hypotheses 
Research from literature, summarised in Chapter 1, revealed that the aetiology of tendinopathy 
is complex and riddled with uncertainty. The possible effects of mechanical stimulation, 
collagen synthesis rates, matrix enzymes, neuropeptides, growth factors and other receptive 
chemicals are difficult to isolate and study using currently established in vivo models, while in 
vitro models have mostly been limited to either 2D or non-physiological 3D systems (Andersson 
et al., 2011; Arnoczky et al., 2007; Butler et al., 2009; Goodman et al., 2004; Jones et al., 2013; 
Zhang and Wang, 2010b).  The fibre composite system was developed to solve this problem, 
allowing research into tenocyte behaviour using a physiologically equivalent cellular 
environment under tightly controlled conditions. More specifically, the composites can 
recapitulate the shear and tension experienced by tenocytes within tendons both 
physiologically and non-physiologically, thus allowing the effect of shear-tension ratios to be 
investigated objectively. 
Tendinopathies are thought to be instigated by changes in cell-matrix interactions triggered by 
microdamage after tendon overuse. Matrix microdamage increases fibre shear, consequently 
increasing the magnitude of cellular shear. Shear is thus a potentially important 
mechanotransduction cue involved in ECM maintenance, but its effects on matrix anabolism 
and catabolism are unknown. An imbalance in ECM synthesis and degradation is also thought 
to contribute to the failed healing response seen in tendinopathies. 
As ECM changes are prominent in tendinopathies, the fibre composite system was used to 
investigate the effect of varying levels of shear on ECM matrix turnover. This included the 
physiological tendon equivalent (40% fibre tension and 60% fibre shearing within the matrix), 
along with non-physiological conditions of high shear (25% tension and 75% shear) and low 
shear (60% tension and 50% shear). Furthermore, the response of tenocytes derived from 
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healthy Hamstring tendons were compared to those derived from tendinopathic Achilles 
tendons to investigate differences between diseased and healthy cells. 
The net response of cells (i.e. anabolic or catabolic) can be established by monitoring the gene 
expression levels of substances involved in ECM turnover. This was used to determine the type 
of response evoked by different shear-tension ratios, hypothesising that the shear ratio would 
affect ECM turnover. It was also hypothesised that the response pattern of the two cell types 
(tenocytes derived from healthy and tendinopathic tissue) would not differ as both are 
essentially tenocytes and shear would affect both in a similar manner. 
To investigate the changes in matrix turnover, a broad spectrum gene expression analysis was 
performed. This included gene expression levels of several MMPs, ADAMTSs, proteoglycans and 
collagen types, along with the gene expression of a few other specific ECM proteins, cell type 
markers and interleukins. An overview of the function and associations of these components 
with tendinopathies are provided in the Chapter 1 (section 1.4.2). 
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4.2 Experimental Overview 
A broad spectrum gene expression analysis was performed using custom TaqMan® low density 
array (TLDA) cards. The benefit of TLDA cards is the ability to analyse a large variety of genes 
with a small volume of sample. The TLDA cards were chosen with a 48 well layout (Figure 61); 
each card had 8 sample reservoirs, with each port connected to 48 wells and each well 
containing the TaqMan® assay for a different gene. As the quantity of ECM related genes is 
extremely large and the chosen TLDA cards limited to 48 genes, genes associated specifically 
with tendons and tendinopathy were selected to perform a more targeted investigation. The 
genes selected for analysis (listed in Table 28) covered a variety of collagens, MMPs, ADAMTS, 
proteoglycans, interleukins, other ECM proteins and some cell type markers.  
 
Figure 61: TLDA card graphic showing 8 port layout and connected wells. Cards are custom-ordered to specify 
TaqMan gene expression assays for each well. Image adapted from Applied Biosystems (2006). 
Performing such a broad spectrum gene analysis is costly, therefore only one cell attachment 
peptide type was investigated to reduce unnecessary variables. Due to the slightly more 
consistent cell coverage observed with PEG-RGD than PEG-DGEA fibres and wider use of RGD 
with PEG in literature (DeLong et al., 2005; Dettin et al., 2009; Lynn et al., 2011; Steinmetz and 
Bryant, 2011; Yang et al., 2005), YRGDS peptide was used for these studies instead of DGEA. 
The study used human tenocytes derived from healthy and tendinopathic tissue in PEG-RGD 
fibre composites containing either physiological or non-physiological shear-tension ratios 
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Cell Type Fibre Type Soak Time 
(variables summarised in Figure 62). These were loaded to 5% strain at 1Hz for 24 hours, after 
which the samples were snap frozen.  
Experiments with all 4 shear-tension conditions were repeated 4 times with cells from 4 
different cell donors (2 healthy and 2 tendinopathic). Due to the limited number of human cell 
donors available for each cell type at the time of experiment, the data is presented as 
preliminary data. As such, statistical analysis in this chapter is only used to identify possible 
trends and are specific for the cells used only. The statistics cannot be used as conclusive 
evidence for the trends of tenocytes in all humans. 
   
 
NP = Non-physiological shear-tension ratio 
P = Physiologically equivalent shear-tension ratio 
 
Figure 62: Overview of variables within experiment. Healthy (n=2) and tendinopathic (n=2) cells were tested within 
composites made using PEG-RGD fibres of 20% and 60% PEG. Fibres are also left to soak for either 0 or 60 minutes 
before polymerisation, thus a total of 4 composite types are created per cell type. 6 composites of each type were 
made (n=6), but after loading the specimens are combined in pairs for RT-qPCR, so n=3 for the final results. 
Healthy
20% PEG
60 min
10 min
60% PEG
60 min
10 min
Tendinopathic
20% PEG
60 min
10 min
60% PEG
60 min
10 min
Te
n
si
o
n
 
Sh
ea
r 
Te
n
si
o
n
 
Sh
ea
r 
- NP 
- P 
- P 
- NP 
- NP 
- P 
- P 
- NP 
2 Donors 
2 Donors 
n=6 n=2 
Chapter 4 Healthy and Tendinopathic Tenocyte Metabolism  
 
Section 4.3 - Methods 184 
 
4.3 Methods 
Note 1: The protocols for cell culture, manufacturing composites, setting up the Bose strain 
system and RNA extraction are detailed comprehensively in Chapter 3 and only stated in brief 
under this section. Other additional procedures, such as RT-qPCR with TLDA cards which have 
not been previously detailed, are described fully.  
Note 2: Further details of all chemicals used, including supplier details, are present in Table 35 
and Table 36, in Appendix B: Chemicals and Materials List. 
Cells and Cell Culture 
Frozen human tenocytes derived from healthy hamstring tendons (19 year old female and 22 
year old male) and tendinopathic Achilles tendons (45 year old male and 51 year old male) were 
received from the University of East Anglia (further details and ethics statement provided in 
Appendix A: Human cell source and ethics). Both healthy and tendinopathic tenocytes were 
resuscitated and grown in culture flasks in the same manner until the required cell number were 
reached (P3-4 and P5-6, respectively). Human tenocyte growth media (referred to as 10% FBS 
media) used during cell culture consisted of Dulbecco’s Modified Eagle Medium with low 
glucose and GlutaMAX™ (DMEM-G), 10% FBS (Batch No. 111M339) and 1% 
Penicillin/Streptomycin (Pen/Strep).  
PEG-RGD Fibre Production 
PEG-RGD fibres were made by preparing solutions of 60% or 20% w/v PEGDM in PBS, with 0.05% 
w/v Irgacure 2959 and 5mM YRGDS peptide conjugated to acrylate-PEG-NHS. These were 
pipetted into Teflon fibre moulds and polymerised for 10 minutes under UV light (365 nm 
wavelength, ~4mW/cm2). Fibres were then extracted from the moulds and stored in a petri dish 
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with 70% ethanol. A total of 3200 fibres were made; 1600 20% PEG-RGD fibres and 1600 60% 
PEG-RGD fibres.  
Fibre Seeding 
Fibres were prepared for seeding by moving the fibres into a sterile hood and sterilising under 
UV light for 1 hour. Sterile forceps were then used to transfer 400 20% PEG-RGD fibres equally 
into 2 wells of a non-tissue culture treated 24 well plate, i.e. 2 wells with 200 fibres each. The 
same was done with 60% PEG-RGD fibres. This was to ensure enough fibres were seeded to 
create fibre composites with soak times of 0 minutes and 60 minutes for both fibre types. The 
wells containing fibres were filled with 2 mL serum free culture media (media containing only 
DMEM-G and 1% Pen/Strep) and left in an incubator (37°C, 5% CO2) for 30 minutes to 
acclimatise while cells were prepared for seeding.  
One cell type was harvested from flasks via trypsinisation and re-suspended in serum free 
culture media at 3.5 million cells/mL. At this point a cell sample was taken to analyse the gene 
expression of cells in their ‘pre-seeded’ state. To do this, 3 micro-centrifuge tubes were 
prepared with 700 µL QIAzol Lysis Reagent and 40000 cells (11.4 µL of the cell suspension 
above) pipetted into each tube. The tubes were vortexed vigorously for a few minutes to lyse 
the cells and stored at -80°C until ready for RNA extraction. 
The 24 well plate containing PEG-RGD fibres was then retrieved from the incubator and media 
aspirated from the wells. 1 mL of the cell suspension (i.e. 3.5 million cells) was added to each 
well containing fibres and the plate placed back into the incubator. After 1.5 hours, 0.5 mL 
media was removed from each well and 0.5 mL 10% FBS media added. This was left for a further 
1.5 hours in the incubator after which the fibres were transferred into different wells containing 
fresh media with serum. The plate was then left overnight in the incubator for the cells to fully 
attach. 
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Composite Production 
The next day composites were made using the cell seeded fibres. A solution of 20% PEGDM was 
first prepared by mixing 20% w/v PEGDM with 10% v/v FBS media and 0.05% w/v Irgacure 2959. 
The solution was then sterile filtered using 0.22 µm syringe filters and moved into a sterile hood 
along with sterilised tools, Teflon composite moulds, glass slides and a UV lamp. A drop of 20% 
PEGDM was placed on a glass slide and 10 20% PEG-RGD fibres were dipped into the drop 
before placing the fibres in a prepared Teflon composite mould. A glass slide was then placed 
on top of the mould and the 20% PEGDM solution injected in slowly using a 5 mL syringe and 
25 gauge needle. Once filled, the mould was left for 60 minutes for the fibres to soak and then 
polymerised under UV light (365nm wavelength, ~4mW/cm2) for 10 minutes. The composites 
were then extracted from the moulds and stored in separate petri dishes containing 10% FBS 
media. This was repeated until 18 20% PEG-RGD composites with 60 minutes soak were made, 
after which the soak time was decreased to 0 minutes and a further 18 composites made. The 
entire process was repeated again using 60% PEG-RGD fibres until 18 60% PEG-RGD composites 
with 0 and 60 minute soak were made. All composites, in their separate petri dishes, were 
stored in an incubator overnight. Note, only 12 of each type of composite were required for the 
experiment and the 6 additional composites were made in case composites were damaged or 
broken whilst setting up in chambers in the later stages. 
Strain Application 
The next day 48 loading chambers, along with tools for assembly (screwdriver, hex keys, spatula 
and forceps) were autoclaved and moved into a sterile hood. The composites were retrieved 
from the incubator and each composite secured into an individual chamber carefully using 
aseptic techniques and filled with approximately 2 mL 10% FBS media. 24 chambers, 6 of each 
composite type, were allocated as non-strained controls, whilst the remaining 24 were labelled 
as strained samples. The chambers allocated for loading were connected to the Bose strain 
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system inside an incubator while the non-strained controls were left secured in their chambers, 
but disconnected in the same incubator. All chambers were then left to equilibrate for 24 hours 
in the incubator before initiating loading.  
The following day, the Bose system was set to load samples to 5% strain at 1 Hz for 24 hours 
(86400 cycles). At the end of the loading regime, the composites from all test groups, strained 
and unstrained, were removed from the chambers and paired into 1.2 mL cryovials; 2 
composites of the same type were put into the same cryovial, so for each composite type there 
were only 3 cryovials instead of 6. The cryovials were then snap frozen in liquid nitrogen and 
stored at -80°C until ready for RNA extraction. 
RNA Extraction 
RNA was extracted, using the optimised protocol described in Chapter 3 and eluted in 15 µL 
RNase free water. The quantity of RNA was measured using a NanoDrop Spectrophotometer 
1000 and 1 µL of sample. All the samples where then diluted to 140.7 ng/9.5 µL using RNase 
free water and stored at -80°C. 
RT-qPCR with TLDA Cards 
The tubes containing diluted RNA were thawed and 9.5 µL of each transferred into new micro-
centrifuge tubes. 250 ng of Random Hexomers (1.5µL of stock solution) was added to each tube 
and then the tubes centrifuged at ~2000g for 10 seconds. These were then placed into a thermal 
cycler (model 2720, Applied Biosystems) set to run at 70°C for 10 minutes and then 4°C until 
opened.  
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A reverse transcriptase mastermix solution was made, enough for 62 samples (60 samples plus 
2 extra in case of loss); 
Table 26: Details of reverse transcription mastermix solution made. 
Substance (Supplier) 
Quantity for 
1 sample (µL) 
Quantity for 62 
samples (µL) 
Superscript II (Life Technologies) 1 62 
5x Sample Buffer (supplied in Superscript II kit) 4.5 279 
Dithiothreitol (DTT) (supplied in Superscript II kit) 2 124 
Deoxynucleotide triphosphates (dNTPs) (Promega) 1 62 
Recombinant RNasin Ribonuclease Inhibitor (Promega) 0.5 31 
 
Once the thermal cycler had stopped in the final hold stage, the tubes were removed and 9 µL 
of the reverse transcriptase mastermix added to each tube. The tubes were then centrifuged at 
~2000g for 10 seconds to collect the solution at the bottom of the tubes and placed in the 
thermal cycler to run for 60 minutes at 42°C, then 70°C for 10 minutes and finally 4°C until the 
thermal cycler was opened.  
Once the reverse transcription process had finished, the tubes containing the resulting 
complimentary DNA (cDNA) were removed from the thermal cycler and kept on ice whilst 
proceeding with the next steps. The cDNA was diluted to a total volume of 55 µL by adding 35 
µL RNase free water and mixed gently through pipetting.  
A 96 well plate was prepared to check the 18S gene expression of all the samples before 
continuing with the TLDA cards. This was to ensure the samples were of good quality before 
using the TLDA cards. 8 µL RNase free water was pipetted into 63 wells - 60 samples plus 3 non-
template controls (NTC), followed by 2 µL of each cDNA sample. A stock gene mix was made 
enough for 62 samples (2 extra included in case of loss) as detailed in the Table 27. 
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Table 27: Details of the components for the stock gene mix made for 18S. 18S design reference from Corps et al., 
2006. 
Substance (Supplier) 
Quantity for 
1 sample (µL) 
Quantity for 62 
samples (µL) 
18S Forward Primer (10 µM) (Life Technologies) 
5’-GCCGCTAGAGGTGAAATTCTTG-3’ 
0.5 31 
18S Reverse Primer (10 µM) (Life Technologies) 
5’-CATTCTTGGCAAATGCTTTCG-3’ 
0.5 31 
18S TaqMan Probe (Life Technologies) 
5’-ACCGGCGCAAGACGGACCAG-3’ 
0.5 31 
KAPA Universal qPCR Kit (Anachem) 8.33 516.46 
RNase free water (Sigma Aldrich) 5.17 320.54 
 
15 µL of this stock gene mix was then pipetted into the 96 well plate containing cDNA and a 
sealing tape (Life Technologies) applied on top of the plate to seal the wells. The plate was 
briefly centrifuged at ~2000g for 10 seconds to collect the solution at the bottom of the wells 
and then placed into the 7500 Real-Time PCR system (Applied Biosystems). The two dyes, FAM 
and TAMRA, were set as the reporter and quencher respectively, and the thermal profile set to 
run at 50°C for 2 minutes, 95°C for 10 minutes and followed by 40 cycles of 97°C for 30 seconds 
and 60°C for 1 minute.  
The resulting 18S amplification curves were analysed to check any anomalies in samples and 
ensure all samples were amplified before proceeding with the TLDA cards. The threshold cycle 
(Ct) values were extracted through the Applied Biosystems 7500 Software V2.0.6 (Life 
Technologies) by setting the threshold near the end of the linear amplification region (example 
shown in Figure 63). The Cts were compared to identify potentially contaminated or degraded 
samples by seeing if any deviated more than ± 2 cycles from the mean Ct. 
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Figure 63: Example of threshold cycle calculation using the Applied Biosystems 7500 software V2.0.6 (Life 
Technologies) for 18S. The threshold line was set to intersect the amplification lines towards the end of the linear 
region, and the cycle number at intersection extracted. This value was labelled as the threshold cycle (Ct). 
Once the samples were confirmed to be of good quality, the remaining cDNA was prepared for 
use in the TLDA cards. As the TLDA cards only have 8 sample reservoirs, only 8 samples could 
be tested at a time and therefore samples were prepared for qPCR in batches of 8. The TLDA 
card gene layout is shown in Table 28  and the TLDA card preparation procedure summarised 
in Figure 64. The first TLDA card was retrieved from 4ᵒC storage and left on the bench for 15 
minutes to bring to room temperature. 8 cDNA samples were diluted with 52 µL TaqMan® 
Universal PCR Master Mix, i.e. 1:1 ratio, and gently mixed through pipetting. The TLDA card was 
then carefully opened from its packaging to avoid contaminating the bottom of the plate and 
100 µL of each sample pipetted into separate sample reservoirs. The plate was then centrifuged 
for 1 minute at 1200 rpm to fill the wells centrifugally and the wells sealed using a plate sealer. 
The reservoir edge of the card was then cut away and the card placed into a 7900HT Real-Time 
PCR System (Applied Biosystems). The thermal profile was set to run at 50°C for 2 minutes, then 
94.5°C for 10 minutes followed by 40 cycles of 97°C for 30 seconds and 59.7°C for 1 minute. 
After the machine had finished 40 cycles, the next TLDA card was prepared and the above 
process repeated until all samples had been processed. 
Threshold line 
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The raw data obtained from the machine was analysed using RQ Manager (Applied Biosystems). 
Similar to the analysis method described in Figure 63, the threshold was set at the end of the 
linear region of the amplification curve and the threshold cycles (Ct) extracted for all the 
samples and genes. The threshold for each gene was set at the same value for all composite 
and cell types, with undetected samples given an arbitrary value of 40 to represent the max 
cycle number. The extracted Ct values were then imported into Excel (Microsoft) to calculate 
the gene expression normalised to the reference gene TOP1 (2ΔCt) and as fold changes (2ΔΔCt) 
using the formulas: 
 
2𝛥𝐶𝑡 = 2𝐶𝑡𝑇𝑎𝑟𝑔𝑒𝑡−𝐶𝑡𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒  
 
2𝛥𝛥𝐶𝑡 = 2𝑆𝑡𝑟𝑎𝑖𝑛𝑒𝑑∆𝐶𝑡/𝐶𝑜𝑛𝑡𝑟𝑜𝑙∆𝐶𝑡 
 
 
 
 
 
 
 
 
 
Where: 
𝐶𝑡𝑇𝑎𝑟𝑔𝑒𝑡 = Ct of target gene 
𝐶𝑡𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒  = Ct of reference gene 
 
 
 
 
 
Where: 
∆Ct = CtTarget − CtReference 
Strained∆Ct = ∆Ct of strained sample 
Control∆Ct = ∆Ct of reference sample 
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Figure 64: Flow diagram depicting the procedure for preparing TLDA cards. The Sample reservoirs are first fill with 
the sample cDNA which is then forced centrifugally into the connected 48 wells. The wells are then sealed in the 
plate sealer and the reservoir edge cut off. Images adapted from Applied Biosystems (2006). 
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Table 28: TLDA card layout for wells 1-35 (wells 36-48 listed in Table 29). Each well contained a different TaqMan® 
gene expression assay. 
Well Gene Symbol Assay ID 
1 Tenomodulin TNMD Hs00223332_m1 
2 Scleraxis SCX Hs03054634_g1 
3 Tenascin-C TNC Hs01115665_m1 
4 Cartilage Oligomeric Protein COMP Hs00164359_m1 
5 Fibronectin FN-1 Hs00365052_m1 
6 Interleukin-1 IL-1β Hs01555410_m1 
7 Interleukin-2 IL-2 Hs00174114_m1 
8 Interleukin-6 IL-6 Hs00985639_m1 
9 Interleukin-8 IL-8 Hs00174103_m1 
10 A Disintegrin And Metalloproteinase with Thrombospondin Motifs-1 ADAMTS-1 Hs00199608_m1 
11 A Disintegrin And Metalloproteinase with Thrombospondin Motifs-2 ADAMTS-2 Hs01029111_m1 
12 A Disintegrin And Metalloproteinase with Thrombospondin Motifs-3 ADAMTS-3 Hs00610744_m1 
13 A Disintegrin And Metalloproteinase with Thrombospondin Motifs-4 ADAMTS-4 Hs00192708_m1 
14 A Disintegrin And Metalloproteinase with Thrombospondin Motifs-5 ADAMTS-5 Hs00199841_m1 
15 A Disintegrin And Metalloproteinase with Thrombospondin Motifs-6 ADAMTS-6 Hs01058097_m1 
16 A Disintegrin And Metalloproteinase with Thrombospondin Motifs-12 ADAMTS-12 Hs00229594_m1 
17 A Disintegrin And Metalloproteinase with Thrombospondin Motifs-14 ADAMTS-14 Hs01548449_m1 
18 Matrix Metalloproteinase-1 MMP-1 Hs00899658_m1 
19 Matrix Metalloproteinase-2 MMP-2 Hs01548727_m1 
20 Matrix Metalloproteinase-3 MMP-3 Hs00968305_m1 
21 Matrix Metalloproteinase-7 MMP-7 Hs01042796_m1 
22 Matrix Metalloproteinase-8 MMP-8 Hs01029057_m1 
23 Matrix Metalloproteinase-9 MMP-9 Hs00234579_m1 
24 Matrix Metalloproteinase-13 MMP-13 Hs00233992_m1 
25 Tissue Inhibitor of Metalloproteinase-1 TIMP-1 Hs00171558_m1 
26 Tissue Inhibitor of Metalloproteinase-2 TIMP-2 Hs00234278_m1 
27 Tissue Inhibitor of Metalloproteinase-3 TIMP-3 Hs00165949_m1 
28 Tissue Inhibitor of Metalloproteinase-4 TIMP-4 Hs00162784_m1 
29 Lubricin PRG-4 Hs00195140_m1 
30 Aggrecan ACAN Hs00153936_m1 
31 Biglycan BGN Hs00156076_m1 
32 Versican VCAN Hs00171642_m1 
33 Decorin DCN Hs00370384_m1 
34 Fibromodulin FMOD Hs00157619_m1 
35 Laminin LAMA-1 Hs00300550_m1 
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Table 29: Continuation of TLDA card layout for wells 36-48. Each well contained a different TaqMan® gene 
expression assay. 
Well Gene Symbol Assay ID 
36 Collagen Type I, Alpha 1 COL-1A1 Hs00164004_m1 
37 Collagen Type II, Alpha 1 COL-2A1 Hs00264051_m1 
38 Collagen Type III, Alpha 1 COL-3A1 Hs00943809_m1 
39 Collagen Type IV, Alpha 1 COL-4A1 Hs00266237_m1 
40 Collagen Type V, Alpha 1 COL-5A1 Hs00609133_m1 
41 Collagen Type VI, Alpha 1 COL-6A1 Hs01095585_m1 
42 Collagen Type IX, Alpha 1 COL-9A1 Hs00932129_m1 
43 Collagen Type XI, Alpha 1 COL-11A1 Hs01097664_m1 
44 Collagen Type XII, Alpha 1 COL-12A1 Hs00189184_m1 
45 Collagen Type XIV, Alpha 1 COL-14A1 Hs00964045_m1 
46 Glyceraldehyde 3-phosphate dehydrogenase GAPDH Hs99999905_m1 
47 18S ribosomal ribonucleic acid 18S Hs99999901_s1 
48 Topoisomerase-1 TOP-1 Hs00243257_m1 
 
Although the n number is low, statistical analysis was used for comparisons between 
experimental repeats and between composite types to assess the possibility of real differences. 
These statistics reflect the differences and trends present in the cells used only, and are not 
intended as statistics for tenocyte trends in all humans. Statistical analysis was performed using 
Student’s t-test for comparing basal gene expression between tendinopathic and healthy cell 
types, while one way analysis of variance (one way ANOVA) was used for comparison of the 
different shear-tension ratios, followed by Tukey’s Honest Significant Difference (HSD) pot-hoc 
test, if differences were found through the one way ANOVA, and P values < 0.05 were 
considered significant. 
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4.4 Preliminary Data and Discussion 
4.4.1 Results: Differences between pre-seeded tendinopathic and healthy 
tenocytes 
The basal gene expression of tenocytes in the pre-seeded state, i.e. after harvesting from 
culture flasks, was analysed to identify differences in cell types before incorporation into 
composites. This included two healthy and two tendinopathic tenocyte types. Interestingly, it 
was found that the two cell types showed differences in their basal gene expression – 
particularly collagens type 12 and 14, MMP-3 and 4, ADAMTS-2, 5 and 12, lubricin, versican and 
IL-8. To look at these in more detail, gene expression data has been graphed in the categories: 
‘Collagens’, ‘MMPs’, ‘ADAMTSs’, ‘TIMPs’, ‘Proteoglycans’, ‘Interleukins’ and ‘Other Proteins’. 
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Collagens 
The collagens investigated via RT-qPCR were collagen type I, II, III, IV, V, VI, IX, XI, XII and XIV. 
Figure 65 shows the basal expression of these collagens for pre-seeded tendinopathic and 
healthy cells. Significant differences were seen in the gene expression levels of COL-12A1 and 
COL-14A1, with both significantly lower in tendinopathic cells than healthy cells. Although not 
statistically significant, COL-6A1 also showed notably lower expression in tendinopathic 
tenocytes compared to healthy tenocytes (p=0.08).  
 
Figure 65: Average collagen basal expression for pre-seeded cells. Expression shown as 2ΔCt (normalised to TOP-1) 
with both healthy and both tendinopathic cell types averaged. Error bars represent standard deviations. 
Tendinopathic tenocytes generally showed more variability in basal gene expression, as seen in COL-1A1, COL-5A1 
and COL-14A1 expression, and also showed significantly less COL12A1 and COL-14A1 expression. Cell type n=2, 
with 3 repeats per cell type. * = P<0.05, ** = P<0.01. 
The gene expression levels of collagens were generally more variable in tendinopathic 
tenocytes compared to healthy tenocytes (indicated by larger standard deviation bars in Figure 
65), particularly in COL-1A1, COL-5A1 and COL-14A1. This was attributed to the tendinopathic 
tenocytes from the two donors having different basal levels; one tendinopathic tenocyte group 
had 9 times higher COL-1A1, 5 times higher COL-5A1 and 3 times less COL-14A1 gene expression 
than the other group. Other distinct differences between tendinopathic donors were also seen 
in other genes (discussed under further subheadings). 
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MMPs 
The MMPs investigated were MMP-1, 2, 3, 7, 8, 9 and 13, however the gene expression levels 
of MMP-8 and 9 were too low for detection in all pre-seeded cell types. MMP-7 was only 
detected in 1 tendinopathic cell sample, in which expression levels were extremely low. MMP-
1 and MMP-2 gene expression were similar for both healthy and tendinopathic tenocytes. 
However, MMP-3 and MMP-13 varied between cell type, and while undetected in all pre-
seeded healthy tenocyte samples, low levels were detected in tendinopathic tenocytes (Figure 
66). The large standard deviations in MMP-3 and MMP-13 expression were again due to 
differences between the two tendinopathic tenocyte donors; one tendinopathic tenocyte 
expressed 20 times less MMP-3 and 42 times less MMP-13 than the other. 
 
Figure 66: Average MMP basal expression for pre-seeded cells. Expression shown as 2ΔCt (normalised to TOP-1) 
and undetected samples given a Ct value of 40 to represent the max cycle number. Both healthy and both 
tendinopathic cell types were averaged and error bars represent standard deviations. MMP-8 and MMP-9 were 
undetected for all samples, while MMP-3 and MMP-13 were only detected in tendinopathic samples. 
Tendinopathic tenocytes showed significantly higher basal MMP-3 and MMP-13 gene expression. Cell type n=2, 
with 3 repeats per cell type. * = P<0.05. 
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ADAMTSs 
The ADAMTSs investigated were ADAMTS-1, 2, 3, 4, 5, 6, 12 and 14. Figure 67 clearly shows that 
many of these genes differed in basal expression levels between healthy and tendinopathic 
cells; the gene expression of ADAMTS-2 and ADAMTS-12 were significantly higher, and 
ADAMTS-5 significantly lower in tendinopathic cells compared to healthy cells. Additionally, 
although not statistically significant, ADAMTS-3 was notably lower (P=0.06) and ADAMTS-4 
higher (P=0.06) in tendinopathic cells compared to healthy cells.  
 
Figure 67: Average ADAMTS basal expression for pre-seeded cells. Expression shown as 2ΔCt (normalised to TOP-
1). Both healthy and both tendinopathic cell types were averaged and error bars represent standard deviations. 
ADAMTS-2 and ADAMTS-12 are seen to be expressed significantly more by tendinopathic cells while ADAMTS-5 is 
significantly less. Cell type n=2, with 3 repeats per cell type. * = P<0.05, ***=P<0.001. 
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TIMPs 
TIMP-1, TIMP-2, TIMP-3 and TIMP-4 gene expression was profiled in the pre-seeded tenocytes. 
No significant differences were seen between healthy and tendinopathic tenocyte types. The 
basal expression for TIMP-4 was found to be lower than that of TIMP-1, TIMP-2 and TIMP-3, 
with TIMP-2 having the highest expression. 
 
Figure 68: Average TIMP basal gene expression for pre-seeded cells. Expression shown as 2ΔCt (normalised to TOP-
1). Both healthy and both tendinopathic cell types were averaged and error bars represent standard deviations. 
TIMP-4 is seen to have the lowest gene expression whilst TIMP-2 is the highest. No significant differences were 
seen between healthy and tendinopathic tenocytes. Cell type n=2, with 3 repeats per cell type. 
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Proteoglycans 
Figure 69 summarises the basal expression levels for aggrecan (ACAN), biglycan (BGN), decorin 
(DCN), fibromodulin (FMOD), lubricin (PRG-4) and versican (VCAN) for pre-seeded cells. FMOD, 
PRG-4 and VCAN were expressed significantly less by tendinopathic cells compared to healthy 
cells. Additionally, BGN also showed notable differences as it was expressed more by 
tendinopathic cells (P=0.06). Interestingly, although both tendinopathic cells expressed PRG-4 
less than healthy cells, one tendinopathic cell type expressed PRG-4 ~38 times less than the 
other, thus contributing to the large standard deviation in tendinopathic PRG-4 gene expression 
seen in Figure 69. The same tendinopathic cells also showed higher ACAN expression (~11 times 
more) than the other tendinopathic tenocytes.  
 
Figure 69: Average proteoglycan basal gene expression for pre-seeded cells. Expression shown as 2ΔCt (normalised 
to TOP-1). Both healthy and both tendinopathic cell types were averaged and error bars represent standard 
deviations. Tendinopathic cells express significantly less FMOD, PRG-4 and VCAN, and notably more BGN (P=0.06). 
ACAN and PRG-4 are also seen to exhibit large standard deviations due to one tendinopathic cell type showing ~17 
times more ACAN and ~21 times less VCAN expression than the other tendinopathic cell type. Cell type n=2, with 
3 repeats per cell type. *=P<0.05, **=P<0.01, ***=P<0.001. 
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Interleukins 
The interleukins profiled were IL-1β, IL-2, IL-6 and IL-8, however, IL-2 was not detected in any 
sample. Figure 70 shows that IL-8 was expressed significantly less by pre-seeded tendinopathic 
tenocytes compared to healthy tenocytes. The basal expression was highest for IL-6 compared 
to the other three interleukins investigated, although overall the expression of interleukins was 
generally lower than the other type of genes investigated. Once again, differences amongst the 
two tendinopathic tenocytes are also observed; gene expression for IL-1β was seen to be ~58 
times more in one tendinopathic group than the other. 
 
Figure 70: Average basal interleukin gene expression for pre-seeded cells. Expression shown as 2ΔCt (normalised to 
TOP-1). Both healthy and both tendinopathic cell types were averaged and error bars represent standard 
deviations. Tendinopathic cells express significantly less IL-8 basally compared to healthy cells. Cell type n=2, with 
3 repeats per cell type. *=P<0.05 
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Other Proteins 
Figure 71 summarises the pre-seeded basal gene expression of proteins classed in the ‘other’ 
category. This included cartilage oligomeric protein (COMP), fibronectin (FN1), laminin (LAMA-
1), scleraxis (SCX) and tenascin-C (TNC). Tendinopathic cells were seen to exhibit significantly 
higher TNC gene expression compared to healthy tenocytes. FN1 was also seen to be notably 
higher in tendinopathic cells compared to healthy cells (P=0.08). Interestingly, the large 
standard deviation bar present for SCX gene expression in tendinopathic cells once again 
highlights differences between the tendinopathic cell donors; the same cells which showed 
differences in PRG-4 and ACAN expression also showed ~21 times less SCX expression compared 
to the other tendinopathic tenocyte type. 
 
Figure 71: Average basal gene expression of a variety of other proteins in pre-seeded cells. Expression shown as 
2ΔCt (normalised to TOP-1). Both healthy and both tendinopathic cell types were averaged and error bars represent 
standard deviations. Tendinopathic cells express significantly more TNC basally compared to healthy cells. FN1 
gene expression is also marginally higher in tendinopathic cells (P=0.08). Cell type n=2, with 3 repeats per cell type. 
***=P<0.001. 
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4.4.2 Discussion: Differences between pre-seeded tendinopathic and 
healthy tenocytes 
From all the genes analysed, COL-2A1, COL9A1, IL-2 and TNMD were undetected in all samples. 
As TNMD is a common gene reported in tenocytes (Andia et al., 2014; Fong et al., 2013; 
Mazzocca et al., 2012; Qiu et al., 2013; Ruzzini et al., 2014; Wagenhauser et al., 2012), it is likely 
the assay sequence chosen for the TLDA card layout might not have be suitable and TND was 
indeed expressed. In the case of COL-2A1 and COL-9A1, both have been previously reported as 
undetected in tenocyte studies (Jelinsky et al., 2011; Jones et al., 2013; Steiner et al., 2012) so 
no detection in this study was considered normal. IL-2 proteins have been found through 
microdialysis in tendons (Waugh et al., 2015), however the gene expression by tenocytes is not 
documented in literature, so it was not determined whether the assay sequence was unsuitable 
or whether IL-2 gene expression is commonly undetected in tenocytes.  
The differences between tenocytes derived from healthy and tendinopathic tendons in their 
pre-seeded state is shown in Figures 65 to 71. From these figures it is evident a number of 
significant differences in the basal gene expression levels were present: 
Higher expression in tendinopathic cells: 
 MMP-3 
 MMP-13 
 ADAMTS-2 
 ADAMTS-12 
 TNC 
 
Lower expression in tendinopathic cells: 
 COL-12A1 
 COL-14A1 
 ADAMTS-5 
 PRG-4 
 VCAN 
 FMOD 
 IL-8 
The basal gene expression levels of collagens were generally much higher than other gene 
types, including MMPs and ADAMTSs, implying a net anabolic state for both cell types. 
However, the higher MMP (MMP-3 and MMP-13) and ADAMTS (ADAMTS-2 and ADAMT-12) 
gene expression along with the lower collagen (COL-12A1 and COL-14A1) and proteoglycan 
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(PRG-4, VCAN and FMOD) gene expression in tendinopathic tenocytes suggested they were set 
towards a slightly more catabolic profile. 
The difference in basal gene expression between healthy and tendinopathic cells was an 
interesting find, as one of the limitations for this study was the cell passage number. Cells 
received from collaborators at the Bio-Medical Research Centre, University of East Anglia, were 
in limited supply and previously passaged past P0. As a large number of cells were required to 
make sufficient composites (~14 million cells for each cell type), cells had to be grown and 
passaged further until the required quantity was reached. It is known that extensive cell culture 
can result in phenotypic drifts, with a study on human tenocytes noting a reduction in collagen 
type I and collagen type III gene expression after P3 and protein content after P4, tenascin-C 
gene expression after P5, and decorin protein content after P4 (Mazzocca et al., 2012). Another 
investigation into phenotypic drifts in human tenocyte culture saw a slight reduction in decorin 
protein levels at P4, with significant differences at P8 Yao et al. (2006). P10 has also been used 
as an arbitrary passage limit in a study using human tenocytes (Jones et al., 2013). Gene 
expression changes from phenotypic drift during in vitro culture would potentially mask 
differences between tendinopathic and healthy cells. However, despite this, the results 
obtained clearly showed differences which persisted after culture. Additionally, the changes 
observed by Mazzocca et al. (2012) were not seen in the results presented here, particularly 
with respect to tenascin-C; the tendinopathic tenocytes were cultured for 1-2 passages more 
than the healthy cells, yet an increase in tenascin-C gene expression was observed instead of 
the decrease which has been previously been associated with excessive culture. Overall, current 
data suggests the effects of phenotypic drift were limited, probably due to the tenocytes being 
cultured for much less than P10, ranging between P3 and P6.  
The fact that differences between tendinopathic and healthy tenocytes were persistent during 
culture could suggest cellular changes after tendinopathy are slow to revert back to normal or 
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that individuals may possess tenocytes which are predisposed to a tendinopathic state. Indeed, 
genetic factors have been implicated in the development of tendinopathies (Magra and 
Maffulli, 2008). This includes polymorphisms of COL-5A1 gene which have been associated with 
Achilles tendinopathy (Abrahams et al., 2013) as well as polymorphisms of TIMP-2, and 
ADAMTS-14 (El Khoury et al., 2013), and tenascin-C (Mokone et al., 2005). Cells which behave 
differently to tenocytes in healthy individuals could lead to a different gene expression balance 
during healing which in turn would contribute to the susceptibility of developing 
tendinopathies. 
It is also possible the differences observed could be due to the source of the tissue; healthy 
tenocytes originated from hamstring tendons while tendinopathic tenocytes were from Achilles 
tendons. However, some of the differences observed were more comparable to changes seen 
in tendinopathies, such as increased MMP-13, ACAN, and TNC gene expression and decreased 
ADAMTS-5 and VCAN gene expression (Corps et al., 2012; Corps et al., 2006; Corps et al., 2004; 
Ireland et al., 2001), providing confidence the differences observed were tendinopathy 
associated. In addition, the age of tendon donors could have played a role in the observed 
differences. Ideally the same age range should have been compared, however the available cell 
types and ages were limited thus the closest matching ages were chosen. The healthy tenocytes 
were obtained from an age range of 20.5 ± 1.5 years and tendinopathic from 48 ± 3 years, a 
relatively young and middle aged group respectively. Typical changes observed with ageing 
include decreased levels of GAGs (Riley et al., 1994a) and SLRPs (Peffers et al., 2014) in the 
tendon matrix. However, apart from a decrease in fibromodulin, other age related differences 
were not observed in the results. The data remains more consistent with gene expression 
changes seen in tendinopathic tissue. It is possible that age related effects were not evident 
here because studies usually go beyond 50 years, typically between ~70-100 years, when 
studying ageing affects in human tendons (Maganaris et al., 2004; Riley et al., 1994a; Yamada 
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et al., 2003). The ages of the donors used here could both be classified as ‘mature’ rather than 
‘old, therefore they might not significantly show changes associated with older age. 
Another interesting observation was the differences amongst the two tendinopathic tenocyte 
samples from different donors. Both were obtained from donors with chronic tendinopathy 
(noted as a duration of more than 18 months), and both had the same general gene expression 
profile and trends when compared to healthy tenocytes. However, a few genes were expressed 
at distinctly different levels between the two tendinopathic donors (summarised in Figure 72). 
For example, one tendinopathic tenocyte sample was found to have ~38 times less PRG-4, 21 
times less SCX, 42 times less MMP-13 and 20 times less MMP-3 than the other. These were 
extremely large differences, which were further emphasised by a range of other genes, such as 
ADAMTS-1, COL-6A1, VCAN and TNC, which showed no difference at all. These results could 
suggest the donors had a different state of tendinopathy or even type of tendinopathy.  
 
Figure 72: Average expression of genes which are distinctly different among the two pre-seeded tendinopathic 
tenocyte populations (normalised TOP-1). Error bars indicate standard deviation. These graphs suggest the two 
tendinopathic tenocytes are of different tendinopathy states or types. Cell type n=2, with 3 repeats per cell type. 
Post-hoc students T Test performed to calculate significance, *=P<0.05, **=P<0.01. 
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It should be noted that the basal gene expression levels of the pre-seeded cells would differ to 
an extent to those during actual culture and therefore are not presented as standalone 
tendinopathic or healthy tenocyte gene expression profiles. This is due to the cells being 
harvested via trypsin-EDTA, an enzyme used to detach cells from culture surfaces, which would 
consequently instigate changes in gene expression. However, as the period of trypsin exposure 
was not excessive (~5 min exposure only) and the same procedure used for both healthy and 
tendinopathic tenocytes, the gene expression profiles obtained can be used comparatively with 
confidence to distinguish differences between the two tenocyte types. Nonetheless, to obtain 
basal expression without the effects of trypsin, further comparisons of tendinopathic and 
healthy tenocytes were made using non-strained composites, with the results discussed in the 
next section. 
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4.4.3 Results: Substrate stiffness effects and differences between 
tendinopathic and healthy tenocytes in non-strained composites 
The gene expression of tenocytes within composites were compared to further assess 
differences between the basal gene expression of tendinopathic and healthy tenocytes and to 
assess the influence of culture within a 3D system. The basal levels were expected to differ 
slightly to those seen with the pre-seeded cells, as the tenocytes were now in an environment 
dissimilar to that found in culture flasks. Firstly, gene expression levels were averaged for all 
non-strained composites, to simply compare tendinopathic tenocytes and healthy tenocytes, 
with Student’s t-tests performed between the two to assess significance. Gene expression 
results of cells analysed in this manner are referred to as non-strained gene expression. 
Additionally, as composites were made of either 60% or 20% PEG fibres, i.e. stiff and less stiff 
fibres respectively, the effect of substrate stiffness on gene expression was also explored. For 
both cell types Student’s t-tests were performed between composites with stiff fibres and 
composites with less stiff fibres. 
As reported for pre-seeded cells, gene expression data is grouped into ‘Collagens’, ‘MMPs’, 
‘ADAMTSs’, ‘TIMPs’, ‘Proteoglycans’, ‘Interleukins’ and ‘Other Proteins’. The observations are 
then summarised and discussed in section 4.4.4. 
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Collagens 
All the collagens detected, apart from COL-11A1, showed statistically significant differences 
between composites containing tendinopathic tenocytes and composites containing healthy 
tenocytes (Figure 73); COL1A1, COL3A1, COL4A1, COL5A1, COL6A1 and COL-12A1 expression 
were all higher in composites containing tendinopathic tenocytes while COL-14A1 expression 
was lower. The gene expression of COL-2A1 and COL-9A1 were once again undetected in all 
samples. From the collagens investigated, the levels of COL-1A1, COL-3A1 and COL-5A1 in 
tendinopathic samples were observed to exhibit high standard deviations. This was once again 
due to the two tendinopathic tenocyte donors having differences in select genes as discussed 
in 4.4.2.  
Substrate stiffness was seen to affect COL-6A1 and COL-12A1 gene expression in composites 
containing tendinopathic tenocytes. No other genes were affected by substrate stiffness. 
 
Figure 73: Average gene expression of collagens in non-strained composites containing either tendinopathic or 
healthy tenocytes (red and green bars respectively), and expression shown as 2ΔCt (normalised to TOP-1). 
Composites made with 60% PEG-RGD fibres (i.e. stiff fibres) compared with composites made with 20% PEG-RGD 
fibres (i.e. less stiff fibres) to assess fibre stiffness effect. COL-6A1 and COL-12A1 were the only genes affected 
significantly by substrate stiffness. All genes, except COL11A1, showed significant differences between 
tendinopathic and healthy tenocytes. Error bars represent standard deviations. * indicates significance due to 
substrate stiffness, while + indicates significance between composites containing healthy and tendinopathic 
tenocytes. Cell type n=2, with 6 composites per cell type. *=P<0.05, +=P<0.05, ++=P<0.01, +++=P<0.001. 
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MMPs 
MMPs 7, 8 and 9 expression levels were extremely low and in some samples undetected. 
However, overall their expression levels were still higher than those seen in pre-seeded cells 
where MMP-8 and MMP-9 were undetected in all samples. MMP-2 was the most highly 
expressed MMP gene and was seen to be extremely consistent across all composite types. No 
substrate stiffness related effects were observed with MMPs. Composites containing 
tendinopathic tenocytes showed significantly higher MMP-13 gene expression and lower MMP-
3 gene expression, contrasting to the observations in pre-seeded cells. 
 
Figure 74: Average gene expression of MMPs in non-strained composites containing either tendinopathic or 
healthy tenocytes (red and green bars respectively), and expression shown as 2ΔCt (normalised to TOP-1). 
Composites made with 60% PEG-RGD fibres (i.e. stiff fibres) were compared with composites made with 20% PEG-
RGD fibres (i.e. less stiff fibres) to assess the effect of fibre stiffness on gene expression. No substrate dependent 
differences were observed, however differences in MMP-13 and MMP-3 were seen when comparing composites 
containing and healthy cells. Cell type n=2, with 6 composites per cell type. (Error bars represent standard 
deviations, +++=P<0.001). 
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ADAMTSs 
Many significant differences in ADAMTS gene expression were seen when comparing 
composites containing tendinopathic and healthy tenocytes. ADAMTS-2, ADAMTS-4, ADAMTS-
12 and ADAMTS-14 were all expressed more in composites containing tendinopathic tenocytes, 
while ADAMTS-1 and ADAMTS-6 were expressed less. Tendinopathic tenocytes also showed 
substrate dependent differences in ADAMTS-14, which was expressed more on stiffer 
substrates. No other substrate stiffness effects were observed. 
 
Figure 75: Average gene expression of ADAMTS in non-strained composites containing either tendinopathic or 
healthy tenocytes (red and green bars respectively), and expression shown as 2ΔCt (normalised to TOP-1). 
Composites made with 60% PEG-RGD fibres (i.e. stiff fibres) were compared with composites made with 20% PEG-
RGD fibres (i.e. less stiff fibres) to assess the effect of fibre stiffness on gene expression. ADAMTS-14 is seen to 
increase with higher stiffness substrates in tendinopathic cells only. ADAMTS-1, 2, 4, 6, and 12 are all seen to differ 
significantly between tendinopathic and healthy cells. * indicates significance due to substrate stiffness, while + 
indicates significance between composites containing healthy and tendinopathic tenocytes. Cell type n=2, with 6 
composites per cell type. *=P<0.05, +=P<0.05, ++=P<0.01, +++=P<0.001. 
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TIMPs 
TIMP-1 and TIMP-2 were the most highly expressed TIMPs while TIMP-4 was the lowest. Similar 
to the pre-seeded cells, there were no differences in the TIMP expression between 
tendinopathic and healthy tenocytes. However, substrate dependent differences were seen in 
composites containing tendinopathic tenocytes, with TIMP-1 and TIMP-3 expressed more when 
tenocytes were on stiffer substrates. 
 
Figure 76: Average gene expression of TIMPs in non-strained composites containing either tendinopathic or 
healthy tenocytes (red and green bars respectively), and expression shown as 2ΔCt (normalised to TOP-1). 
Composites made with 60% PEG-RGD fibres (i.e. stiff fibres) were compared with composites made with 20% PEG-
RGD fibres (i.e. less stiff fibres) to assess the effect of fibre stiffness on gene expression. Tendinopathic tenocytes 
increase TIMP-1 and TIMP-3 gene expression significantly when seeded on stiffer substrates. Cell type n=2, with 6 
composites per cell type. *=P<0.05, *=P<0.01. 
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Proteoglycans 
Interestingly, the gene expression levels of all the proteoglycans was seen to be significantly 
different when comparing composites containing tendinopathic tenocytes to those containing 
healthy tenocytes. ACAN, DCN, FMOD, PRG-4 and VCAN were expressed less by tendinopathic 
cells while BGN was expressed more. Tendinopathic cells also showed dependence on substrate 
stiffness for ACAN and PRG-4, with both genes expressed more when tenocytes were on stiffer 
substrates. 
 
Figure 77: Average gene expression of proteoglycans in non-strained composites containing either tendinopathic 
or healthy tenocytes (red and green bars respectively), and expression shown as 2ΔCt (normalised to TOP-1). 
Composites made with 60% PEG-RGD fibres (i.e. stiff fibres) were compared with composites made with 20% PEG-
RGD fibres (i.e. less stiff fibres) to assess the effect of fibre stiffness on gene expression. Tendinopathic tenocytes 
increase ACAN and PRG-4 gene expression significantly when seeded on stiffer substrates. Tendinopathic 
tenocytes also exhibit significantly different expression levels of all proteoglycan genes investigated when 
compared to healthy tenocytes. * indicates significance due to substrate stiffness, while + indicates significance 
between composites containing healthy and tendinopathic tenocytes. Cell type n=2, with 6 composites per cell 
type. *=P<0.05, +=P<0.05, ++=P<0.01, +++=P<0.001. 
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Interleukins 
IL-2 was undetected in all samples, similar to that seen with pre-seeded cells. IL-8 was found to 
be the most highly expressed interleukin investigated. No substrate dependent differences 
were found for interleukins, however, composites containing tendinopathic tenocytes did show 
significantly less IL-6 and IL-8 gene expression than the healthy cells. 
 
 
Figure 78: Average gene expression of interleukins in non-strained composites containing either tendinopathic or 
healthy tenocytes (red and green bars respectively), and expression shown as 2ΔCt (normalised to TOP-1). 
Composites made with 60% PEG-RGD fibres (i.e. stiff fibres) were compared with composites made with 20% PEG-
RGD fibres (i.e. less stiff fibres) to assess the effect of fibre stiffness on gene expression. Tendinopathic tenocytes 
exhibit significantly less expression levels of IL-6 and IL-8 when compared to healthy tenocytes. Cell type n=2, with 
6 composites per cell type. ++=P<0.01, +++=P<0.001. 
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Other Proteins 
Substrate stiffness was seen to affect the gene expression levels of most of the other proteins 
to an extent. FN-1 gene expression was seen to increase when tendinopathic tenocytes were 
on stiffer substrates, while healthy tenocytes decreased COMP, LAMA-1 and TNC when seeded 
on stiffer substrates. The gene expression levels of FN-1 and TNC were also seen to be 
significantly more in tendinopathic tenocytes than healthy tenocytes.  
 
Figure 79: Average gene expression of a range of other proteins in non-strained composites containing either 
tendinopathic or healthy tenocytes (red and green bars respectively), and expression shown as 2ΔCt (normalised 
to TOP-1). Composites made with 60% PEG-RGD fibres (i.e. stiff fibres) were compared with composites made with 
20% PEG-RGD fibres (i.e. less stiff fibres) to assess the effect of fibre stiffness on gene expression. Higher substrate 
stiffness increases FN-1 gene expression in tendinopathic tenocytes, while higher stiffness decreases COMP, 
LAMA-1 and TNC gene expression in healthy tenocytes. Tendinopathic tenocytes also exhibit significantly more 
FN-1 and TNC gene expression when compared to healthy tenocytes. * indicates significance due to substrate 
stiffness, while + indicates significance between composites containing healthy and tendinopathic tenocytes. Cell 
type n=2, with 6 composites per cell type. *=P<0.05, +=P<0.05, ++=P<0.01. 
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4.4.4 Discussion: Substrate stiffness effects and differences between 
tendinopathic and healthy tenocytes in non-strained composites 
Non-strained composites made with tendinopathic and healthy tenocytes were compared to 
further assess differences between basal gene expression levels of healthy and tendinopathic 
tenocytes within a 3D culture environment, and also to review the effects of substrate stiffness 
on these cells. All gene expression data is summarised in the heatmap in Figure 80. Statistically 
significant differences were evident in a number of genes including ADAMTS-2, ADAMTS-4, 
ADAMTS-12, BGN, COL-12A1, COL-1A1, COL-3A1, COL-4A1, COL-5A1, COL-6A1, FN-1, and MMP-
13 (all higher in composites containing tendinopathic tenocytes) and TNC, ACAN, ADAMTS-1, 
ADAMTS-6, COL-14A1, DCN, FMOD, IL-6, IL-8, MMP-3, PRG-4 and VCAN (all lower in composites 
containing tendinopathic tenocytes).  
 
 
 
Figure 80: Heatmap summarising average gene expression (ΔCt, normalised to TOP-1) of non-strained composites 
containing tendinopathic tenocytes (bottom half) and healthy tenocytes (top half). Each row represents a 
composites type with all technical and biological repeats averaged. The non-strained gene expression of a number 
of genes are seen differ between tendinopathic and healthy tenocytes (‘+’ indicates significant differences 
between composites containing tendinopathic and healthy tenocytes, + = P<0.05, ++ = P<0.01, +++ = P<0.001). 
Substrate stiffness was seen to effect more genes in composites containing tendinopathic tenocytes (‘*’ above and 
below the heatmap indicate genes significantly affected by substrate stiffness in composites containing healthy 
cells and tendinopathic cells, respectively (* = P<0.05, ** = P<0.01). Cell type n=2, with 6 composites per cell type. 
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Although many of the cell type differences observed in the pre-seeded cell comparison were 
present when the cells were seeded in composites, there were also a couple of changes. For 
example, MMP-3 and TNC gene expression was seen to be higher in the pre-seeded 
tendinopathic tenocytes than the healthy tenocytes, whereas in the non-strained composites 
the opposite was true. This is likely due to the pre-seeded cells being exposed to trypsin right 
before processing for RNA analysis, as described earlier in section 4.4.2. Specifically, trypsin 
exposure would likely decrease matrix degradation related gene expression, as cells would 
respond to the catabolic nature of the enzyme. Indeed it has been found that trypsin can change 
the expression of a number of genes, including a reduction in MMP-3 gene expression by cells 
(Chaudhry, 2008).   
The gene expression profile of tendinopathic tenocytes in constructs was even more fitting to 
that seen in typical tendinopathic tissue; more BGN, COL-1A1, COL-3A1, and MMP-13 
expression and lower MMP-3 and VCAN observed in composites containing tendinopathic cells, 
as seen in tendinopathy (Corps et al., 2012; Corps et al., 2006; Corps et al., 2004; Ireland et al., 
2001; Legerlotz et al., 2012; Riley et al., 1994b). As discussed with the pre-seeded cells, this 
supported the idea that the differences seen between the tenocyte types in this study are more 
likely due to tendinopathy and less likely due to phenotypic drift, tendon age or tendon type, 
although each of the latter will probably have a small effect. Moreover, the results showed that 
tenocytes could retain a tendinopathic profile during culture and after incorporation into 
composites, suggesting that tendinopathy development is not simply a case of microdamage, 
but that there are long lasting phenotypic changes in cells, which may mean they are unable to 
respond like normal tenocytes to the microdamage. 
IL-6 and IL-8 were less expressed in tendinopathic tenocyte than healthy tenocytes. This 
observation was counterintuitive to the findings in tendinopathic tissues, where IL-6 is 
increased (Legerlotz et al., 2012). However, inflammation, and consequently interleukins, are 
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associated with the early stages of tendinopathy (Dakin et al., 2014; Millar et al., 2010; Rees et 
al., 2013), and in chronic tendinopathies, inflammation and inflammatory chemicals are not 
evident (Alfredson and Lorentzon, 2002; Dakin et al., 2014). The tenocytes used in this study 
were obtained from donors exhibiting chronic tendinopathy, thus it is possible the lower IL-6 
and IL-8 was a reflection of this advanced state of tendinopathy.  
It should be noted that some differences observed between the non-strained gene expression 
levels of tendinopathic and healthy tenocytes, although statistically significant, were quite 
small. This is also evident from the heatmap where the colour differences between the two cell 
types cannot be distinguished visually in some cases. However, the gene expression differences 
emphasised in this summary as those associated with tendinopathy were clear as larger, 
discernible differences, providing confidence in the results.  
Substrate stiffness has been seen to affect the behaviour of cells. In Human fibroblasts, MMP-
2, TIMP-2 and COL-3 gene expression increase with substrate stiffness (Karamichos et al., 2007) 
while cardiac fibroblasts have been reported to decrease MMP-2 and MMP-9 gene expression 
on decreasing substrate stiffness (Xie et al., 2014). Substrate stiffness has also been shown to 
affect the differentiation of human mesenchymal stem cells (Guvendiren and Burdick, 2012). In 
the current study, substrate dependent changes were seen in a number of genes. Healthy 
tenocytes showed significant changes in 3 genes whereas 8 genes were significantly affected by 
substrate stiffness in tendinopathic tenocytes:  
 
 COl-12A1 ↑ 
 COL-6A1 ↑ 
 ADAMTS-14 ↑ 
 TIMP-1 ↑ 
 TIMP-3 ↑ 
 ACAN ↑ 
 PRG-4 ↑ 
 FN-1 ↑ 
 COMP ↓ 
 LAMA-1 ↓ 
 TNC ↓ 
 
 
Tendinopathic tenocytes 
on stiffer substrates: 
Healthy tenocytes on 
stiffer substrates: 
↑ = Increase 
↓ = Decrease 
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It is interesting the tendinopathic cells showed more sensitivity to the substrate stiffness than 
the healthy tenocytes, particularly in genes which can be related to an anabolic response such 
as COL-12A1 and COL-6A1 which are collagens associated with type I collagen fibrils, TIMP-1 
and TIMP-3 which are involved in the inhibition of various matrix degrading MMPs and 
ADAMTSs, and ADAMTS-14 which is a procollagen I and II N-propeptidase (i.e. involved in 
collagen type I and II synthesis). It was not possible to conclude why the tendinopathic 
tenocytes are more sensitive to the substrate within this study, but the results do suggest they 
were more active in sensing and responding to their surrounding environment than healthy 
tenocytes.  
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4.4.5 Results: Shear-tension ratio effect and tenocyte differences 
Gene expression data for tenocytes exposed to different shear-tension ratios are compared in 
this section for both tendinopathic and healthy tenocytes. Composites creating the high shear 
condition were made with stiff 60% PEG-RGD fibres while composites creating a low shear 
condition were made of less stiff 20% PEG-RGD fibres. To reduce the effects of substrate 
stiffness, composites of physiologically equivalent shear were made of each fibre type, to find 
relative expression, leading to four test groups; a low shear-high tension ratio (20% PEG fibres 
with 60 min soak), 2 physiologically equivalent shear-tension ratios (20% PEG fibres with 0 min 
soak, and 60% PEG fibres with 60 min soak) and a high shear-low tension ratio (60% PEG fibres 
with 0 min soak). Conditions were analysed as high shear relative to physiological and low shear 
relative to physiological.  
As some variability with the basal gene expression was observed with cell type and substrate 
stiffness (discussed in previous sections of this chapter), a fold change of 2 was used as a 
threshold for identifying changes, to provide confidence the observations were large enough to 
be a result of shear-tension ratio changes and not due to other effects. Volcano plots were used 
to visualise results with this 2 fold change boundary and separated into two figures; ‘high shear’ 
relative to ‘physiological shear’, and ‘low shear’ relative to ‘physiological shear’. Volcano plots 
were created using DataAssistTM (Applied Biosystems), plotting “-log10(p-value)” against 
“log2(fold change)” for each gene. Additionally, tendinopathic and healthy tenocytes are shown 
in separate volcano plots. 
Bar graphs showing 2ΔCt results for each shear-tension ratio and cell type are provided as 
supplementary figures in Appendix C: Additional shear-tension ratio graphs (2ΔCt).  
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The volcano plots in Figure 81 show that the healthy and tendinopathic tenocytes respond 
differently to shear. In healthy tenocytes, low shear was seen to significantly increase IL-8 and 
MMP-3 gene expression, and significantly decrease FN-1 gene expression. High shear 
significantly increased COL1-A1 gene expression and significantly decreased ADAMTS-4 and IL-
6 gene expression. In tendinopathic tenocytes, low shear did not cause any statistically 
significant changes, but extremely large negative fold changes were seen in IL-8, IL-6, MMP-3 
and IL-1β.  High shear caused a significant increase in VCAN gene expression and a significant 
decrease in MMP-1 and MMP-13 gene expression. Although not statistically significant, 
ADAMTS-3 and ADAMTS-14 showed large negative fold changes with high shear in 
tendinopathic tenocytes. 
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Figure 81: Volcano plots for healthy and tendinopathic tenocytes showing gene fold change vs significance, 
expressed as Log2(fold change) vs –log10(p-value), under low and high shear conditions. The horizontal dotted 
line indicates the 5% significance level (P<0.05) and the vertical dotted lines indicate values for ±2 fold change. 
Graphs show that tendinopathic tenocytes have more expression variability and larger fold changes compared to 
healthy tenocytes, particularly under low shear conditions. Genes regulated by shear also differ between the two 
tenocyte types. Cell type n=2, with 6 composites per cell type. 
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4.4.6 Discussion: Shear-tension ratio effect and tenocyte differences 
The shear-tension ratio effect was compared between tendinopathic and healthy tenocytes 
after cyclically loading fibre composites of each type to 5% strain for 24 hours at 1Hz. As 
composites used 60% PEG-RGD fibres and 20% PEG-RGD fibres to create high and low shear 
conditions, respectively, physiologically equivalent shear conditions were created for each fibre 
type as controls to eliminate substrate stiffness effects. The results of these comparisons show 
some genes responded in low shear conditions while others responded to high shear 
conditions. 
It was not surprising that the genes regulated by shear differed for both tenocyte types, as it 
has already been established in sections 4.4.2 and 4.4.4 that the tendinopathic and healthy 
tenocytes used in this study exhibit different basal expression levels and respond to substrate 
stiffness differently. It was interesting to note that high shear caused more downregulation of 
genes in both tenocyte types than upregulation, suggesting that shear strains above and below 
the physiological equivalent initiate different responses from tenocytes and there is not a 
simple linear relationship between applied shear and cell response. Healthy tenocytes showed 
a significant increase in IL-8 gene expression with low shear and a significant decrease in IL-6 
gene expression with high shear. In addition to inflammatory roles, IL-6 has been shown to 
stimulate collagen type I synthesis (Andersson et al., 2011), increase with loading (Langberg et 
al., 2002; Legerlotz et al., 2013), and also regulate TGFβ (Zhang et al., 2005) which is also capable 
of inducing collagen type I and III synthesis (Heinemeier and Kjaer, 2011). This could suggest the 
high shear-low tension condition was reducing matrix synthesis in healthy tenocytes as both IL-
6 and COL-1A1 are downregulated. Little has been studied with IL-8 in tendons, a marker often 
only associated with inflammatory responses by tendons and tenocytes (Ackermann et al., 
2013; Andia et al., 2014). IL-8 has also been found to increase immediately after extracorporeal 
shock wave therapy, a tendinopathy treatment, in human Achilles tendons (Waugh et al., 2015) 
so it is potentially involved in promoting changes in tendon matrix during healing. The 
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upregulation of IL-8 and MMP-3 in the low shear-high tension condition could therefore signify 
that healthy tenocytes were instigating remodelling of the matrix in response to low shear. 
In contrast to the healthy tenocytes, tendinopathic tenocytes did not show any significant 
changes in gene expression in the low shear condition, but the high shear-low tension condition 
significantly downregulated MMP-3 and MMP-13 gene expression in tendinopathic tenocytes. 
Both MMP-3 and MMP-13 act on a number of common substrates which include, but are not 
limited to, collagen type III, IV, IX and X, aggrecan, decorin and tenascin. However unlike MMP-
3, MMP-13 can also degrade collagen type I fibrils. Moreover, MMP-3 is also involved in the 
activation of MMP-13 (Klein and Bischoff, 2011; McCawley and Matrisian, 2001; Nagase et al., 
2006). Therefore the downregulation of both MMP-3 and MMP-13 by tendinopathic tenocytes 
subjected to low shear potentially signifies an attempt to reduce matrix degradation. 
Although tendinopathic tenocytes did not show statistically significant changes in the low shear 
condition, they did show much more variability. As such some extremely high fold changes in 
some genes were noted, but with low significance values. This included a ~52 fold decrease in 
IL-8, ~30 fold decrease in IL-6 , ~8 fold decrease in MMP-3 and ~6 fold decrease in IL-1β. 
Moreover, comparing healthy tenocyte and tendinopathic tenocyte volcano plots for both high 
and low shear, the data points for the tendinopathic tenocytes were seen to be generally wider 
spread with larger fold changes, whereas the healthy tenocytes data points were more closely 
packed. This suggested the tendinopathic tenocytes were less stable than the healthy tenocytes 
and produced larger expression changes, possibly due to more mechano-sensitivity. This was 
further emphasised by the tendinopathic tenocytes showing substrate stiffness dependent 
changes in the previous section. Although not statistically significant, the fact that IL-8 and 
MMP-3 were regulated in the opposite direction to healthy tenocytes in the low shear condition 
further highlights the extent of differences between the two tenocyte types. It should be noted 
that the variability in gene expression changes of tendinopathic tenocytes also results in low 
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significance, but if more samples were repeated, it is possible the changes observed would be 
more pronounced. 
Shear has been observed to alter matrix turnover related gene expression in tenocytes, 
including an increase in MMP-2, 3, 7, 9, 10, 12, 13, 23 and 24 gene expression and a decrease 
in TIMP-2 and TIMP-3 gene expression (Fong et al., 2005). However such studies are not 
completely comparable to the study performed in this chapter as the former neglected the 
inclusion of tension and was restricted to fluid shear. Nonetheless, as some MMPs did show 
changes with shear (healthy tenocytes in the low shear condition and tendinopathic tenocytes 
in the high shear condition), the involvement of shear in regulating matrix turnover can be 
agreed upon. 
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4.5 Conclusion 
The study described in this chapter employed the fibre composite system to explore differences 
in gene expression of tenocytes derived from healthy and tendinopathic tissue, both basally 
and in response to altered shear-tension ratios. The results clearly indicated significant 
differences between the two cell types, with tendinopathic tenocytes showing higher ADAMTS-
2, ADAMTS-4, ADAMTS-12, BGN, COL-12A1, COL-1A1, COL-3A1, COL-4A1, COL-5A1, COL-6A1, 
FN-1, and MMP-13 gene expression, and lower TNC, ACAN, ADAMTS-1, ADAMTS-6, COL-14A1, 
DCN, FMOD, IL-6, IL-8, MMP-3, PRG-4 and VCAN gene expression. Furthermore, it was 
established that phenotypic changes between tenocyte types remained throughout culture and 
after encapsulation into composites. The persistent nature of these differences was theorised 
to either be due to persistent cell changes during long term tendinopathy or possibly inherent 
genetics, consequently leading to individuals being more susceptible to tendinopathies than 
others. Differences between the two tendinopathic tenocyte donors were also found, with 
ACAN, COL-1A1, COL-5A1, COL-1A1, IL-1β, MMP-3, PRG-4 and SCX all being significantly 
different, possibly due to a different stage or even type of tendinopathy. 
Using the composites, it was found the tendinopathic tenocytes were more mechano-sensitive 
than healthy tenocytes, responding more significantly to substrate stiffness and exhibiting more 
variability after loading. Shear was also found to be an important cue in altering the behaviour 
of both type of tenocytes. Shear higher and lower than the physiological equivalent was found 
to evoke responses different from one another; healthy tenocytes downregulated matrix 
synthesis with high shear and upregulated matrix degradation with low shear, while 
tendinopathic tenocytes downregulated matrix degradation with high shear. Although it 
appears the cells responded to the different shear-tension ratios, a simple linear relationship 
between gene expression and shear was not exhibited in the genes analysed. Differences in the 
response to shear by the healthy and tendinopathic tenocytes, along with the different basal 
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gene expression levels and mechano-sensitivity, suggested the behaviour of tendinopathic 
tenocytes was fundamentally different to healthy tenocytes and could be a response of cells 
perceiving the same stimuli differently. 
Limitations within the study included the tendon type, tendon donor age and potential for 
phenotypic drift during culture. However, as discussed earlier in this chapter, the possible 
effects of these factors on gene expression seen in literature, along with the magnitude of 
differences observed, could not wholly account for the differences between the tenocyte types. 
Additionally, as the changes were more in line with those seen in tendinopathy, it was 
concluded the differences between cell types were indeed related to tendinopathy. The low n 
number for the experiments is another limitation to the study, and a result of the difficulty in 
obtaining human tenocytes. However the data can be considered as preliminary data in its 
current form, and used as an indicator for possible trends exhibited by human tenocytes. 
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Cell Attachment Peptides and Shear-Tension Sensitivity 
: Cell Attachment Peptides - A critical 
factor for shear-tension sensitivity 
5.1 Introduction and Hypotheses 
The hierarchical tendon structure results in a complex mechanical strain environment, with 
tenocytes experiencing both tension and shear during tendon loading. The previous chapter has 
shown that tenocytes alter their gene expression in response to different levels of shear-tension 
as well as substrates of different degrees of stiffness. There has been increasing investigation 
into the mechanisms involved in sensing these environmental cues, with integrins implicated as 
key components (Arnaout et al., 2007; Chiquet, 1999; Legate et al., 2009; Pavalko et al., 1998; 
Roca-Cusachs et al., 2013; Schwartz, 2010).  
Integrins are transmembrane structures used by cells to adhere to extracellular proteins 
(summary provided in Chapter 1). Different combinations of integrin subunits recognise 
different ligands, providing cells the utility to distinguish between different proteins (Plow et 
al., 2000). Additionally, the intracellular portion of integrins can connect to the cytoskeleton 
resulting in direct force transmission (Giannone et al., 2003; Roca-Cusachs et al., 2013). The 
mechanical environment is therefore thought to regulate integrins in tenocytes and 
subsequently direct ECM organisation (Bayer et al., 2014). As different integrins are used to 
attach to different proteins, it is possible the response to a mechanical stimulus could differ 
depending on the integrin employed. For example, the integrins used to attach to collagen 
include α1β1, α2β1, α3β1, α10β1, α11β1 and αIIbβ3 (Hynes, 1992; Jokinen et al., 2004; Plow et 
al., 2000; Yamamoto et al., 1995), while those for fibronectin have been reported to include 
α2β1, α3β1, α4β1, α4β7, α5β1, α8β1, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and αIIbβ3 although with 
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different affinities (Askari et al., 2009; Campbell and Humphries, 2011; Hynes, 1992; Plow et al., 
2000). Moreover, it has been seen that integrin α2β1 is more important than α1β1 for cell 
attachment and spreading on fibrillar type I collagen (Abair et al., 2008; Jokinen et al., 2004), 
while α1β1 is suggested to function more for collagen type IV recognition (Grzesiak and Bouvet, 
2007). Integrin α1β1 has also been suggested to function to induce cell proliferation and reduce 
collagen synthesis while integrin α2β1 increases matrix remodelling (Heino, 2000), emphasising 
the unique functions of each integrin combination.  
Peptides DGEA and GFOGER are sequences found in fibrillar collagen, which can bind to integrin 
α2β1, leading to their description as collagen mimetic peptides (Knight et al., 2000; Luzak et al., 
2003; Mizuno et al., 2000). RGD is a sequence commonly associated with fibronectin, although 
it is also a functional attachment site in other proteins such as vitronectin, and can bind to a 
number of integrins, mainly α5β1, αVβ3, and αIIbβ3 (Danen et al., 2002; Hynes, 1992; Ruoslahti, 
1996; Sechler et al., 1996), which are all different to those used by cells on native type I collagen.  
The fibre composite system developed in Chapter 2 incorporates changeable cell attachment 
peptides. It was hypothesised that the cell attachment peptide, and consequently the integrins 
engaged in cell attachment, alter the gene expression of tenocytes and their response to shear-
tension ratios.  The fibre composite system was used to compare a collagen mimetic peptide, 
DGEA, with a non-collagen-like peptide, YRGDS. This allowed investigation of integrins that 
would be involved in tenocyte attachment to collagen in native tendon. 
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Cell Type Peptide Stiffness Soak Time 
5.2 Experimental Overview 
The experiment was conducted using primary bovine tenocytes digested from bovine extensor 
tendons. 8 types of composites were made; 4 with RGD and 4 with DGEA as the cell attachment 
peptide. Two degrees of rod stiffness (20% and 60% PEG) and two soak times (0 and 60 min) 
created a range of shear-tension ratios for each peptide. Composites were cyclically strained to 
5% for 24 hours at 1 Hz, after which RT-qPCR analysis was used to investigate the expression of 
a number of genes. Other analysed samples included pre-seeded cells and composites in a non-
strained free-swelling state. 3 experimental repeats were performed, using different bovine 
tenocyte donors each time (i.e. 3 biological repeats). 
 
 
NP = Non-physiological shear-tension ratio 
P = physiologically equivalent shear-tension ratio 
Figure 82: Overview of composite types used in study. The resulting type of shear-tension ratio is indicated by the 
arrows on the right hand side, with both RGD and DGEA composites having the same conditions (emphasised by 
the dotted line). 3 bovine feet were used to provide 3 biological repeats, with 2 composites for each condition in 
each biological repeat. 
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5.3 Methods 
Note 1: The protocols for manufacturing composites and RNA extraction are detailed 
comprehensively in Chapter 3 and only stated in brief under this section. Other additional 
procedures, such as cell isolation via tendon digestion, which have not been previously detailed 
are described fully.  
Note 2: Further details of all chemicals used, including supplier details, are present in Table 35 
and Table 36, in Appendix B: Chemicals and Materials List. 
 
Cell Isolation through Tissue Digestion  
Fresh surplus bovine feet joints obtained from a local abattoir (Arapahoe Meat Co, USA) were 
cleaned in water and soaked in 70% ethanol. The extensor tendon was then dissected from the 
joint in a sterile hood, and the tendon diced into ~ 3mm3 pieces using a scalpel. Diced tendon 
was rinsed twice in a PBS solution containing 1% Pen/Strep and placed into a 50mL falcon tube. 
A digestion media was then made by adding 2mg/mL Collagenase Type 2 to a Dispase solution 
(1 U/mL), which was then sterile filtered using 0.22µm syringe filters and warmed to 37°C in a 
water bath. The diced tendon pieces in the 50mL tubes were covered with digestion media in a 
1:2 volume ratio, i.e. ~10mL tendon pieces covered in 20mL digestion media. The tubes were 
then tightly closed, wrapped in parafilm and placed onto a rocker inside an incubator (37°C, 5% 
CO2). This was left for 48 hours for the tissue to completely digest. After complete digestion, 
the digested tendon solution was diluted 10 times with PBS containing 1% Pen/Strep. This 
solution was subsequently filtered using a 100 µm cell strainer, taking care to slowly pipette the 
tendon solution through the strainer into another 50 mL falcon tube and changing the strainer 
whenever necessary. The resulting cell suspension was then centrifuged for 10 minutes at 1500 
rpm. The supernatant was discarded and the cell pellet washed by re-suspending in PBS 
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containing 1% Pen/Strep. The cell solution was then centrifuged again at 1500 rpm for 10 
minutes and re-suspended in PBS containing 1% Pen/Strep to further wash the cells. After the 
second wash, the solution was centrifuged for 10 minutes at 1500 rpm and the pellet re-
suspended in 10% FBS media (DMEM, 1% Pen/Strep and 10% FBS). The cells were then counted 
using trypan blue and a haemocytometer, and re-suspended at 1.75 million cells/mL.  
Fibre Production and Seeding 
PEG-RGD fibres were made by preparing solutions of 60% or 20% w/v PEGDM in PBS, with 0.05% 
w/v Irgacure 2959 and 5mM YRGDS peptide conjugated to acrylate-PEG-NHS. PEG-DGEA fibres 
were made by preparing solutions of 60% or 20% w/v PEGDM in PBS, with 0.05% w/v Irgacure 
2959 and 5mM DGEA peptide conjugated to acrylate-PEG-NHS. To make fibres, the solutions 
were pipetted into Teflon fibre moulds and polymerised for 10 minutes under UV light (365 nm 
wavelength, ~4mW/cm2) as described previously. Fibres were then extracted from the moulds 
and stored in a petri dish with 70% ethanol. A total of 1600 fibres were made; 400 20% PEG-
RGD fibres, 400 60% PEG-RGD fibres, 400 20% PEG-DGEA fibres, and 400 60% PEG-DGEA fibres. 
Sterile forceps were used to transfer 100 of each fibre type (20% PEG-RGD, 60% PEG-RGD, 20% 
PEG-DGEA and 60% PEG-DGEA) into separate wells of a non-tissue culture treated 48 well plate. 
The fibres were then seeded with 1.75 million cells per well using the optimised seeding 
protocol described previously. 
A cell sample was taken to analyse the gene expression of cells in their ‘pre-seeded’ state. To 
do this, 3 micro-centrifuge tubes were prepared with 700 µL QIAzol Lysis Reagent and 100000 
cells (~57.2 µL of the cell suspension above used to seed fibres) pipetted into each tube. The 
tubes were vortexed vigorously for a few minutes to lyse the cells and stored at -80°C until 
ready for RNA extraction. An extra tube of 100000 cells was lysed with QIAzol to use for primer 
validation and efficiency calculations. 
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Composite Production 
The next day composites were made using the cell seeded fibres using the method described in 
section 3.2. The procedure was repeated to make 20% PEG-RGD, 60% PEG-RGD, 20% PEG-DGEA 
and 60% PEG-DGEA fibres with either 0 minutes or 60 minutes soak time. All composites were 
stored in separate wells of a 6 well plate containing 10% FBS media, and left in an incubator 
overnight. 3 biological repeats were performed using the same procedure (n=3). 
Strain Application 
Composites were retrieved from the incubator and 2 of each composite type (strained group) 
were set up into the strain rig, with each composite submerged in 2 mL 10% FBS media. An 
additional 2 composites of each type (non-strained group) were placed into separate wells in a 
6 well plate and filled with 2 mL 10% FBS media. Both the rig (strained samples) and well plates 
(non-strained samples) were placed into an incubator overnight before initiating loading.  
Once the composites had stabilised for 24 hours, the strain system was set to apply 5% 
sinusoidal cyclic strain at 1 Hz for 24 hours (86400 cycles). At the end of the loading regime, the 
composites were removed from the rig or well plates and paired into 1.2 mL cryovials, i.e. 2 
composites of the same type were put into the same cryovial. The cryovials were then snap 
frozen in liquid nitrogen and stored at -80°C until ready for RNA extraction. 
RNA Extraction 
RNA was extracted, using the optimised protocol described in Chapter 3. First cryovials 
containing frozen composites were retrieved from the -80°C storage and chromium steel 
grinding balls (9mm diameter) added to each tube. The tubes were then further cooled in liquid 
nitrogen before homogenising the composites with a Tissue Lyser II system (QIAgen). This ball 
mill homogeniser was set to 30 Hz and run for two 30 second bursts. Homogenised tubes were 
placed back in liquid nitrogen and taken into a fume hood, where 700 µL QIAzol was added to 
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each tube. The QIAzol/homogenate solution was mixed thoroughly and transferred into 
individual QIAshredder columns which were then centrifuged for 2 minutes at full speed to fully 
lyse the cells.  The MiRNeasy micro kit was then used to collect and wash the extracted RNA. 
The clean RNA was released from the spin column membrane in 15 µL RNase free water 
(supplied in MiRNeasy kit). 
The quantity of RNA was measured using a NanoDrop Spectrophotometer 1000 and 1 µL of 
sample. All samples where then diluted to 18 ng/µL using RNase free water and stored at -80°C. 
RT-qPCR 
The tubes containing diluted RNA were thawed and 10 µL of each RNA sample transferred into 
new micro-centrifuge tubes. A reverse transcription mastermix was made, enough for 85 
samples (including extra in case of loss), according to the formula in Table 30. 
Table 30: Reverse transcription mastermix was made by combining components of the High-Capacity cDNA 
Reverse Transcription Kit (Life Technologies) as detailed in the table. 
Substance 
Quantity for 
1 sample (µL) 
Quantity for 85 
samples (µL) 
MultiScribe Reverse Transcriptase 1 85 
10x Sample Buffer 2 180 
Deoxynucleotide triphosphates 0.8 68 
25x RT Random Primers 2 170 
RNase free Water 4.2 357 
 
10 µL of the reverse transcription mastermix was then added to each RNA tube and centrifuged 
at ~2000g for 10 seconds. Tubes were then placed into a thermocycler (model 2720, Applied 
Biosystems) set to run at 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes and 
then 4°C until opened.  
Once the reverse transcription process had finished, the tubes containing the resulting 
complimentary DNA (cDNA) were removed from the thermal cycler and kept on ice whilst 
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proceeding with the next steps. The cDNA was diluted to a total volume of 200 µL by adding 
180 µL RNase free water and mixed gently through pipetting.  
A stock gene mix was made for all genes and enough for all samples (plus extra in case of loss) 
as detailed in the Table 31. A list of primer sequences for the genes investigated is provided in 
Table 32. 
Table 31: Details of the components for the stock gene mix made for each gene type. Sequences for forward and 
reverse primers for each gene are provided in Table 32. 
Substance (Supplier) 
Quantity for per 
sample (µL) 
Forward Primer (10 µM) (Custom primers from Life Technologies) 0.5 
Reverse Primer (10 µM) (Custom primers from Life Technologies) 0.5 
FastStart Universal SYBR Green Master (Roche Life Science) 5 
 
The primer efficiencies were first calculated using the cDNA samples allocated for primer 
validation before running the experimental samples. This cDNA was diluted 1:1, 1:10 and 1:100 
in RNase-free water. A 96 well plate was then prepared by pipetting 4 µL of each cDNA sample 
in triplicate, along with 3 wells of 4 µL RNase free water to act as non-template controls (NTC). 
Each well was then filled with 6 µL of the relevant stock gene mix. 
The plates were sealed and briefly centrifuged at ~2000g for 10 seconds to collect the solution 
at the bottom of the wells. Plates were then placed into the 7500 Fast Real-Time PCR system 
(Applied Biosystems). SYBR was set as the reporter, and the thermal profile set to run at 95°C 
for 10 minutes, followed by 40 cycles of 95°C for 10 seconds and 60°C for 30 seconds. This was 
repeated until all genes had been run. 
 
 
Chapter 5 Cell Attachment Peptides and Shear-Tension Sensitivity  
 
Section 5.3 - Methods 236 
 
 The threshold cycles (Ct) were extracted through the Applied Biosystems 7500 Software V2.0.6 
(Life Technologies) by setting the threshold near the end of the linear amplification region (as 
previously described in Chapter 4. The extracted Ct values were then imported into Excel 
(Microsoft) and plot against log10 of the initial cDNA dilution. The gradient of the correlation 
was then used to calculate the efficiency of the primer as: 
 
𝐸 =  101/𝑆𝑙𝑜𝑝𝑒 
 
 
Once the efficiency of primers had been calculated, PCR was run on the experimental samples. 
Similar to the method for primer validation, a 96 well plate was prepared by pipetting 4 µL of 
each cDNA sample in duplicate, along with 3 wells of 4 µL RNase free water (NTC) and each well 
then filled with 6 µL of the relevant stock gene mix. The plates were then sealed, briefly 
centrifuged at ~2000g for 10 seconds and then placed into the 7500 Fast Real-Time PCR system 
(Applied Biosystems). SYBR was set as the reporter, and the thermal profile set to run at 95°C 
for 10 minutes, followed by 40 cycles of 95°C for 10 seconds and 60°C for 30 seconds. For any 
sample where duplicates (i.e. technical repeats) showed differences of more than 1 Ct, RT-qPCR 
was repeated to verify the true value by eliminating pipetting or contamination error. 
Ct values were extracted as described previously and used to calculate the gene expression 
normalised to the reference gene L30 and efficiency corrected (EΔCt). The expression of strained 
composites were also calculated as efficiency corrected fold changes normalised to L30 (EΔΔCt) 
using the Pfaffl analysis Method (Pfaffl, 2001): 
𝐸𝛥𝐶𝑡 = 𝐸𝐶𝑡𝑇𝑎𝑟𝑔𝑒𝑡−𝐶𝑡𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒  
Where: 
𝐸 = Primer Efficiency 
Slope = Gradient of line when Ct plotted against Log10(dilution) 
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𝐸𝛥𝛥𝐶𝑡 =
𝐸𝑇𝑎𝑟𝑔𝑒𝑡
∆𝐶𝑡𝑇𝑎𝑟𝑔𝑒𝑡
𝐸𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒
∆𝐶𝑡𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒
 
 
 
 
Statistical analysis was performed using student T-Tests for comparing basal gene expression, 
while one way analysis of variance (one way ANOVA) was used for comparison of the different 
shear-tension ratios and followed by Tukey’s Honest Significant Difference (HSD) pot-hoc test if 
differences were found through the one way ANOVA, with p values < 0.05 considered 
significant. 
 
 
 
 
 
 
 
 
 
Where: 
𝐶𝑡𝑇𝑎𝑟𝑔𝑒𝑡 = Ct of target gene 
𝐶𝑡𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒  = Ct of reference gene 
𝐸 = Primer efficiency of target gene 
 
 
 
 
 
 
 
 
Where: 
∆𝐶𝑡𝑇𝑎𝑟𝑔𝑒𝑡 = CtControl − CtSample of target gene 
∆𝐶𝑡𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒  = CtControl − CtSample of reference gene 
𝐸𝑇𝑎𝑟𝑔𝑒𝑡  = Primer efficiency of target gene 
𝐸𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒  = Primer efficiency of reference gene 
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Table 32: List of all custom primers used for gene expression analysis. Primers ordered from Life Technologies. 
Gene Primer Sequence 
Amplicon 
Size (bp) 
Location (bp) 
ADAMTS-5  
Forward 5’-AGCTGTGCGGTGATTGAAGA-3’  
54 1189-1243 
Reverse 5’-GCCAAGCAGATGTCCAATTTC-3’ 
COL1  
Forward 5’-GCCTGGTCAGAGAGGAGAAAGA-3’  
50 3004-3054 
Reverse 5’-CCTTGTTTGCCGGGTTCAC-3’ 
COL-11A1  
Forward 5’-GTCTACCAGGTGACAAGGGTC-3'  
170 2166-2336 
Reverse 5’-CGGCTATACCAGGCTGTCC-3’ 
COL-3  
Forward 5’-CTGACATTTAGACATGATGAG-3’  
105 63-168 
Reverse 5’-ACTGACCGAGATGGGAGCAT -3’ 
IL6  
Forward 5’-CCAGACAAAACCGAAGCTCTCA-3’  
56 190-246 
Reverse 5’-CTCATCATTCTTCTCACATATCTCCTTT-3’ 
ITGA-2  
Forward 5’-TGTGGTGCAGAAGACACCTC-3’  
130 1215-1345 
Reverse 5’-GGAGCACCAGCAACAAAGTG-3’ 
ITGA-3  
Forward 5’-CGGTTTTCCGTGGACATTGA-3’  
153 3246-3399 
Reverse 5’-CTTCATACAGGGCGCGAGT-3’ 
L30  
Forward 5’-GGCAGGCGGATTCTTTACC-3’  
62 113-175 
Reverse 5’-TAGAGGCTTTCTCTCGGACAGATG-3’ 
MMP-1  
Forward 5’-GCTTTCTCAGGACGACATTGATG-3’  
51 752-803 
Reverse 5’-CGACTGGCTGAGTGGGATTT-3’ 
MMP-13  
Forward 5’-TCCTGGCTGGCTTCCTCTT-3’  
88 14-102 
Reverse 5’-GTAGCTCTCTGCAAACTGGAAGTCT-3’ 
MMP-2  
Forward 5’-TACGACCGCGACAAGAAGTAT-3’  
89 1151-1240 
Reverse 5’-TTGTTGCCCAGGAAAGTGAAG-3‘ 
MMP-3  
Forward 5’-TCCGCCTTTCTCAGGATGAT-3’  
62 801-863 
Reverse 5’-GGCACCACAGGGTCATTAGG-3‘ 
SCX  
Forward 5’-GAGAAAGTTGGTGAGTGTTGC-3’  
82 
1839436-
1839518 Reverse 5’-GGGTGGTTTGGAGGTGG-3‘ 
TIMP-3  
Forward 5’-AGTCTCTGTGGCCTTAAGCTTGA-3’  
88 549-637 
Reverse 5’-TGGTCCCACCTCTCTACAAAGTTAC-3’ 
TNMD  
Forward 5’-TCTGGCGTGACGGGTCTT-3’  
54 637-691 
Reverse 5’-AAAAAAGGCATTGAACAAAACGA-3’ 
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5.4 Results and Discussion 
5.4.1 Basal Gene Expression of RGD and DGEA Composites 
The basal gene expression of pre-seeded primary bovine tenocytes (i.e. tenocytes after isolation 
from tendon tissue) was first compared with the gene expression levels of tenocytes in non-
strained composites made of PEG-RGD and PEG-DGEA fibres. Composites with RGD and DGEA 
peptides were additionally separated by substrate stiffness (i.e. those with 20% or 60% PEG 
fibres) to assess the effect of substrate stiffness on expression level. 
The pre-seeded tenocytes were found to have similar basal gene expression levels amongst the 
biological repeats. Comparing non-strained composites showed that substrate stiffness did not 
any effect any of the genes investigated, except COL-3 in composites with PEG-DGEA fibres. 
Accordingly, fibre stiffness was removed from the comparisons, and all non-strained 
composites with PEG-DGEA fibres and all with PEG-RGD fibres were averaged to focus 
specifically on the differences caused by peptide type. Indeed, the results from this comparison 
showed that the type of cell attachment peptide affected tenocyte gene expression differently, 
with DGEA resulting in increased mechano-sensitivity. 
The results are presented in groups of genes, relating to: 1. Collagen synthesis, 2. Matrix 
proteinases and inhibitors, and finally 3. Other characteristic genes. This is then followed by a 
discussion of the results. 
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Collagens 
From the 3 collagen genes analysed (Figure 83), COL-1 was found to be the most highly 
expressed. After encapsulation, the expression of COL-1 by cells decreased significantly in PEG-
DGEA composites, while tenocytes in PEG-RGD composites showed a smaller drop (P=0.12). 
COL-11A1 gene expression was seen to be the same for pre-seeded cells and PEG-RGD 
composite cells, however the expression level was seen to increase significantly in PEG-DGEA 
composite cells. Although not statistically significant, COL-3 gene expression by tenocytes was 
seen to increase notably after encapsulation for both PEG-RGD and PEG-DGEA composites 
(P=0.07 and P=0.11, respectively). When composites were separated by substrate stiffness, the 
only gene seen to be substrate stiffness dependent was COL-3: PEG-DGEA composite cells 
showed a significant decrease (6 fold) in COL-3 gene expression when cells were seeded on stiff 
(60% PEG) fibres compared to less stiff (20% PEG) fibres (P<0.05).  
 
Figure 83: Average collagen gene expression levels of pre-seeded primary bovine tenocytes, cells in non-strained 
PEG-RGD composites (both stiffness types) and cells in PEG-DGEA composites (both stiffness types) (n=3). Each 
gene was normalised to the reference gene L30 and corrected for primer efficiency (EΔCt). Error bars indicate 
standard deviation between biological repeats. PEG-DGEA composite cells were found to have significantly less 
COL-1 gene expression compared to pre-seeded tenocytes and significantly more COL-11A1 gene expression than 
cells in PEG-RGD composites. PEG-DGEA composite cells also exhibited downregulation of COL-3 gene expression 
on stiffer substrates, contributing to the large standard deviation. * = P<0.05, S = P<0.05 for substrate stiffness 
comparison. 
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Matrix Proteinases and Inhibitors 
A selection of proteinases, ADAMTS-5, MMP-1, MMP-2, MMP-3 and MMP-13, were analysed 
at the gene expression level along with the inhibitor TIMP-3 (Figure 84). The response of these 
genes after encapsulation and to different cell attachment peptides is notably more 
pronounced than those seen with collagens. Pre-seeded tenocytes exhibited significantly more 
ADAMTS-5 and MMP-3 than tenocytes in both PEG-RGD and PEG-DGEA composites, and were 
also found to have significantly lower MMP-1, MMP-13, MMP-2 and TIMP-3 gene expression 
levels compared to tenocytes in PEG-RGD composites. PEG-DGEA composite cells showed 
significantly less MMP-1, MMP-2 and TIMP-3 gene expression than cells in PEG-RGD 
composites, in each instance, data showing a similar response in pre-seeded tenocytes and 
DGEA composite cells, with expression levels only increasing when cells attached to RGD. No 
substrate dependent changes were observed in any of these genes. 
 
Figure 84: Average gene expression levels of matrix proteinases and their inhibitor comparing pre-seeded primary 
bovine tenocytes, cells in non-strained PEG-RGD (both stiffness types) and cells in PEG-DGEA composites (both 
stiffness types) (n=3). Each gene was normalised to the reference gene L30 and corrected for primer efficiency 
(EΔCt). Error bars indicate standard deviation between biological repeats. PEG-RGD composites exhibited more 
differences from pre-seeded tenocytes than PEG-DGEA composites. This was particularly evident with MMP-1, 
MMP-2 and TIMP-3 where the gene expression is similar for both pre-seeded tenocytes and PEG-DGEA 
composites, but significantly higher in PEG-RGD composites. * = P<0.01, ** = P<0.01, *** = P<0.001. 
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Other Characteristic Genes 
Other characteristic genes analysed include the inflammatory cytokine inteleukin-6 (IL-6), 
tenocyte associated phenotypic markers scleraxis (SCX) and tenomodulin (TNMD), and cell 
attachment associated genes integrin-α2 (ITGA-2) and integrin-α3 (ITGA-3) (Figure 85). Pre-
seeded tenocytes showed significantly higher IL-6 gene expression compared to cells in both 
PEG-RGD and PEG-DGEA composites, while PEG-RGD composite cells showed significantly 
higher IL-6 gene expression than PEG-DGEA composite cells. ITGA-2 was seen to increase 
significantly in PEG-DGEA composite cells compared to pre-seeded cells, while PEG-RGD 
composite cells showed an even larger increase. ITGA-3 was seen to increase for cells in both 
PEG-DGEA and PEG-RGD composites, but was significant only in the latter (P=0.12 for PEG-DGEA 
composites). SCX was seen to significantly decrease in PEG-RGD composite cells compared to 
pre-seeded cells whilst TNMD significantly decreased in both PEG-RGD and PEG-DGEA 
composite cells. Once again, no substrate stiffness dependent gene expression changes were 
observed in any of these genes. 
 
Figure 85: Average gene expression levels of other characteristic genes in pre-seeded primary bovine tenocytes, 
cells in non-strained PEG-RGD (both stiffness types) and cells in PEG-DGEA composites (both stiffness types) (n=3). 
Each gene was normalised to the reference gene L30 and corrected for primer efficiency (EΔCt). Error bars indicate 
standard deviation between biological repeats. IL-6 gene expression was significantly less in PEG-DGEA composite, 
while ITGA-2 differed for both composite types. PEG-RGD composite cells were also found to have lower SCX gene 
expression. * = P<0.01, ** = P<0.01, *** = P<0.001. 
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Table 33: a) Summary of gene expression fold changes observed in RGD and DGEA composite cells compared to 
pre-seeded tenocytes (n=3). b) Summary of gene expression fold changes of cells in RGD composites compared to 
cells in DGEA composites (n=3). RGD composite cells showed higher gene expression of many genes, while DGEA 
composites tended to show expression closer to that in pre-seeded tenocytes. * = P<0.05, ** = P<0.01 and *** = 
P<0.001. 
 
Gene 
RGD 
Composites 
DGEA 
Composites 
COL-1  * 
COL-11A1   
COL-3   
ADAMTS-5 ** ** 
MMP-1 *  
MMP-13 *  
MMP-2 *  
MMP-3 *** *** 
TIMP-3 *  
IL-6 ** * 
ITGA-2 *** ** 
ITGA-3 *  
SCLERAXIS *  
TNMD * * 
 
               
 
5.4.2 Discussion – Cell attachment peptide effect on basal gene expression 
The comparison of basal gene expression levels in pre-seeded primary bovine tenocytes with 
tenocytes in non-strained composites made of PEG-RGD and PEG-DGEA fibres revealed the 
importance of attachment peptide on cellular behaviour, with a number of differences in cell 
response once encapsulated into composites with either PEG-RGD or PEG-DGEA fibres. The 
significant differences between the two types of composites are summarised in Table 33. 
Pre-seeded tenocytes showed more changes once encapsulated in RGD composites than in 
DGEA composites with MMP-1, MMP-2, MMP-13, TIMP-3 and ITGA-3 gene expression all 
Gene 
RGD 
Composites 
COL-1   
COL-11A1 * 
COL-3   
ADAMTS-5 * 
MMP-1 * 
MMP-13   
MMP-2 * 
MMP-3   
TIMP-3 * 
IL-6 * 
ITGA-2 * 
ITGA-3   
SCLERAXIS   
TNMD   
 
a) Compared to pre-seeded tenocytes: b) RGD compared to DGEA Composites: 
128 -128 
Fold Change 
-2 -8 8 -32 32 2 
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increased, and SCX gene expression decreased specifically, while tenocytes in DGEA composites 
showed a basal expression profile closer to that of the pre-seeded primary bovine tenocytes.  
It should be noted that the gene expression profile of pre-seeded primary bovine tenocytes 
would show some differences compared to tenocytes in tendon tissue due to the method used 
to collect the cells and therefore it is not presented here as a standalone profile. Tenocytes 
were isolated by digesting the tendons with a dispase/collagenase solution. These enzymes, 
similar to trypsin described in Chapter 4, would instigate changes in gene expression during 
tissue digestion. However, the gene expression profile of these cells are still suitable for use as 
a reference point for comparison of changes once tenocytes were encapsulated into 
composites. The gene expression change due to dispase/collagenase exposure could explain 
why some genes in pre-seeded tenocytes showed significant differences in DGEA composites 
(i.e. collagen like composites), while other genes such as MMP-1, MMP-2 and SCX remained 
similar. Additionally, pre-seeded tenocytes showed little variability between biological repeats 
(indicated by small standard deviation bars), indicating little difference between the cell sources 
used and consistent expression levels between biological repeats. 
A direct comparison of cell response in non-strained RGD and non-strained DGEA composites 
provided further evidence for attachment peptides altering basal gene expression profiles. 
Tenocytes in RGD composites showed significantly higher ADAMTS-5, MMP-1, MMP-2, TIMP-3, 
IL-6 and ITGA-2 gene expression and significantly lower COL-11A1 gene expression than 
tenocytes in DGEA composites. These differences are interesting, as ADAMTS-5, MMP-1 and 
MMP-2 are all functionally related to matrix degradation, while IL-6 is associated with 
inflammation. This indicates that PEG-RGD fibres potentially evoked an inflammatory and 
catabolic response in tenocytes. Furthermore, IL-6 has also been associated with increased 
collagen synthesis in human tendons (Andersen et al., 2011). So, although an increase in 
collagen synthesis is not observed, the cells could be in the process of initiating collagen 
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synthesis, suggesting tenocytes could be targeting remodelling of the matrix rather than just 
matrix degradation. The integrin predominantly used to bind to RGD is α5β1 (Hynes, 1992; 
Ruoslahti, 1996) while α2β1 is primarily adapted for DGEA binding (Knight et al., 2000; Luzak et 
al., 2003; Mizuno et al., 2000). As RGD does not require an α2 integrin subunit for recognition, 
it is possible the higher expression of ITGA-2 in RGD composites was a response by tenocytes 
to increase the availability of integrin α2β1, a collagen type I receptor (Heino, 2000; Jokinen et 
al., 2004), which in turn would aid in sensing collagen type I. Increased cell surface integrin α2β1 
has also been previously found to correlate with MMP-1 expression (Langholz et al., 1995; 
Riikonen et al., 1995), suggesting that integrin α2β1 functions as a feedback mechanism for 
collagen type I turnover. Collectively, these attributes suggest that tenocytes perceived the 
local environment differently when attached to RGD due to the different integrins involved, 
resulting in a gene expression profile biased towards matrix remodelling through an 
upregulation of matrix degradation, collagen synthesis promotion and increased sensitivity to 
collagen type I. 
Comparison of cell response in RGD and DGEA composites grouped by fibre stiffness showed 
that the only gene to exhibit stiffness dependent changes was COL-3, and that the stiffness 
response was only evident for DGEA composite cells. This is interesting as, although RGD 
composite cells saw more differences compared to pre-seeded tenocytes, the replacement of 
RGD with DGEA may have increased the sensitivity of tenocytes to the substrate stiffness. The 
idea of increased mechano-sensitivity in cells attached to different peptides is further explored 
in the next section, where the results showing the effect of shear-tension ratio on gene 
expression using both RGD and DGEA composites is discussed. 
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5.4.3 Shear Tension Ratio Effect on Tenocyte Gene Expression 
Composites made from PEG-RGD and PEG-DGEA fibres and seeded with primary bovine 
tenocytes were strained at 5% strained for 24 hours (86400 cycles) at 1Hz to investigate the 
effect of shear-tension ratio on gene expression. The previous section showed the substrate 
stiffness did not affect bovine tenocyte gene expression except for COL-3 in the DGEA 
composites. This led to the possibility of comparing the effect of shear-tension ratios on other 
genes without interrelated effects of substrate stiffness, while bias from stiffness effects was 
taken into consideration specifically for COL-3 gene expression. Results were consequently 
analysed as strained composites relative to non-strained control composites, using the 
efficiency corrected Pfaffl analysis method (described at the end of section 5.3). The results are 
presented in subheadings as before, followed by a discussion of the results. 
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Collagens 
All composites made from PEG-RGD fibres showed downregulation of COL-1 with loading (~2 
fold on average), while highly variable changes were observed with COL-11A1 and COL-3 gene 
expression (Figure 86a). No genes were found to be regulated by shear-tension ratios in RGD 
composites. Conversely, in composites made from PEG-DGEA fibres, significant differences 
were seen in COL-3 gene expression between the composite conditions (Figure 86b).  
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Figure 86: Average COL-1, COL-11A1 and COL-3 gene expression in strained RGD composites (a) and DGEA 
composites (b), expressed as fold changes relative to the non-strained controls and normalised to reference gene 
L30 using the Pfaffl analysis method (EΔΔCt) (n=3). Composite types labelled as “peptide-XX-YY”, where “peptide” 
is either DGEA or RGD, “XX” indicates the fibre type and “YY” indicates the soak time. Error bars indicate standard 
deviation between biological repeats. DGEA composites exhibited changes between composites types in COL-3 
gene expression, while RGD composites showed no such changes. * = P<0.01, ** = P<0.01, *** = P<0.001. 
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Matrix Proteinases and Inhibitors 
Gene expression changes in RGD composite cells after loading resulted in high variability in 
ADAMTS-5, MMP-1 and MMP-13 as evident from the large error bars (Figure 87a). MMP-3 gene 
expression was found to generally increase with loading (~4 fold increase on average) in RGD 
composite cells, while TIMP-3 was generally downregulated. Only one gene showed a response 
to shear-tension ratio, with high shear downregulating TIMP-3 gene expression by up to ~4 fold.  
There was notably less variability in gene expression overall in PEG-DGEA composite cells 
(Figure 87b). PEG-DGEA composite cells exhibited downregulation of MMP-13 by 4-16 fold after 
loading and showed significant shear mediated changes in MMP-3 gene expression, which was 
upregulated by ~4 fold in the high shear condition. Although not significant, notable shear 
mediated changes were also observed in MMP-2 gene expression, with low shear 
downregulating gene expression (P=0.07). 
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Figure 87: Average gene expression of matrix proteinases and their inhibitor in strained RGD composites (a) and 
DGEA composites (b), expressed as fold changes relative to the non-strained controls and normalised to reference 
gene L30 using the Pfaffl analysis method (EΔΔCt) (n=3). Composite types labelled as “peptide-XX-YY”, where 
“peptide” is either DGEA or RGD, “XX” indicates the fibre type and “YY” indicates the soak time. Error bars indicate 
standard deviation between biological repeats. TIMP-3 was found to be regulated by shear in RGD composites 
while MMP-3 was regulated by shear in DGEA composites. Higher gene expression variability was also observed 
in RGD composites compared to DGEA composites. * = P<0.01, ** = P<0.01, *** = P<0.001. 
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Characteristic Genes 
Loading upregulated IL-6 gene expression in all RGD composite types by up to 16 fold (Figure 
88a). No significant shear-tension regulated changes were observed in RGD composite  cells, 
however, a trend for upregulation of ITGA-3 with decreasing shear (P=0.24 between the high 
and low shear conditions) was noted, such that there was a ~9 fold increase at the lowest shear 
condition relative to the highest.  
All DGEA composite types showed an upregulation of IL-6 gene expression after loading. 
Additionally, IL-6 was found to be significantly upregulated with shear in PEG-DGEA composite 
cells, with the high shear condition resulting in a ~16 fold upregulation relative to the non-
strained controls (Figure 88b). SCX gene expression was also found to be downregulated by 
shear, increasing by ~3 fold in the low shear condition and decreasing by ~5 fold in the high 
shear condition. 
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Figure 88: Average gene expression of other characteristic genes in strained RGD composites (a) and DGEA 
composites (b), expressed as fold changes relative to the non-strained controls and normalised to reference gene 
L30 using the Pfaffl analysis method (EΔΔCt) (n=3). Composite types labelled as “peptide-XX-YY”, where “peptide” 
is either DGEA or RGD, “XX” indicates the fibre type and “YY” indicates the soak time. Error bars indicate standard 
deviation between biological repeats. Shear regulated changes were observed in DGEA composites (IL-6 and SCX) 
while none were observed in RGD composites. * = P<0.01, ** = P<0.01, *** = P<0.001. 
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5.4.4 Discussion – RGD and DGEA effect on shear-tension ratio sensitivity 
Shear-tension ratio mediated gene expression changes were investigated in primary bovine 
tenocytes seeded on PEG-RGD and PEG-DGEA fibres. Tenocytes in composites made from PEG-
RGD fibres exhibited shear regulated changes in TIMP-3, while tenocytes in composites made 
from PEG-DGEA fibres showed regulation of COL-3, MMP-3, IL-6 and SCX with shear: 
Shear regulated genes in DGEA Composites 
 COL-3 ↑ 
 MMP-3 ↑ 
 IL-6 ↑ 
 SCX ↓ 
 
Shear regulated genes in RGD composites 
 TIMP-3 ↓ 
 
 
The increased number of shear regulated genes by cells in DGEA composites compared to cells 
in RGD composites suggests that DGEA bound tenocytes possessed increased sensitivity to the 
shear environment. Moreover, as different genes were regulated by shear in RGD and DGEA 
composites, it is apparent that tenocytes can react to the same stimuli differently depending 
on their attachment peptide. Collagen type III is a fibrillar collagen which can form heterotypic 
fibrils with collagen type I (Ricard-Blum, 2011), while MMP-3, although not involved in collagen 
type I degradation, is able to process collagen type III (Visse and Nagase, 2003). In addition to 
pro- and anti- inflammatory pathways, IL-6 has been seen to increase collagen type I synthesis 
(Andersen et al., 2011). Taken together the simultaneous upregulation of COL-3, MMP-3 and 
IL-6 with shear by tenocytes in DGEA composites, could indicate a response potentially targeted 
towards remodelling collagen type III within the matrix. Conversely, tenocytes in RGD 
composites only responded to increasing shear with the downregulation of TIMP-3, a wide 
acting proteinase inhibitor. This possibly suggests that tenocytes under these conditions were 
promoting a larger and wider range of catabolic activity through less enzyme inhibition when 
exposed to increasing magnitudes of shear in RGD composite cells. 
↑ = Upregulated with shear 
↓ = Downregulated with shear 
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Integrins have been seen to exhibit unique functions. For example, previous studies have found 
integrin α2β1 to induce MMP-1 gene expression once cells are seeded onto collagen type I 
matrices, and also show some involvement in the regulation of collagen type I gene expression 
(Grzesiak and Bouvet, 2007; Langholz et al., 1995; Riikonen et al., 1995). By contrast integrin 
α5β1, recognising RGD, has been associated with initiating fibronectin fibril assembly (Danen et 
al., 2002; Sechler et al., 1997; Sechler et al., 1996; Takahashi et al., 2007). Cryptic RGD motifs 
are present in collagen type I, i.e. sequences not accessible by cells in the native triple helical 
structure, which can be exposed through denaturing or enzyme digestion (Gullberg et al., 1992; 
Ricard-Blum, 2011).  Indeed, studies exploring this trait have found that cells alter their 
behaviour when attached to partially-denatured collagen type I compared to native collagen 
type I (Taubenberger et al., 2010). Therefore, as the functions of integrins differ, it is not 
completely surprising the translation of shear-tension by integrins into cellular cues also differs 
The differences in the mechanisms by which RGD and DGEA (and the integrins involved in their 
binding) translate mechanical cues was not investigated and is out of the scope of this study, 
particularly due to the variety of possible pathways which range from integrin-actin 
cytoskeleton links to integrin regulation of ion channels (Arcangeli and Becchetti, 2006). 
However, it is interesting to note that the force required to unbind fibronectin (i.e. the 
fibronectin and integrin α5β1 interaction) has been reported to range from 69-93 pN, while that 
of collagen type I (i.e. the collagen type I and integrin α2β1 interaction) is 160 pN (Roca-Cusachs 
et al., 2012), suggesting that collagen integrins are more specialised for force transmission as 
they can withstand higher loads. 
Characterisation of tendinopathic tissue has shown increased collagen type III (Bank et al., 1999; 
Corps et al., 2012; Riley et al., 1994b). As previously described in Chapter 1 and Chapter 4, 
tendinopathies are thought to be instigated by changes in cell-matrix interactions triggered by 
microdamage after tendon overuse. Matrix microdamage would result in increased fibre shear, 
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consequently increasing the magnitude of cellular shear. The results obtained with DGEA 
composites is consistent with this concept as COL-3 gene expression was seen to be 
downregulated with less shear, lending weight to the hypothesis that shear is an important 
aspect in tendinopathy development.  
It should be noted that when looking at non-strained controls, COL-3 gene expression was found 
to be significantly downregulated by cells on stiffer PEG-DGEA fibres (Figure 83). However, in 
strained PEG-DGEA composites, COL-3 was seen to be downregulated by cells on less stiff PEG-
DGEA fibres, a trend opposite to the non-strained controls (Figure 86b). Consequently, this 
stiffness dependent trend also contributes to the appearance of shear highly upregulating COL-
3 gene expression in strained PEG-DGEA composites. Although non-strained composites of the 
same fibre type, stiffness and soak time were used as controls for each strained composite type, 
allowing the effect of substrate stiffness to be eliminated to an extent, it is difficult to separate 
the effects of the shear-tension ratio on COL-3 gene expression to those from fibre stiffness. 
Therefore the results for COL-3 gene expression in Figure 86b represents a combination of both 
fibre stiffness and shear-tension ratio effects. 
A limitation of this study was the use of free swelling non-strained controls rather than 
composites held taut in the rig under a small static strain, essentially creating a stress deprived 
condition. Stress deprivation has been seen to alter matrix related gene expression in tenocytes 
(Leigh et al., 2008), hence it is possible the control condition used in the current study may 
contain such changes. Additionally, it was observed that composites would warp and curl 
slightly once made and stored in media. Tenocytes are known to exert contractive forces onto 
their substrates (Tilley et al., 2012; Torres et al., 2000), thus it is possible such forces contributed 
towards composite warping, altering the stress experienced by cells in the process and 
potentially changing the basal gene expression of control composites. However, care was taken 
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to position composites flat onto the base of the 6 well plates, helping to keep composites flat 
during the experiment and limiting problems arising from using a non-confined condition. 
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5.5 Conclusion 
This study successfully used two different attachment peptides, RGD and DGEA, to compare 
shear-tension mediated changes in primary bovine tenocytes. The main integrin involved in 
DGEA binding is α2β1 while the integrins associated with RGD attachment include α5β1, αVβ3 
and αIIbβ3, thus the fundamental difference between the use of RGD and DGEA was the 
integrins involved in ligand binding. Consequently, the findings of this study emphasises the 
importance of integrins in the role of mechanotransduction as both peptides resulted in 
different responses to shear-tension. Specifically, the results suggest integrins involved in 
collagen type I binding induce functionally different responses in tenocytes to those not 
involved in collagen type I binding when sensing mechanical stimuli comprised of shear and 
tension. This information is critical in future studies investigating tenocyte behaviour and tissue 
engineering approaches, as physiological integrin binding may be key in maintaining normal 
tenocyte pathways.  
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Overall Conclusion and Future Work 
: Overall Conclusion and Future Work 
 
Research into the effects of shear on cellular metabolism and its involvement in 
mechanotransduction pathways have been limited, due to the lack of appropriate systems 
which create controllable, physiologically representative in vitro strain environments. The fibre 
composite system detailed in Chapter 2 was developed to meet this need, creating a platform 
to provide physiologically representative cellular shear and tension ratios, in addition to the 
ability to control the amount of tension and shear. The precise and reproducible nature of the 
manufactured composites allows the investigation of shear and tension ratio effects in a 
reproducible manner.  The fibre composite system also possesses a number of beneficial 
aspects, including optical transparency to allow imaging and monitoring of cells encapsulated 
within, and customisable attachment peptides to alter the method of attachment by cells. 
Furthermore, the system is based on PEG chemistry, which has been used extensively in 
research and allows modifications such as enzyme degradable or photodegradable cross-links 
(Kloxin et al., 2010; Liu et al., 2010; Zhu, 2010), providing extra versatility to the system for 
future applications. 
Using the fibre composite system with PEG-RGD fibres, it was shown that healthy and 
tendinopathic human tenocytes respond to shear differently, with tendinopathic cells 
exhibiting more mechano-sensitivity. The relationship between applied shear and cell response 
was also found to be complex and not a simple linear relationship, with high and low shear-
tension ratios altering gene expression levels differently. The shear-tension ratios tested ranged 
from approximately 40% shear and 60% tension to 75% shear and 25% tension. This range of 
shear-tension ratios is small, with 5% applied strain at a whole composite level translating to 
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1.5% - 3% local strain, specifically along each fibre. However, even with these comparatively 
small changes in local mechanisms, gene expression regulation is still observed, suggesting 
tenocytes are extremely sensitive to this mechanical cue.  
Differences between healthy and tendinopathic human tenocytes was also found in the basal 
gene expression level: ADAMTS-2, ADAMTS-4, ADAMTS-12, BGN, COL-12A1, COL-1A1, COL-3A1, 
COL-4A1, COL-5A1, COL-6A1, FN-1, and MMP-13 gene expression were all higher, and TNC, 
ACAN, ADAMTS-1, ADAMTS-6, COL-14A1, DCN, FMOD, IL-6, IL-8, MMP-3, PRG-4 and VCAN gene 
expression lower in tendinopathic tenocytes. This data supports the observations from the 
shear-tension ratio comparison, emphasising that differences were present between healthy 
and tendinopathic tenocytes.  The fact that differences between tendinopathic and healthy 
tenocytes remained after in vitro culture and encapsulation into composites suggests that 
either cell behaviour is fundamentally changed during tendinopathy and tenocytes are slow to 
revert to normal, or that some individuals are genetically prone to tendinopathies with cells 
always showing a different profile. Basal gene expression differences were also found between 
the two tendinopathic tenocyte donors, with one showing significantly higher ACAN, COL1-A1, 
COL5-A1 and IL-1B gene expression and lower COL-14A1, MMP-13, MMP-3, PRG-4 and SCX gene 
expression than the other. This finding suggests the two donors may have had different states 
of tendinopathy, or even a different type of tendinopathy altogether.  
Further experiments using bovine tenocytes in composites with PEG-DGEA and PEG-RGD fibres 
found the peptides used by tenocytes to attach to fibres dramatically affected cell behaviour. 
The peptide DGEA, a collagen mimetic peptide associated with integrin α2β1 binding, was found 
to increase mechano-sensitivity of bovine tenocytes and result in many genes being regulated 
by shear, compared to the RGD based fibronectin associated peptide which binds to integrin 
α5β1. RGD composite cells down regulated TIMP-3 gene expression in response to shear, while 
cells in DGEA composites upregulated COL-3, MMP-3 and IL-6 and downregulated SCX gene 
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expression in response to shear. These findings reveal that shear and tension are interpreted 
differently by tenocytes depending on the integrins employed in perceiving strains, emphasising 
the importance of integrins in mechanotransduction pathways and future applications where 
cell behaviour manipulation is required. This finding could also explain why many genes were 
not seen to be regulated by shear in the human tenocyte study (Chapter 4), as composites used 
in that study were made with RGD peptides.  
Additionally, another factor which could contribute to differences between the human tenocyte 
and bovine tenocyte experiments (i.e. Chapter 4 and Chapter 5) is the method by which cells 
were isolated: human tenocytes were obtained via an explant outgrowth method whereas 
bovine tenocytes were obtained through enzymatic digestion. Enzymatic digestion extracts cells 
from the whole tendon tissue, whereas explant outgrowth is inherently more selective, 
favouring tenocytes closer to the perimeter of the explant, i.e. those more likely to migrate onto 
the tissue culture plastic. As tenocytes in vivo reside on collagen fibres and between fascicles in 
the IFM (Clegg et al., 2007; Richardson et al., 2007; Spiesz et al., 2015; Thorpe et al., 2015a), 
and populations of tendon progenitor stem cells (TSCs) reported to exist (Bi et al., 2007; de Mos 
et al., 2007; Zhang and Wang, 2010a; Zhang and Wang, 2013),  possibly localised in the IFM, the 
two isolation methods would result in cell populations with different characteristics. This 
population difference could potentially result in different shear responses, as cell function and 
local micro-environment in vivo would differ. Indeed, cell populations extracted through the 
two different methods have shown differences in studies with periodontal ligament cells 
(Tanaka et al., 2011), keratinocytes (Orazizadeh et al., 2015), osteoblastic cells (Declercq et al., 
2004) and dental pulp cells (Souza et al., 2010). Furthermore, MSCs derived from equine SDFT 
tendons have been shown to express higher COL-1A2 and SCX gene expression when isolated 
through tissue digestion rather than explant outgrowth (Gittel et al., 2013). Studies comparing 
cells from the two cell isolation methods have found that cells digested from tissue generally 
exhibit higher proliferation rates (Declercq et al., 2004; Souza et al., 2010; Tanaka et al., 2011). 
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This is in contrast to the logic that explant outgrowth would favour isolation of more active, 
migratory and proliferative cells. One possible reason for more proliferative activity in digested 
cells could be the exposure to catabolic enzymes and dramatic matrix changes, which are 
stressful events, potentially stimulating cells into an active state. Explant outgrown cells could 
also be influenced by the increased time spent on tissue culture plastic, potentially allowing 
more time for tenocytes to de-differentiate.  
Overall, the results obtained from this work broadens the knowledge on tendinopathy, 
confirming tenocytes do indeed behave differently compared to normal healthy tenocytes. It 
also shows that tenocytes behave differently under non-physiological shear-tension ratios. As 
microdamage from tendon overuse alters this property, increasing the amount of shear 
experienced by tenocytes, the results strengthen the idea that microdamage is involved in 
tendinopathy development. Cell attachment peptides, and thus integrins, are implicated as 
important structures used by tenocytes to sense this environment and therefore needs to be 
investigated further to assess the extent of their involvement in tendinopathy development.  
6.1 Future work 
6.1.1 Response to shear over time and under different loading regimes 
The studies conducted in this thesis involved applying 5% cyclic strain at 1Hz for 24 hours, after 
which gene expression was analysed. Different genes have been shown to peak at different 
time points in tenocytes, such as MMP-1 gene expression downregulation peaking at 48 hours 
and collagen type I upregulation peaking at 24 hours (Jones et al., 2013), and IL-6 content 
peaking immediately after exercise (Andersen et al., 2011; Langberg et al., 2002). Thus, 
although 24 hours was selected as a compromise to obtain a general overview of changes, many 
shear mediated changes may have been lost if they occurred before or after the 24 hours 
loading period.  
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The duration of loading could be another parameter to alter. The number of cycles used in this 
study was 86400 (total duration of 24 hours), and is more representative of extensive use rather 
than normal physiological use. Short loading periods of 100 cycles and intermittent loading have 
been shown to invoke gene expression changes (Huisman et al., 2014; Scott et al., 2011) and 
would be interesting to explore. Loading mimicking tendon overuse has also shown an increase 
in IL-6 levels (Spiesz et al., 2015). Therefore shorter loading periods to represent normal 
exercise could be used in addition to strains representing tendon overuse to investigate 
tenocyte behaviour under normal and overuse exercise. 
The aspects analysed could also be expanded to include protein quantity and protein level 
expression changes. As described in section 1.4.2, MMPs and ADAMTS have many levels of 
regulation. Therefore, although gene expression may appear to stay constant, the activated 
protein levels of these components could be regulated. Similarly, genes which appear to be 
regulated by loading may show different trends in the protein levels due to post translation 
interactions. Investigating the protein levels via zymography would therefore provide a more 
holistic view of tenocyte response to loading. 
Proposed Future Study: 
 Use fibre composites made from PEG-DGEA fibres 
 Loading composites for 15 and 30 minutes at 1Hz (i.e. 900 and 1800 cycles) to create 
shorter loading periods  
 Using both 5% and 10% cyclic strain to simulate normal and excessive strains  
 Analyse gene expression immediately (0 hours), 6 hours, 24 hour and 48 hours after 
loading. 
 Analyse protein levels immediately (0 hours), 6 hours, 24 hours and 48 hours after 
loading. 
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6.1.2 Tendinopathic tenocyte gene expression changes 
Results in Chapter 4 showed that tendinopathic tenocytes reported gene expression changes 
similar to those seen in tendinopathic tissue even after in vitro culture and encapsulation into 
composites, suggesting that the changes which occur during tendinopathy development are 
slow to revert. It would be interesting to monitor the gene expression of tendinopathic and 
healthy tenocytes during in vitro culture to characterise the difference between the two cells 
types and to monitor the time required for tendinopathic tenocytes to lose their tendinopathic 
profile. 
Proposed Future Study: 
 Obtain samples from one individual - one healthy and one tendinopathic tendon. 
 Culture tenocytes obtained from healthy and tendinopathic tissue. 
 Analyse tenocyte gene expression directly from the tissue, followed by analysis at every 
passage number throughout culture. 
6.1.3 Characterising tenocyte deformation under load 
The studies conducted were focused on the effects of shear and tension on tenocyte gene 
expression. Investigation of the mechanisms by which tenocytes sense these mechanical cues 
was limited to integrins.  
The fibre composite system is optically transparent allowing cells within to be imaged, as shown 
in section 2.3 where cell attachment was characterised. Tenocytes could therefore be 
monitored during loading to characterise the extent of cellular deformation, providing 
information on how cells deform under the different shear-tension ratios. Characterisation can 
be achieved through staining the cytoskeleton and nucleus of tenocytes in composites and 
applying load whilst imaging the cells in real-time. 
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Proposed Future Study: 
 Stain the cytoskeleton and nucleus of tenocytes within composites. 
 Load composites up to 10% strain. 
 Image cells via confocal microscopy at increments of 2% to characterise cellular 
deformation. 
6.1.4 Integrin involvement in tendinopathy 
Tendons are predominantly comprised of collagen type I and provide the matrix for cellular 
attachment. Tenocytes would consequently use integrin α2β1 to bind to this matrix. Cell 
attachment peptides RGD and DGEA, and the integrins involved in their binding, were shown to 
affect the gene expression of tenocytes, with tenocytes behaving differently when exposed to 
the same mechanical stimuli. Thus, integrins are key components in translating the shear-
tension environment into cellular cues and important for tendon homeostasis.  
Tendinopathy is seen to be accompanied by severe matrix degeneration. Cryptic RGD motifs 
are known to be present in collagen type I, which can be exposed to cells after its degradation 
or denaturation (Gullberg et al., 1992; Ricard-Blum, 2011). Therefore it is possible that tenocyte 
integrin binding is altered in tendinopathy due to the release of these cryptic motifs, 
contributing further to the severe degenerative process by altering mechano-sensitivity. 
Consequently, it would be interesting to analyse the integrins expressed by tenocytes in healthy 
and tendinopathic tendon samples, which can be achieved through confocal imaging after anti-
body staining. 
Proposed Future Study: 
 Obtain and section healthy and tendinopathic tendon samples. 
 Stain sections with anti-bodies for integrin α2β1 (collagen type I specific integrin), along 
with other collagen associated integrins (α1β1, α3β1, α10β1, α11β1 and αIIIβ3) and 
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integrins associated with RGD motifs (α2β1, α3β1, α4β1, α4β7, α5β1, α8β1, αvβ1, 
αvβ3, αvβ5, αvβ6, αvβ8 and αIIbβ3). 
 Image sections via confocal microscopy to characterise differences in integrin 
deployment. 
 Analyse gene expression levels post treatment to assess the effects of substances. 
6.1.5 Further Improvements to the Fibre Composite System 
 One of the limitations of the fibre composite system was the diameter of the fibres. Fibres were 
made from moulds containing holes of 0.3 mm in diameter. Considering the diameter of 
collagen fibres is considerably less, found to be up to 30 µm in human tendons (Jarvinen et al., 
2004), tenocytes in the composites are likely perceive the fibres as flat surfaces. This may affect 
the response of tenocytes as wrapping around fibres potentially changes cellular structures and 
stresses distributed to integrins. 
To address this limitation, the method of creating fibres could be adapted to allow production 
of thinner fibres, more representative of collagen fibres. As the fibres within the composites 
are made using a PEG solution containing peptides, methods such as electrospinning could be 
used to achieve thin fibres. This would also require re-characterisation of the fibre composite 
as the micromechanics would inevitably change. 
Proposed Future Study: 
 Create pre-polymer PEG-Peptide solutions compatible with electrospinning. 
 Determine electrospinning parameters to create fibres of desired diameters. 
 Seed electrospun fibres with cells and encapsulate into composites. 
 Characterise cell morphology, viability, gross mechanics and micro-micromechanics of 
composites. 
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Appendix A: Human cell source and ethics 
 
Human tenocytes ranging from passage 2 to passage 4 were provided by Dr Graham Riley from 
the Biomedical Research Centre, University of East Anglia, which were originally obtained by his 
group under ethical approval (REC reference 09/H0302/3). As primary human tenocytes were 
not handled or used in the studies described in the current thesis, the cells were not considered 
relevant material by the Human Tissue Authority (HTA) under the Human Tissue Act 2004, and 
consequently a tissue storage licence was not required for use of said material at Queen Mary 
University of London. 
Table 34: Details of the human cells and their use in the thesis. 
Tenocyte Type Tendon 
Source 
Donor 
Age 
Donor 
Sex 
Use and Other Details 
Healthy Achilles 
Tendon 
76 M Chapter 3 – used for preliminary stable gene 
expression study. 
Healthy Hamstring 
Tendon 
22 M Chapter 4 – used for shear-tension ratio study. 
Healthy Hamstring 
Tendon 
19 F Chapter 4 – used for shear-tension ratio study. 
Tendinopathic Achilles 
Tendon 
51 M Chapter 4 – used for shear-tension ratio study. 2 
year duration tendinopathy. 
Tendinopathic Achilles 
Tendon 
45 M Chapter 4 – used for shear-tension ratio study. 
More than 18 month duration tendinopathy. 
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Appendix B: Chemicals and Materials List 
Table 35: Chemical and material list, part 1 of 2. 
Chemical or Material Abbrev. Supplier Product no. 
1-1' Carbonyl Diimidazole CDI Sigma Aldrich 115533 
24 well plates, Non-tissue culture treated   Sigma Aldrich CLS3738 
2-hydroxyethyl methacrylate HEMA Polysciences Inc. 04675 
3-morpholinopropanesulfonic acid 
MOPS 
buffer 
Sigma Aldrich PHG0007 
4-(dimethylamino) pyridine   Sigma Aldrich 107700 
48 well plates, Non-tissue culture treated   Fisher Scientific 08-772-52 
6 well plates, sterile   Sigma Aldrich SIAL0516 
Acrylate-PEG-NHS   JenKem Technology A5022-1 
Agarose   Sigma Aldrich A9539 
Aspartic Acid-Glycine-Glutamic Acid-Alanine DGEA GenScript 
Custom 
peptide 
Bovine Serum Albumin BSA Sigma Aldrich A3311 
Calcein AM   Life Technologies C1430 
Cell Strainer, 100um   Life Technologies 431752 
Chloroform   Sigma Aldrich C2432 
Collagen Type I (Rat tail)   BD Biosciences 354236 
Collagenase Type 2   
Worthington Biochemical 
Corp. 
CLS-2 
Conical tube, 50 mL    Sigma Aldrich CLS430897 
Corning Glass slides (75x25x1mm), Clear non-frosted   Sigma Aldrich CLS294775X25 
Cryovials, 1.2 mL   Sigma Aldrich V4757 
DAPI (4',6-Diamidino-2-Phenylindole, Dilactate) DAPI Life Technologies D3571 
Deoxynucleotide, 10mM dNTPs Promega U1515 
Dialysis membrane, MWCO 500:1000   
Spectrum Laboratories 
Inc. 
734-0549 
Dichloromethane   Sigma Aldrich D65100 
Diethyl Ether   VWR International 23809.328 
Diethylpyrocarbonate DEPC Sigma Aldrich D5758 
Dimethyl Sulfoxide DMSO Sigma Aldrich 276855 
Dispase Solution, 1U/mL   STEMCELL technologies 07923 
Disposable Pestle   Sigma Aldrich Z359947 
Dry Acetone, water-free   Sigma Aldrich 650501 
Dulbecco’s Modified Eagle Medium with GlutaMAX, low 
glucose 
DMEM-G Life Technologies 21885 
Dulbecco’s Modified Eagle Medium, low glucose DMEM Life Technologies 11880 
Ethanol, 200 proof   Sigma Aldrich E7023 
Ethidium Homodimer   Life Technologies E1169 
Ethylene glycol   Sigma Aldrich 10246-6 
FastStart Universal SYBR Green Master   Roche Life Science 04913850001 
Fluoraldehyde O-phthalaldehyde OPA Thermo Scientific PN26025 
Fluorescein O-methacrylate   Sigma Aldrich 568864 
Foetal Bovine Serum FBS Sigma Aldrich F7524 
Formaldehyde loading dye   Sigma Aldrich R4268-5VL 
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Table 36: Chemical and material list, part 2 of 2. 
Chemical or Material Abbrev. Supplier Product no. 
Glycogen   Sigma Aldrich AM9510 
HEPES, 1M   Sigma Aldrich H0887 
Hydroquinone   Sigma Aldrich H9003 
Irgacure 2959   Ciba Speciality Chemicals Irgacure2959 
Irgacure 651   Ciba Speciality Chemicals Irgacure651 
Isopropanol   Sigma Aldrich I9516 
KAPA Universal qPCR kit   Anachem KK4702 
L-Glutamine, 200mM   Sigma Aldrich G7513 
Loctite Power Flex Control Gel   RS Components 330-4018 
Methacrylic Anhydride MA Sigma Aldrich 27668-5 
MultiScribe Transcriptase Kit (including 10x sample 
buffer, Deoxynucleotide triphosphates, 25x RT Random 
Primers)  
  Life Technologies 4368814 
N,N'-Dissucinimidyl Carbonate DSC Sigma Aldrich 225827 
Non-essential amino acids NEAA Sigma Aldrich M7145 
Paraformaldehyde   Sigma Aldrich P6148 
Penicillin/Streptomycin, 10000U/10mg per mL Pen/Strep Sigma Aldrich P4333 
Phalloidin (Alexa Fluor 488)   Life Technologies A12379 
Phase Lock Gel Heavy   5 Prime 232830 
Phosphate buffered saline PBS Sigma Aldrich P5368 
Polyethylene glycol (MW3000) PEGDM Merck Schuchardt 8.19015.1000 
Primers and Probes   Life Technologies Custom order 
QIAgen MiRneasy Micro Kit (including QIAzol lysis reagent 
and MinElute Spin Columns) 
  QIAgen 217084 
QIAshredder   QIAgen 79654 
Random Hexomers   Life Technologies 48190-011 
Rhodamine methacrylate   Polysciences Inc. 23591 
RNase Free Water   Sigma Aldrich W4502 
RNasin ribonuclease inhibitor   Promega N2511 
Sodium Bicarbonate   Sigma Aldrich S-8875 
Superscript II Kit, 200U/µL (including Dithiothreitol (DTT) 
and 5X Sample Buffer) 
  Life Technologies 18064-014 
Syringe filters, 0.22 µm   Merck Millipore 10497342 
TaqMan Low Density Array Cards, 48 gene layout 
TLDA 
cards 
Life Technologies 4342253 
TaqMan Universal PCR Master Mix   Life Technologies 4324018 
Tetraethylene glycol dimethacrylate TEGDM Polysciences Inc. 02654 
Tissue culture flasks, filter cap   Sigma Aldrich C7481 
Triton X-100   Sigma Aldrich X100 
Trizol (Tri-reagent)   Sigma Aldrich 15596-026 
Trypan Blue   Sigma Aldrich T8154 
Trypsin-EDTA (1X concentration)   Sigma Aldrich T3924 
Tyrosine-Arginine-Glycine-Aspartic acid-Serine YRGDS GenScript 
Custom 
peptide 
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Appendix C: Additional shear-tension ratio graphs (2ΔCt) 
Collagens – Tendinopathic Tenocytes 
 
Figure 89: Average collagen gene expression for strained composites with tendinopathic tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error bars 
represent standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Tend.’ Or ‘2nd Tend.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates the 
soak time. n=6 per composite type. 
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Collagen – Healthy Tenocytes 
 
Figure 90: Average collagen gene expression for strained composites with healthy tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error bars represent 
standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Heal.’ Or ‘2nd Heal.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates the soak time. 
n=6 per composite type. 
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MMPs – Tendinopathic Tenocytes 
 
Figure 91: Average MMP gene expression for strained composites with tendinopathic tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error bars 
represent standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Tend.’ Or ‘2nd Tend.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates the 
soak time. n=6 per composite type. 
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MMPs – Healthy Tenocytes 
 
Figure 92: Average MMP gene expression for strained composites with healthy tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error bars represent 
standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Heal.’ Or ‘2nd Heal.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates the soak time. 
n=6 per composite type. 
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ADAMTSs – Tendinopathic Tenocytes 
 
Figure 93: Average ADAMTS gene expression for strained composites with tendinopathic tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error bars 
represent standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Tend.’ Or ‘2nd Tend.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates the 
soak time. n=6 per composite type. 
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ADAMTSs – Healthy Tenocytes 
 
Figure 94: Average ADAMTS gene expression for strained composites with healthy tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error bars represent 
standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Heal.’ Or ‘2nd Heal.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates the soak time. 
n=6 per composite type. 
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TIMPs – Tendinopathic Tenocytes 
 
Figure 95: Average TIMP gene expression for strained composites with tendinopathic tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error bars 
represent standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Tend.’ Or ‘2nd Tend.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates the 
soak time. n=6 per composite type. 
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TIMPs – Healthy Tenocytes 
 
Figure 96: Average TIMP gene expression for strained composites with healthy tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error bars represent 
standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Heal.’ Or ‘2nd Heal.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates the soak time. 
n=6 per composite type. 
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Interleukins – Tendinopathic Tenocytes 
 
Figure 97: Average interleukin gene expression for strained composites with tendinopathic tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error bars 
represent standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Tend.’ Or ‘2nd Tend.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates the 
soak time. n=6 per composite type. 
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Interleukins – Healthy Tenocytes 
 
Figure 98: Average interleukin gene expression for strained composites with healthy tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error bars 
represent standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Heal.’ Or ‘2nd Heal.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates the 
soak time. n=6 per composite type. 
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Proteoglycans – Tendinopathic Tenocytes 
 
Figure 99: Average proteoglycan gene expression for strained composites with tendinopathic tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error 
bars represent standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Tend.’ Or ‘2nd Tend.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates 
the soak time. n=6 per composite type. 
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Proteoglycans – Healthy Tenocytes 
 
Figure 100: Average Proteoglycan gene expression for strained composites with healthy tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error bars 
represent standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Heal.’ Or ‘2nd Heal.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates the 
soak time. n=6 per composite type. 
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Other Proteins – Tendinopathic Tenocytes 
 
Figure 101: Average other protein gene expression for strained composites with tendinopathic tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error 
bars represent standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Tend.’ Or ‘2nd Tend.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates 
the soak time. n=6 per composite type. 
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Other Proteins – Healthy Tenocytes 
 
Figure 102: Average other proteins gene expression for strained composites with healthy tenocytes. Expression shown as 2ΔCt (normalised to TOP-1) and both shown separately. Error bars 
represent standard deviations. Data labelled as ‘XX. YY – ZZ strain’, where XX is either ‘1st Heal.’ Or ‘2nd Heal.’ representing the donor, ‘YY’ indicates the fibre type and ‘ZZ’ indicates the 
soak time. n=6 per composite type.
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ratios. D. Patel, S. Sharma, S.J. Bryant, and H.R.C. Screen.  
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